Network Medicine Characterisation of Genetic Disorders by Propagation of Disease Phenotypic Similarities by Caceres Silva, Juan
Network Medicine Characterisation
of Genetic Disorders by Propagation
of Disease Phenotypic Similarities
Juan José Cáceres Silva
Supervisor: Prof. Alberto Paccanaro
Department of Computer Science
Royal Holloway, University of London
This dissertation is submitted for the degree of
Doctor of Philosophy
September 2018

Declaration
I Juan José Cáceres Silva hereby declare that this thesis and the work presented in it
is entirely my own. Where I have consulted the work of others, this is always clearly
stated.
Juan José Cáceres Silva
September 2018

Acknowledgements
I am very grateful to my supervisor Prof. Alberto Paccanaro, who served as an
example to follow for many years. We have shared frequent meetings and discussions
along the past 4 years, even during a handful of research trips abroad. Alberto has
granted me his friendship, support and guidance, and I hope to have learned a thing
or two from his work ethics and kindness.
I would like to thank the staff and students for making our department a nice
environment. I thank Nuno Barreiro for his support and trust in many academic
projects. I thank Prof. Dave Cohen for his contagious enthusiasm and interest for all
forms of science and technology.
I thank my fellow permanent and visiting labmates at the PaccanaroLab, Dr.
Horacio Caniza, Dr. Alfonso Romero, Mateo Torres, Diego Galeano, Dr. Cheng Ye,
Rubén Jimenez, Jessica Gliozzo, Michele Nacucchi, Víctor Yubero and Santiago
Noto for the work, the sleepless nights at the lab, the grind for funding, the interesting
discussions and the silly moments we shared these four years. I feel obliged to give
a further acknowledgement to Horacio for his help and advice, and without whom I
would have not applied for this PhD. I also thank all the friends I found during these
years that made me feel at home, I will dearly cherish the many memories we shared.
Last, but not least, I am grateful to many dear people back home for their
unending affection and warmth. To Claudia, for being an example of courage. To
my family, Ercilia, José, Tatiana, Rocío and María, for their love. To my dad Víctor,
who inspired me to study and gave me all the opportunities when I needed them the
most. To my aunt María Esther, who had my back so often when I was far.

Abstract
The elucidation of the genetic causes of diseases is central to understanding the
mechanisms of action of a pathology and the development of treatments. Disease
gene prediction methods streamline the discovery of the molecular basis for a disease
by prioritizing genes for experimental validation. Technological advances, such as
high throughput sequencing and screening techniques, have led to an increasing ac-
cumulation of genomic data. Despite this growth, the mechanisms of action through
which genomic variants drive disease development are not fully understood. Earlier
approaches to find non-experimental disease gene associations such as linkage analy-
sis or genome-wide association studies, produce either limited results or hundreds of
candidates, making experimental validation expensive and time consuming.
Modern biological networks have been exploited to capture significant features
of the highly complex protein interactions, leading to the rise of computational
methods in network medicine. Recent network medicine based approaches bypass
the lack of functional annotation by drawing inferences from interaction data. My
approach, called Cardigan (ChARting DIsease Gene AssociatioNs), is based on a
semi-supervised algorithm that propagates labels on the interactome. These labels
integrate disease phenotypic information expressed as a similarity measure between
diseases, which is obtained by mining and comparing MeSH terms relevant for each
disease on the MeSH ontology. Thorough experimentation shows that Cardigan
vastly outperforms state-of-the-art disease gene prioritisation methods. This work
additionally presents an exploratory extension of the approach, which, to the best of
my knowledge, allows network methods for the first time to handle protein interfaces.
As a ramification of disease characterisation, this work presents an analysis of
viral induced lymphoid malignancies on mice. In particular, the characterisation
of the clonality of viral insertions to classify different stages of lymphomagenesis.
The results show that we can identify rare driver mutations from late stage samples,
with infrequent occurrences as clonal mutations, by adding statistical support of their
occurrence as subclonal mutations. Several known rare cancer drivers were found to
appear as subclonal mutations in late stage cancer samples more often than expected
by random chance. Another research ramification focuses on a pipeline to infer
8drug cocktails for the chronic phase of Chagas Disease, which were assembled from
drugs with prospective efficiency against the parasite. The drug set is obtained by
homology analysis of known drug targets and enzymes found in inferred metabolic
pathways for the pathogen, and a random forest model trained with a large compound
essay against the pathogen.
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Chapter 1
Introduction
1.1 Motivation
The elucidation of the genetic causes of diseases is a central element to understand
the mechanisms of action of a pathology, not only for the development of diagnosis
or treatments, but also for a deeper understanding of cell biology. High throughput
sequencing and screening techniques have led to an increasing accumulation of
genomic data [129, 168]. Despite this growth, the mechanisms of action through
which genomic variants drive disease development are not fully understood [209].
As genomic alleles and malignant mutations are continuously sequenced, most of
them still miss a functional annotation. While traditional approaches fail to unveil
the causes, Genome-Wide Association Studies (GWAS) often produce hundreds of
candidates, making experimental validation expensive and time consuming.
Modern network medicine methods to predict disease genes improve upon pre-
vious approaches by exploiting biological networks to capture significant features
of the highly complex protein interactions [213]. Generally speaking, these com-
putational methods streamline the discovery of molecular basis for a disease by
establishing a gene priority for experimental validation [3, 90, 231]. A subset of
prioritised genes can be used to reduce the search space of the genome, such as in
pathway analysis [77]. This reduction in search space greatly increases the sensitivity
of the experimental validation, which allows genome wide enrichments of p < 0.05
to be significant [43], compared to enrichments of p < 5×10−8 required in GWAS
[66].
Most network medicine methods relay on the guilt-by-association principle and
prioritise to a certain degree genes which are close to disease genes. Approaches
which exploit this idea differ in how they quantify the distance between candidate
genes and known disease genes in the interactome [213]. Common measures for
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the proximity are the number of direct connections, the length of shortest paths and
diffusion kernels, including random walkers with restart and propagation flow. Fur-
thermore, some approaches add other biological networks, or add disease phenotype
information to enhance their performance.
Disease phenotype is a particularly rich and interesting data source, as well-
known public databases are being constantly updated. For instance, the Online
Mendelian Disease in Man (OMIM), which focuses on the association of genes to
disease, comprises over 8,500 genetic disorders and 15,100 genes [125]; and ClinVar,
which focuses on the association of genetic variation to phenotypes, includes records
of over 440,000 unique variants and 30,000 diseases [102]. However, most methods
that use disease phenotype use outdated pre-calculated matrices, which also limits
the amount of diseases they can predict [206, 135, 107].
An important point to be made here is that there are many molecularly un-
characterised diseases, for which no disease gene is currently known – as of 2018
these comprise 3,359 diseases in OMIM – i.e. 39% of the entire OMIM database.
Henceforth, molecularly uncharacterised diseases are called uncharted, while those
diseases for which at least one disease gene is currently known are called charted.
This work presents a disease gene prediction method that predicts disease genes
for both charted and uncharted diseases, and can also predict disease modules. Our
approach, which we have called Cardigan (ChARting DIsease Gene AssociatioNs), is
based on a semi-supervised algorithm that propagates labels on the interactome using
a diffusion kernel. These labels integrate disease phenotypic information expressed
as a similarity measure between diseases, which is obtained by mining and comparing
MeSH terms relevant for each disease on the MeSH ontology. Furthermore, we
show that Cardigan outperforms state-of-the-art methods in disease gene and disease
module prediction.
This work also explores an extension which allows the usage of the Cardigan
methodology to predict genes using protein interfaces and known genetic variants. A
recent database of computationally predicted protein interfaces called Interactome
INSIDER [130] is mined to produce a PPI where proteins are linked through inter-
faces. The extension has two variants: the first modifies the diffusion kernel used in
Cardigan to embed the interface information into a protein-protein network, and the
second proposes a diffusion method for a network with interfaces. This extension
enhances the performance of Cardigan on charted diseases, showing the potential of
a new data source for network medicine.
In addition, this work presents research I have done as part of two collaboration
projects with different wet labs. My collaboration for the first project is part of a
large analysis of a mouse lymphomagenesis study [216]. In particular, my work
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consisted in the characterisation of lymphoma stages through the distribution of
insertion clonality, and over-representation analysis to support the selection of novel
candidates. The second project presents a pipeline to produce putative drug cocktails
effective against Chagas disease in its chronic phase.
1.2 Prequels of computational medicine
For the longest period of human history, the practice of medicine was regarded
with mysticism. Although our ancestors could understand that wounds and broken
bones could heal, diseases were not understood until scientific progress provided
the microscopes which revolutionised the field. We discovered that the basic unit of
life was the cell, which composed all complex organs. The cells themselves work
thanks to some small machines they produce in the form of chains of amino acids –
i.e. proteins. The protein activity surprisingly proved to behave in a mechanical way;
it is determined by the three dimensional structure, and the structure depends on the
amino acid sequence. We could also understand that different organisms could be
characterised from their chromosomes, which encode the genes that define the set of
proteins available to be produced in the cells.
Although these concepts are well established, the sheer number of elements
involved in the cell biology makes the study of biomolecules an arduous process.
Simple organisms such as E. Coli has an estimated of 11,000 genes and 2 million
proteins in the cell at any given moment [133]. While humans neither have the
largest amount of genes, nor carry the largest amount of protein molecules in their
cells; the human genome contains about 20,000 to 40,000 [30] genes, and 1 to 2.3
billion protein molecules per cell at any given time [133]. Furthermore, not all
proteins are expressed all the time: many proteins are only produced as a response
to particular stimulus, and in complex organisms different cell types also produce
different subsets of proteins.
Nonetheless, early models of biomolecule interactions, activity or governing
principles were built without the aid of computers. Some of them even precede
genetic discoveries, such as the trait inheritance laws established by Mendel [48],
where the offspring was found to acquire a trait from its parents. After extensive
analysis of plant breeding, traits (later discovered as genetic alleles) were determined
to be either dominant or recessive, and each individual would inherit two factors
(later genes), one randomly from each parent, and that the dominant trait would
be expressed. Likewise, the transformation of air and food nutrients to cell-usable
metabolites led to the idea of metabolic pathways – that is, several proteins establish
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a network of many reactions that lead to the production of desired metabolites [34].
Once organelles could be isolated, enzyme extracts could be obtained and individu-
ally tested on the degradation of substrates. Similar processes with exhaustive testing
based on enzyme isolation and expression analysis established the initial procedures
to find transcription networks, signalling pathways and disease gene associations.
In particular, disease gene associations were established through linkage analysis,
which establishes the likelihood of observing a phenotype and particular genetic
alleles in an organism compared to random chance [149].
1.3 The advent of big data
High throughput sequencing and screening techniques changed dramatically the
amount of genetic data available to study, and pushed forward our understanding
of biology. Starting with the gargantuan 3 year long effort to complete the first
sequenced human genome in 2001 [30, 208], and the following efforts to sequence
model organisms, technology has rapidly evolved reducing the limitations of these
initial efforts. The cost of a human genome sequence decreased 100-fold from the
original estimated over a billion pounds by the end of the Human Genome Project
in 2008 [177], with improvements to the traditional Sanger sequencing. Nowadays,
the cost of a raw sequencing method is less than £2,000 [168] with high throughput
sequencing (HTS) platforms.
Most modern HTS platforms follow a pipeline "template preparation, clonal
amplification, followed by cyclical rounds of massively parallel sequencing. The
specific strategy employed by each platform determines the quality, quantity and
biases of the resulting sequence data and the platform’s usefulness for particular
applications."[168]. We can roughly classify the HTS platforms according to the
technology, inputs and outputs. The popular Illumina analyzers amplify DNA
fragments on the surface of a glass slide, and sequences based on fluorescent base
incorporation, while ThermoFischer’s Ion Torrent analyses the changes pH as the
DNA is extended to sequence the incorporated bases. After the genome of a species is
already characterised, individuals can be sequenced to analyse particular phenotypes.
According to the focus, studies range from small scale gene panels or biomarkers, to
Whole Exome Sequencing (WES), which target the protein coding regions (about 2%
of the genome), and Whole Genome Sequencing (WGS) as the most comprehensive
studies.
The availability of many sequenced individuals has helped the study of genetic
diseases. The traditional linkage studies became a powerful tool for diseases depen-
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dant on high penetration alleles, more so when the parents and the offspring with the
phenotype could be sequenced. The traditional linkage studies were further extended
to Quantitative Trait Loci mapping which can detect interactions between loci of
different chromosomes. While these linkage studies largely failed to detect multi-
factorial and heterogeneous diseases, Genome Wide Association Studies (GWAS),
which work on logistic regressions allow low penetration alleles to be discovered,
however they generally require a much larger amount of samples.
Although the highly praised GWAS greatly advanced our understanding about
some complex diseases such as diabetes, to which it contributed in almost 20 signifi-
cant loci, they failed to deliver the characterisation of complex diseases it originally
intended. Most of single nucleotide polymorphisms (SNPs) do not largely effect the
overall probability of a disease, and their contribution is not detectable in GWAS.
GWAS rely on the linkage disequilibrium principle [209] (the same used in linkage
analysis), which can only identify loci to be strongly correlated to a phenotype
[149]. Moreover, most of the genetic variation showed by the population cannot be
interpreted just through GWAS, which is estimated to account for 20%, and up to
50% in the best cases, when all SNPs are considered together [209].
Network based methods came as an alternative to GWAS studies to explain
diseases after modelling the cell biology.
1.4 Modelling the information
From a network medicine point of view, cellular components and their interactions
are seen like networks or graphs, where the cellular entities are the nodes and the
interactions edges. Commonly studied cellular networks are: protein-protein interac-
tion networks (PPI), where the nodes are proteins and edges represent their physical
interaction, metabolic networks, where nodes are metabolites and edges indicate
their participation in a common biochemical reaction (also known as pathways), reg-
ulatory networks, where a directed edge represents a regulatory relationship between
a transcription factor and a gene and RNA networks, where nodes can be microRNAs
or interfering RNAs linked to each other (RNA-RNA edges) or to DNA (RNA-DNA
edges) [9].
Manually curated databases are available, and serve to guide disease gene re-
search. The OMIM website provides known disease and gene mappings [125]. The
Gene Ontology (GO) provides an ontology of gene functions, and association files
to map genes of different organisms into the ontology [7]. Probably human PPIs
have the largest amount of different manually curated databases, such as the Münich
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Information Center for Protein Sequence (MIPS), protein interaction database, the
Biomolecular Interaction Network Database (BIND), the Database of Interacting Pro-
teins (DIP), the Molecular Interaction database (MINT),and the protein Interaction
database (IntAct), the Biological General Repository for Interaction Datasets (Bi-
oGRID) and the Human Protein Reference Database (HPRD), the Human Integrated
Protein-Protein Interaction rEference (Hippie), among others [9, 175]. The Kyoto
Encyclopedia of Genes and Genomes (KEGG) is the main referral for metabolic net-
works, but the Biochemical Genetic and Genomics (BIGG), the Human Metabolome
Database (HMDB) and Reactome also are commonly used databases [9, 220, 33].
Regulatory networks are available through the Universal Protein Binding Microarray
Resource for Oligonucleotide Binding Evaluation (UniPROBE) and JASPAR, but
this type of networks are considered to still be the most incomplete [9]. Some
microRNA-gene networks are available in databases such as TargetScan, PicTar,
microRNA, miRBase and miRDB [9].
Biological networks present some interesting topological properties that reveal
organizing principles, which are thought to stem from evolutionary reasons. The
following are some of the main properties common to most biological networks:
• Scale-free distribution: the edge degree distribution of PPIs and metabolic
networks follow a power-law, defined as P(k) k−γ , where k is the edge degree
and γ is the degree exponent of the network. A consequence of this distribution
is the existence of hubs (highly connected nodes) that dominate the structure
of the network. This is known as the Barabasi-Albert model, which became
the standard PPI model, over the random Erdös-Renyi model [5].
• Small-world: the longest path between any two nodes in the networks is
relatively short (i.e. a protein is only a few interactions of any other protein
in a PPI) [215]. This effect can be seen as a consequence of the degree
distribution of PPIs. The main visible consequence, in a biological sense, is
that the perturbation in any node can affect its entire neighbourhood, which in
turn may affect the behaviour of the overall network [10].
• Modules and network bridges: a high degree of modularity is present in most
of the networks; areas around hubs are likely to be highly connected. Although
most modules are highly overlapping, some low degree nodes connect big
modular regions – i.e. the network bridges [62, 197].
• Motifs: particular small network subgraphs are observed to be under or over
represented in biological networks. These subgraphs are likely to be associated
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highly specialized functions, such as negative feedback loops or biological
oscillators [10].
• Guilt-by-association: interacting genes are likely to perform a similar function.
These interactions usually imply that the interactive proteins participate in
common cellular functions, as they are part of common pathways, or form
compounds [145].
A great amount of computational methods in network medicine derive from the
application of the guilt-by-association principle taking into account the topological
properties of the biological networks. Some notable applications are described in
Section 2.4.
An approach to use the network motifs, is to transform the PPI network into
a network of small subgraphs (graphlets), and analyse their distribution and con-
nections. Geometric random graphs [153] were shown to be good models for the
graphlet distribution in eukaryotic PPI networks [163], and graphlet networks can be
used to discover motifs associated with biological processes, and network functions
[132].
However, most computational methods utilise machine learning to exploit the
network structure in different applications, such as gene function [136, 184], protein
complexes [2, 140], or disease genes [148, 206, 186]. Relevant machine learning
methods and their relation to disease gene prediction are presented in Chapter 2.
1.5 Contextualising the network medicine paradigm
A thorough understanding of the genetic characteristics and their implications for
human traits and conditions is far from simple. Millions of variations occur naturally
in the human genome and are responsible for many phenotypes, such as physical
traits, drug response or disease [142]. Despite many of these notions are generally
understood, a precise definition may be impossible to accommodate all the required
biological facts. Furthermore, these concepts need to be set in the context of network
medicine to follow the paradigm of this work.
The human genome is a complex structure that presents a noticeable heterogeneity
when comparing individuals. The most common variation consists in the mutation
a single nucleotide, roughly every 300 nucleotides – i.e. humans are expected to
have 10 million single nucleotide polymorphisms (SNPs) [69]. While SNPs occur in
coding and non-coding regions of the genome, observable phenotypes are generally
associated only to SNPs within genes or regulatory regions of the genome [69].
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Fig. 1.1 A disease module in an interactome. The nodes in the network represent
genes (or proteins), and the edges represent interactions between these genes. The
most common type of interactomes used in the area are protein-protein interaction
networks, which are connected by edges if they physically interact. A known disease
gene is coloured and the perturbed area in the network affected by the variant is
highlighted – the disease module.
Variant forms of a gene that appear with a significant frequency on the population
(i.e. 1%) are known as alleles, and may include multiple SNPs. It is important to
notice that some alleles are expected to produce the same trait, and only a fraction of
the known traits represent deleterious mutations [102].
Although a medically correct definition for disease is a complicated affair, the
general notion will suffice for the understanding of this work. Without technicality, a
disease is a disorder with specific characteristics which produces a negative impact
in an organism. As the focus of this work is on genetic diseases, the term disease
will not include illnesses produced by external factors, such as bacteria or viruses,
unless specifically stated. Note that with this notion, the term disease is used as a
generic label which also includes genetic syndromes and phenotypes.
Simple genetic diseases are known to be caused by a single gene with a mutation.
Complex diseases include multiple mutations and potentially different combinations
of these mutations [63], and the onset of some complex diseases are known to
require one of several combinations of low penetration mutations [63]. Furthermore,
environmental factors may also play a role for the onset and development of a
disease [37]. Taking into account all these confounding issues, in many cases it is
still impossible to determine the exact combination of factors that cause complex
diseases. This work uses a common denomination, in which a disease gene is the
cause of a single gene disorder or a high penetration mutation for a complex disease.
Regardless of their number, disease genes rarely act in isolation. A disease
module can be described as all genes and proteins affected during the disease
process. From a network medicine paradigm, where the expected functions in an
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organism are represented by standard biological networks, diseases are seen as
perturbations in a network. The areas affected by the perturbations are known as the
disease modules. However, the literature is far from a universal consensus about the
definition of disease module (or what means for a gene to be involved with a disease).
For instance, publications from the well known Barabasi group uses the network
medicine interpretation [10, 9], or may refer to the known molecular basis as the
disease module [127], or resort to the accumulation of genes known to be associated
to similar phenotypes [55] to capture a more comprehensive module. The molecular
basis interpretation appears to be aligned with a more frequent approach for wet-
lab publications, which build modules by collecting differentially expressed genes
[39, 44, 166]. Additionally, publications about complex diseases might consider
the module as the collection driver and statistically significant passenger mutations
[63, 51]. This work allows the concept of disease module to the wider comprehension
of the term.
Following the network medicine paradigm, we can see that disease modules
describe the disease genotype, and correlate with topological modules in the network
[55]. Therefore, computational methods quantify distances within a machine learning
approach to prioritise candidate disease genes according to their closeness to known
disease genes. For example, Oti et al. [148] use direct neighbours, Köhler et al. [90]
use random walkers with restart, and Navlakha et al. [139] include propagation flow
and clustering techniques. Other types of data are also informative of the location
of disease genes such as phenotype, gene expression, gene ontology, metabolic
pathways, and for this reason have been included in different methods. One group of
methods integrates the data into a unique graph that is then used for the prediction.
Lage et al. [99] include disease phenotype in the form of clinical features extracted
by text mining from scientific papers; Wu et al. [222] create binary networks where
nodes represent genes, and these are connected when their BLAST [6] E-value is
higher than a predefined threshold; Chen et al. [25] include information from the
Gene Ontology, the Mammalian Phenotype [188] and various types of pathway
annotations; Li et al. [107], Vanunu et al. [206] and Mordelet et al. [135] include
the van Driel disease similarity information [205] to enhance the network; and other
authors use heterogeneous networks where nodes can be either diseases or genes –
Xie et al. [223] connect the nodes with OMIM and MGI mouse phenotype- gene
associations [45], and Zeng et al. [231] use HeteSim scores [185]. Another group
of methods carries out inferences for each different type of data separately, and
then integrate the results. In particular, Aerts et al. [3] use co- expression networks,
metabolic pathways, Gene Ontology, among others; Franke et al. [50] include the
Gene Ontology and co- expression networks; Radivojac et al. [165] use the Gene
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Ontology, the Disease Ontology [179], and features based on protein sequence; Karni
et al. [83] use disease based co-expression networks; and George et al. [54] use
metabolic pathways and Pfams [13].
1.6 Contributions
• It presents a state-of-the-art network-based disease gene prediction method,
named Cardigan, which is shown to outperform various state-of-the-art meth-
ods. Cardigan allows the prediction of genes for both molecularly unchar-
acterised and molecularly characterised diseases, through the addition of
plausible genes obtained by disease phenotype analysis. Notably, tying the pre-
diction to the inclusion of a phenotype similarity does not reduce the coverage
of the predictable diseases from the OMIM database.
• It presents a novel exploratory analysis about the usage of graphs of protein
interfaces for the prediction of disease genes. The approach presents a new
diffusion method, and a procedure to assemble the protein interface graph
from a state-of-the-art database of inferred protein interactions at residue level.
This exploratory analysis is, to the best of my knowledge, the first network
medicine application to use a protein interface graph. The usage a protein
interface graph appears to be a promising source of information for disease
gene prediction methods.
• It provides a further insight in the complex relation between disease modules
and the guilt-by-association principle. Disease phenotype similarity appears to
capture additional features than protein function which allows the prediction of
common genotype. Additionally, it shows that while drug targets are diverse,
etiological drugs form modules which can help in the characterisation of
disease modules.
• It presents a procedure to assemble a heterogeneous interactome that combines
protein-protein interaction networks from different organisms, which shows
utility for the analysis of experiments on model organisms in the context
of human genetics. This proposal also shows applications as a simple edge
completion technique.
• It presents several computational techniques used in collaborative projects
which contain wet lab components. The first project is analysis of viral induced
lymphoid malignancies on mice, which yields candidate genes for the disease.
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Here, it describes the usage of entropy of mutation clonality for the classifica-
tion of tumour stage. The second project presents a computational pipeline
to predict drug cocktails for Chagas disease. This shows the production of a
putative drug set by homology-based and machine learning approaches, and
the assembly of drug cocktails by a multi-objective approach.
1.7 Structure of the book
Chapter 2 presents an overview of the machine learning approach to computational
biology. In particular, it develops deeper into the semi supervised learning paradigm
on graphs and its application to modern biological problems, such as protein function
prediction, phenotype characterisation and disease gene prediction.
Chapter 3 presents the state-of-the-art disease gene prediction methods, and
discusses current strengths and weaknesses of the competing approaches.
Chapter 4 describes the experiments, evaluation procedures and datasets used for
the validation of the different methods presented in this work.
The following three Chapters (5, 6 and 7) are the core contributions of this work,
and present a sequence of intrinsically connected methods for the characterisation of
disease. Ordinal (Chapter 5) describes a method to identify disease modules based
exclusively on disease phenotype data, and sets the basis for a prediction method
which includes a network component to the procedure. Then, Cardigan (Chapter
6) presents a semi supervised disease gene prediction method, which incorporates
phenotypic information to predict uncharted diseases on standard interactomes.
Finally, an extension of Cardigan (Chapter 7) is presented as an exploratory analysis
to improve Cardigan’s performance by exploiting a network with interfaces, built
from a state-of-the-art database of inferred protein interface interactions. This
Chapter also presents a theoretical framework for label diffusion on networks with
interfaces.
Chapter 8 presents a compilation of additional research I have done related to dis-
ease characterisation. The Lymphomagenesis and Chagas projects are collaborations
with other research groups. The analysis on the Human-Mouse interactome and the
drug module analysis stem from these projects. LanDis is a web based application
used to visualise and explore a disease landscape established by phenotype similarity.
Chapter 9 discusses the overarching contributions of this work on the field of
computational biology and machine learning. Notice that Chapters 3, 5, 6 and 7
include discussions about their particular topics to preserve the context.
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Chapter 10 presents an application in development derived from Cardigan, and
interesting additional projects that appear to be viable follow ups of Cardigan and
the usage of protein interface networks.
Appendix A is a manual to use the Cardigan software. Cardigan is given as
a library for Python 2.7, and the manual includes code snippets to produce the
experiments used in this work. Appendix B provides categorical and identifier
mappings produced for particular applications presented in this work.
Chapter 2
Learning with biological networks
This Chapter intends to contextualise the network medicine approach of disease
gene prediction within machine learning, and present some of the main learning
techniques used in state-of-the-art disease gene prediction methods.
First, Section 2.1 presents an overview of Machine Learning methods and
presents some benefits of graph methods (i.e. network medicine methods) when
compared to other approaches. Then, Section 2.2 explores the production of PPI
networks, which in turn becomes the main biological network used in this work.
Thereupon, Section 2.2 introduces the rich history of graph theory and adds support
to the usage of graphs as prime data structures for machine learning. It also presents
the intuition and the essential formulation of two widespread approaches: graph
diffusion and Support Vector Machines (SVMs).
Additionally, Section 2.4 shows that network medicine methods are relevant for
several biological applications, such as the identification of protein complexes [140],
drivers for drug response [40], network architectures [65, 119], disease genes [213],
and genome annotation [228, 79].
2.1 Fundamentals of learning
A holistic description of a machine learning can be thought as any type of algo-
rithm related to artificial intelligence: cognitive simulation, expert systems, model
generation, knowledge representation, among others [131]. However, as this work
focuses on data analysis, only methods focused on predictions of “hidden” informa-
tion are considered. These methods can be thought of as mathematical models to
unveil regularities from the data [14]. Common applications are data classification,
dimensionality reduction, regression and modelling [182].
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The mathematical representation of the available data is an input vector, and the
outcome of the method is an output vector [182]. Usually, these methods require a
separation of the data to avoid biases in the predictions. Data used for the construction
of the model is known as training, while the data used for the validation is known as
test.
A helpful way to analyse machine learning approaches is to divide them according
to the training data available. This division is not trivial, as the type of data available
also determines the possible applications for the learning procedure. The main
difference stands from the availability of the expected outputs for particular inputs,
known as targets:
• Supervised Learning: input vectors and target vectors are available in the
training and testing sets. This situation can be understood as the search for a
translation function between these sets. Classification and regression are the
traditional applications for supervised learning: when the input vector is being
translated to a discrete category, the problem is known as classification; when
the output is translated to some continuous range, the problem is known as
regression [14].
• Unsupervised Learning: the training and testing sets contain no known tar-
gets for any input. As less information is available, under these circumstances
the applications are traditionally designed to uncover the structure of the data.
Common applications are clustering, visualisation and modelling: clustering
applications characterise the data by segregating inputs into groups of simi-
lar elements [14]; dimensionality reduction problems produce projections of
high-dimensionality data onto low-dimensionality spaces, traditionally for data
visualisation or as a pre-process for further learning [14]; modelling problems
search for a generative method to produce elements which fit the distribution
of the input set, for instance as a density estimation [182].
• Semi-supervised Learning: some of the input vectors have target vectors
associated, while most of the input vectors have none. Applications for semi-
supervised learning methods are shared with supervised or unsupervised learn-
ing through extensions to account for the diversity in the data. Common
applications are semi-supervised clustering and semi-supervised classification.
Semi-supervised clustering is basically a boost for unsupervised clustering
algorithms which includes known examples of some clusters. While most clus-
tering problems do not favour a particular type of learning, anomaly detection
has a prominent semi-supervised clustering approach [22]. Semi-supervised
2.2 Assembly of interactomes 39
classification fundamentally changes the supervised approach, as missing
targets must be accounted for. For this reason this application derived into
several subdivisions [237]: generative models when the input is generated by
an identifiable mixture model, self training when the classifier uses its own
predictions to train itself, co-training and multiview learning when multiple
classifiers are used and they cross train other classifiers, avoiding changes in
dense regions when the input data can be kept in a space where regions of
different density can be appreciated.
The production of datasets inherently comes with a cost, while in many contexts
the acquisition of unlabelled data is cheap, inputs with known targets are generally
scarce [182]. The production of targets can be particularly difficult for computational
medicine datasets, such as disease development, rare trait expression, drug response
or survival rates. For this reason, semi-supervised methods are of particular interest
in this area.
An orthogonal classification for learning discerns when method performs an
inference by building a model, known as induction, or when the inference is per-
formed in a case by case basis for the unlabelled data, or transduction [53]. While
the learning methods can be inductive regardless of the availability of known targets,
the transductive approach is inherent to semi-supervised learning; in particular, many
graph based methods have a natural transductive inference [23]. Note that graph
based methods are not exclusive to a particular type of learning procedure; the name
only implies the usage of data which holds a graph structure. However, if the problem
domain holds the guilt-by-association principle, a manipulation of local and global
properties of the manifold can produce effective propagations of inferences within
the unlabelled data [235].
This work considers the task of predicting disease genes as a semi-supervised
problem using a graph based method. The prediction is given as a ranking of all
genes within a PPI network, where a missing gene is meant to be ranked as high as
possible.
2.2 Assembly of interactomes
Modern PPI networks usually come from the curation of high-throughput techniques,
such as yeast two-hybrid (Y2H) and co-affinity purification followed by mass spec-
trometry (AP-MS). These experiments produce a confidence value for the interaction
between pair of proteins, which usually needs a further processing to obtain the high
quality interactions [202, 95, 192, 171, 161, 28]. As the results of these experiments
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are intrinsically noisy, networks rendered by simple thresholding are too sparse or
of low quality. Studies show that Y2H screens yield false negative rates of 43-71%
and false positive rates of 64% [42]. AP-MS screens somewhat improve on the false
negative rates, which range between 15-50%, however, false positive rates range
between 63-77% [67].
In order to decrease these error rates, computational techniques were used to
clean the resulting data based on expected properties of PPIs [115, 64, 28]. Addi-
tional techniques developed generative models to improve the classification errors
(i.e. reduce the false positive and false negative ratios) of interactions based on
experimental data [229, 96]. For instance, some improved the association errors by
using Bayesian classifiers [115, 28], Gene Ontology annotations [118], topological
features [229], and random graph models [162, 96].
High quality PPIs are frequently aggregated into protein-protein collections for
different organisms in publicly available databases [160, 24, 175, 195, 178]. These
databases are provided by different groups with their own curation standards; they
provide different information under many formats [233]. For instance, they may
include binary or weighted edges, overlapping data, conflicting identifiers, and
various evidence types. In weighted networks the links between two proteins are
labelled with a weight whose value is related to the probability of the interaction.
In binary networks, links are not labelled and a link is either present or missing
(denoting the existence or the lack of interaction). Moreover, interaction data can be
experimental or predicted.
2.3 Graphs and learning
The origins of graph theory take place hundreds of years before the development
of machine learning. This provides a rich theoretical background and a wide set
of mathematical properties which become exploitable within the machine learning
paradigm.
Early problems of graph theory can be dated to Euclidean geometry and are
intrinsically related to combinatorial problems. It was not until Euler’s analysis
of the Königsberg bridges that the geometric component of the problem took a
second place in favour of the node degree analysis [218]. While graphs became
more complex in the representation of topological properties of higher dimensional
geometry, chemical bonds and map colouring, the analysis of Hamiltonian paths can
be seen to settle the link between topology and graph theory [60]. Graphs were also
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linked to algebraic theory initially by Kirchhoff [218], extending its use to many
areas in mathematics.
The concept of graphs is rather simple to understand, as they are composed by
a set of nodes and the connections between those nodes. However, they are useful
in many contexts due to their flexibility to encode information within a meaningful
structure. Common graphs examples are road maps which in different scales connect
houses, cities and countries; atoms connected by bonds; houses connected in tree like
structures to local electricity distribution systems, then to city, and even nation wide
providers; cellular components connected by different interactions; people connected
by social relations; web pages connected by hyperlinks; among others. Graphs
can also be designed to convey knowledge in the form of ontologies, for instance
the taxonomical classification of species, categorisation of medical information,
language semantics, and others. Graph data can be rich and complex, and there is
no universal method of analysis. Nodes and edges may be heterogeneous, and the
expected output of the process is tied to the nature of the data at hand. This derived in
the development of machine learning approaches suitable for different applications.
Among the many approaches, Graph Diffusion and Support Vector Machines
are presented as they are the core for several reference disease gene prediction
methods. Interestingly, both approaches derive in the usage of Kernels [14] by
different constructions.
2.3.1 Graph diffusion
The main idea behind graph diffusion is that some nodes contain a value which must
be passed to its neighbours, and is an analogy of the a physical diffusion process.
The original formulation of a diffusion process comes from Fick’s laws [47]. The
first law states that the flux J is proportional to the negative of the concentration
gradient:
J =−D∇c,
where D is a diffusion coefficient, and c is the concentration. The second law states
that the rate of change of concentration is proportional to the second derivative of
the concentration:
∂c
∂ t
= D∇2c, (2.1)
where t is the time variable and ∇2 is the Laplace operator or Laplacian. Equation
2.1 has the same formulation as the well known Heat equation by swapping the
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concentration c by heat f , and the diffusion coefficient D for thermal diffusivity α:
∂ f
∂ t
= α∇2 f . (2.2)
Then, setting the heat as a function of the position f (x) within an m dimensional
object, gives the extended notation for the Laplacian:
∇2 f (x) =
∂ 2 f (x)
∂ 2x1
+ · · ·+ ∂
2 f (x)
∂ 2xm
. (2.3)
The following transformation is made to account for the discrete nature of the
graphs. Taking m = 1 yields a 1-dimensional object, where the finite element
approximation of the Laplacian is:
∇2 f (x) = f ′′(x)≈ f (x+∆x)−2 f (x)+ f (x−∆x)
(∆x)2
. (2.4)
Considering a uniform basis ∆x = h, points f (xi) = fi are f1, . . . fn, with f (xi+h) =
fi+1. Then, the Laplacian over the entire object is:
∇2 =−
n
∑
i=1
2 fi− fi−1− fi+1
h2
. (2.5)
Finally, this sum can be understood as the addition of vectors [−1 2 −1 ] centred
on i, this is:
∇2<i> =−
1
h2 ∑a∈Ω−∂Ω
[
−1 2 −1
]
, (2.6)
where ∇2<i> is a sub-vector of 3 components centred in i, and Ω−∂Ω represents the
interior of the object. The coefficients from the finite elements Laplacian inside the
sum can be rearranged in a matrix LFE as:
LFE =

1 −1 0 · · · 0 0
−1 2 −1 · · · 0 0
0 −1 2 · · · 0 0
...
...
... . . .
...
...
0 0 0 · · · 2 −1
0 0 0 · · · −1 1

. (2.7)
The analogy follows by considering the adjacent finite elements as the nodes in
a graph. The ensuing formulation is given for an unweighted graph for the sake of
simplicity, however the results are valid if the adjacency matrix A is changed for a
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weighted matrix W . Given an unweighted graph G = ⟨V,E⟩ the graph Laplacian L
(a matrix size n×n), is produced by the addition of matrices:
L[i j] = ∑
(i, j)∈E
[
1 −1
−1 1
]
, (2.8)
where L[i j] represents the 2× 2 sub-matrix of rows and columns i and j. This
definition is equivalent to the traditional formulation of the graph Laplacian given
as the construction L = D−A, where the degree matrix D is diagonal of size n×n,
with non-zero elements:
Dii =
n
∑
j=1
Ai j, (2.9)
and A is the adjacency matrix of graph G of size n×n.
The graph Laplacian can be used as a quadratic operator yT Ly to produce:
yT Ly =
n
∑
i=1
n
∑
j=1
Ai j(yi− y j)2, (2.10)
where y is a vector of n components. An intuition behind this solution is given by
comparing Equations 2.8 and 2.10, where the sums correspond to the same elements.
Notice that Ai j = 0 if there is no edge between nodes i and j. While not identical,
Equations 2.5 and 2.10 represent the flux density of the diffusion process.
The graph Laplacian can be also given in a normalised form Lsym =D−1/2LD−1/2,
where the elements are:
Lsymi j =

1 if i = j
−Ai j√
DiiD j j
otherwise
, (2.11)
and is used as the following quadratic operator:
yyLsymy =
n
∑
i=1
n
∑
j=1
Ai j
(
yi√
Dii
− y j√
D j j
)2
. (2.12)
These quadratic forms (Equations 2.10 and 2.12) can used as cost functions which
have a global optimum, and serve to produce label diffusions in graphs since the
matrices can be inverted [27].
Naturally, the graph Laplacian is not used for all diffusion methods. However, it
suffices to consider the quadratic forms as Kernels to see similarities between multi-
ple methods. The usage of Positive Definite kernels is widespread [136, 184, 206] as
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they produce invertible matrices. Other common graph propagation approaches are
exponential Kernels, tensor products, Gaussian Processes and random walks [92].
2.3.2 Support Vector Machines
The basic support vector machine (SVM) is a supervised learning method to classify
positive and negative elements. The main idea is to produce a hyperplane that
divides the hyperspace into the positive and the negative subspaces, and the ideal
hyperplane is the one that leaves the widest gap between the known positive and
negative examples – i.e. SVMs are maximum margin classifiers [14]. Formally, an n
dimensional hyperplane H is characterised by a real vector w of n components and a
real constant d, and is defined by all real points x in an n dimensional space such
that:
w · x+d = 0.
The geometrical interpretation is that all lines in H are orthogonal to w.
Ideally, this hyperplane H will separate the positive samples x+ from the negative
samples x− in different subspaces – i.e. x+ ·w+ d > 0 and x− ·w+ d < 0. The
hyperplane H that separates positive and negatives samples with the largest margin
is calculated by solving:
minimise ∥w∥
s.t. yi(w · xi+d)≥ 1
,
where yi is 1 if xi is a positive label, and -1 otherwise. This formulation can be solved
by calculating the Lagrangian and equating to zero [191]. The Lagrangian is:
L = ∥w∥−
n
∑
i=1
λi(yi(w · xi+d)−1),
where n is the number of samples, and λi are the Lagrange multipliers. The derivative
is zero when:
w =
n
∑
i=1
λiyixi and
n
∑
i=1
λiyi = 0.
This gives the dual formulation of the SVM:
minimise
n
∑
i=1
λi− 14
n
∑
i, j=1
λiλ jyiy j(xi · x j)
s.t. λi ≥ 0 and
n
∑
i=1
λiyi = 0
.
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While many extensions allow SVMs to handle multiclass classification, soft
separability constraints and the ability to work with unlabelled data [23], the most
notable contribution is the kernel trick [68]. The kernel trick produces a high
dimensional embedding of points xi, which can be separable when in the original
space they are not. The kernel formulation is trivial on the dual problem, in that it
replaces the dot product (xi · x j) with a kernel K(xi,x j).
2.4 Biological Applications
Network medicine approaches have been developed for many biological applications
which shows their versatility and power. The following list of applications is not
exhaustive, but serves to portray diverse scenarios where network medicine are
applied.
Notice that the list does not include Disease Gene Prediction, the main application
discussed in this work, as it is presented at length on Chapter 3.
Protein Function Prediction
The need of protein function prediction methods comes from the exponentially in-
creasing gap between the amount of sequenced proteins, and the amount of annotated
proteins [168]. In practice, computational methods produce a putative set of Gene
Ontology terms which is used to define the protein function. Among the three Gene
Ontology categories, Molecular Function and Biological Process are regarded to be
of particular interest [164].
These annotations would ideally come in the most specific terms of the ontology
to provide the maximum amount of information about a protein. The hierarchical
nature of the ontology allows the propagation of a annotation to all its ancestors
through the is_a or part_of associations.
Following the results of the critical assessment of functional annotation (CAFA)
competitions [79, 164], the usage of simple sequence similarity or shared domains
has proven insufficient to transfer functional annotations. The integration of multiple
alignments through machine learning techniques such as SVMs proved to increase
the prediction accuracy. The CAFA results show that no method is superior in
all function prediction categories, and similar types of prediction methods lead
to somewhat similar results (roughly speaking sequence based methods discover
a cluster of functions, while PPI based methods discover another cluster). This
suggests that ensemble approaches, which integrate high quality predictions, may
benefit by including predictions of different method types [79].
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Discovery of network architectures
In addition to protein function, the identification of protein-protein interactions and
pathways are essential to characterise an organism. The prediction of these network
architectures allows the study of the growing amount of newly sequenced organisms,
and serves to guide experimental trials for interaction discovery [123].
It is easy to understand the benefit of the identification of missing protein protein
interactions if only for the sake of network based methods, as it forms the basis of
the multiple methods with biological applications. This problem can also be seen as
graph edge completion, and has seen benefits from integration of annotations across
different species [28, 195], Bayesian classifiers [115], GO annotations [118] and
random graph models [96].
Additional techniques are used to infer dynamical biological networks, such as
transcriptomic networks, or signalling and metabolic pathways. An edge between a
pair of interactors can be inferred from an homologous pair of interacting proteins
(an interolog) observed in another species [123], nodes for transcriptomic networks
are identified from the genome by hidden Markov models [41] and quantification
of RNA-Seq (Cufflinks algorithm) [200], and ensemble of expert predictions on
different benchmark sets [119]. Similar approaches are used for pathway predic-
tion, which are based on exhaustive extraction of biological features and ensemble
prediction [35].
Protein Complex Prediction
The protein complexes are seen as dense connected components in a PPI network.
However, PPI networks are incomplete [178], and sets of proteins from dense
topological modules in these networks frequently only share a fraction of their
functions [140]. This can be expected as proteins from the same topological module
can part of more than one complex, or be involved in different biological processes
[140]. Therefore, the identification of protein complexes can be seen as a process
to cluster possibly overlapping groups of proteins with significant connectivity and
with coherent function.
Network method approaches for the identification of protein complexes differ in
the process used to collect sets of proteins, the measure to quantify the connectivity
of the putative complex, and the usage of data other than PPI for further validation
[190].
Based on the analysis by Srihari et al. [190], protein complex prediction methods
can be classified in two main groups: those solely based on PPI topology, and
those which use additional biological data. Some network clustering approaches
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are: Markov clustering (MCL) based on random walkers [204], Clustering based
on Maximal Cliques (CMC) based on iterative merges up to reliability threshold
[112], Clustering with Overlapping Neighbourhood Expansion (ClusterONE) based
on greedy neighbourhood expansion and a customised cohesiveness measure which
accounts for missing PPIs [140], and Hierarchical Agglomerative Clustering with
Overlaps (HACO) based on non unique merges of hierarchical clusters to allow
complexes to overlap [211]. Some methods that use additional data are: COre
AttaCHment (COACH) based on producing a small and topologically compact set of
proteins that provide core function for the complexes, which are rounded up with
proteins that interact with at least half of the core; and Restricted Neighbourhood
Search Clustering (RNSC) which trades proteins within putative complexes until a
cost function is minimised, and filters the resulting complexes based on functional
coherence [89].
Characterisation of drug response
The characterisation of drug response is a rich topic and has many further applications
in drug design and repositioning. The identification of drug targets can be seen as
the starting point to discover a mechanism of action, which often involves metabolic
pathways, signalling and transcriptomic networks [174, 176].
Computational inference of drug targets is an alternative approach to large scale
component screening, aimed to lower the cost of drug discovery. Studies estimate
that Pharmaceutical companies spent £ 2,000 million in 2014 for screening-based
discovery, which shows an upward trend from the £ 620 million estimated in 2003
[137]. These costs can be lowered further by drug repositioning, which comes with
the added benefit of identifying drugs that are approved and have cleared clinical
trials.
Some approaches are devoted to produce more adequate networks, such as the
integration of drug-gene interactions in various biological networks [105, 74, 227],
or creation of drug-disease networks [75]. Several methods predict drug response by
annotating drug features such as chemical properties, structure, molecular targets,
derived gene expression and variants in the effected genotype, with neural networks
and random forests [128], logistic regression [59] or integrating them to produce
SVM kernels [138, 214]. Other computational methods select candidate genes for
drug repositioning by clustering heterogeneous drug-disease networks [221], using
Bayesian regression on drug off-target effects [80], or by minimising the loss function
in a drug-disease network assembled from several drug similarity matrices and
disease similarity matrices [234]. While each method presents particular advantages
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and limitations, integrative approaches [59, 214] seem to improve the performance
in the prediction of drug-disease associations [106].
Quantification of disease similarity
Throughout human history, medicine has focused on the diagnosis, treatment and
prevention of illness and disease. Modern computerised medical support systems
exploit disease phenotype information and aid the efforts of medical doctors through
personalised patient recommendations, automated differential diagnosis, and other
applications [86].
The characterisation of disease phenotypes involves a massive amount hetero-
geneous information collected with little standardisation. However, there are some
reference resources that curate this knowledge, for instance some ontologies are
used as de facto annotation standards for medical vocabulary (MeSH [143]) or gene
functions (GO [7]), and others provide catalogues of human genetic disorders (e.g.
OMIM [125] and UNIPROT [31]).
Multiple computational methods for diverse biological applications use disease
data in the form of a disease similarity, which becomes an application on its own.
Disease similarity methods score disease relatedness based on phenotype or molecu-
lar properties. Phenotype approaches mine MeSH terms and annotate diseases on
the MeSH ontology and quantify the similarity based on multiple ontology measures
[20, 91, 205]. Molecular approaches derive the similarity from likelihood of co-
localisation of disease genes [151], and the function similarity of the disease genes
[122].
Further sections reference two main phenotypic disease similarity measures: one
by van Driel et al. [205] used in methods by other authors, and one by Caniza
et al. [20] used in my methods. van Driel et al. initially model a disease with
a vector of MeSH term frequencies, which contains the count of terms from the
disease descriptions found in OMIM. The count vector is then transformed in a
refinement step so that close terms in the MeSH ontology can share their counts
(e.g. a child term will contribute to the counts of its parents). Each term is further
scaled by the inverse frequency of each term in the disease description corpus (this
enhances the contribution of the infrequent terms). The similarity between diseases
is computed by the cosine similarity between their refined vectors. The Caniza
similarity is based on the the Resnik similarity [167] between the sets of MeSH
terms found in publications associated to each disease in OMIM (more details on
Section 4.3.3). The Caniza similarity was chosen for this work as it showed to
correlate the closeness between disease genotypes and phenotypes better than several
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well established semantic similarities. The comparison [20] evaluated proposals by
Jiang and Conrath [78], Lin [110], Pesquita [154], and van Driel [205]. Notice also
that the van Driel similarity is a fixed matrix with 5,080 diseases (from the 2005
OMIM release), while the Caniza similarity provides an algorithm to calculate the
similarity between all diseases found in any OMIM release.

Chapter 3
Literature review on disease gene
prediction methods
Network medicine methods have been the state-of-the-art approaches for the compu-
tational prediction of disease genes. A key component of these methods is the usage
of the guilt-by-association principle to find prospective genes: the new candidates
are located close to known genes in an interactome.
This Chapter presents a review of the reference disease gene prediction methods
and discusses the notable features and possible drawbacks of the approaches.
3.1 Endeavour
Endeavour is an ensemble method which combines independent inductive models
given for multiple data sources into a single aggregated prediction. Each data source
provides its own information (i.e. the known genes depend on the source), which
is used to produce each prioritisation model. Then, the models are used to produce
gene rankings, which are finally integrated by using Order Statistics [199]. Notice
that Endeavour is not a network based method, however, it includes a data source
integration approach, which makes it interesting to study.
Endeavour predicts genes by training the initial models with a set of genes of
interest, and then evaluates other sets of genes according to how well they match the
trained models. There is one model produced per data source, which requires indepen-
dent training. ENDEAVOUR considers two big types of data sources: attribute-based,
vector-based, and then has a some data sources with particular treatment.
Attribute-based: each data source produces a set of labels for any given set of
genes. The training consists in the selection of overrepresented labels L1, . . . ,Lk for
the training gene set according to Fisher’s Omnibus Meta analysis. Gene sets are
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evaluated independently for each label Li and is ranked according to the resulting
Fisher’s Omnibus Meta analysis. The used sources are the Gene Ontology [7], EST
expression [187], InterPro [230] and KEGG [82].
Vector-based: each data source produces a vector for any given set of genes. The
training consists in producing the vector V for the training gene set. The evaluation
consists in the Pearson correlation between vector V and the vector for the gene
set. The vector-based sources are literature abstracts mined for GO terms using
IDF profiles [172], microarray expression data or TRANSFAC weight matrices for
cis-regulatory motif predictions [124].
BLAST [6] evaluates a test set by the lowest e-value produced when compared to
the train set. BIND [8] evaluates the Jaccard coefficient between the neighbourhood
1 of the test and the train sets. And finally cis-regulatory module (CRM) databases
are evaluated by matching motifs of the test set with transcription factor binding
sites of the training set [4].
Ranks from multiple data sources are merged by using order statistics. The
algorithm evaluates a set of N rankings per gene using the Q statistic. The Q statistic
is calculated from a joint cumulative distribution of an N-dimensional order statistic
[194]. This is Q(r1, . . . ,rN) = N!VN , where VN is calculated as:
Vk =
k
∑
i=1
(−1)i−1Vk−i
i!
riN− k+1,
where V0 = 1, and ri is the rank ratio of data source i, calculated as the position of
gene in the ranking i divided by the number of genes in the ranking i. The Q statistics
are sorted, from lowest to highest, to produce the consensus ranking. Furthermore,
a one-tailed p-value corresponding to the Q statistic is added to each gene, which
corresponds to the confidence of the consensus ranking [3].
3.2 PRINCE
PRINCE (PRIoritizatioN and Complex Elucidation) is a graph method which uses
the guilt-by-association principle, and establishes a strength of association between
proteins through network properties [206]. PRINCE creates a prior information
vector Y (v) based on the van Driel disease similarity [205]. The graph represents
a human PPI network, which serves to connect genes, and allows weighted edges
[58]. They propose an iterative formulation to produce a smooth score distribution
over the graph. A node v receives score F(v) from its neighbours N(v) and its initial
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value Y (v) by the formula:
F(v) = α
[
∑
u∈N(v)
F(u)w(v,u)
]
+(1−α)Y (v)
where, w is w= Lsym−I and Lsym is the symmetric normalised Laplacian of the graph,
and Y (v) is the initial score of node v, defined as Y (v) = disease_similarity(q,d) if v
is associated to disease d, and Y (v) = 0 if no disease is associated with v [116]. The
regularisation parameter α serves to trade balance the contribution of the neighbour
score and the initial score.
PRINCE boosts its performance by removing predictions which fail to produce a
score higher than 0.021 on the entire network after the diffusion. The improvement
reported nearly doubles the amount of genes predicted in rank 1, while reducing the
recall by 74% [206].
Finally, PRINCE shows an application to predict protein complexes, where each
complex is produced taking all genes in the network up to a diffused score t. If less
than 20 proteins are obtained, the neighbour of the current putative complex with the
highest score is added iteratively until 20 are collected.
The putative complexes C are then reduced in size iteratively by removing the
protein which causes the biggest improvement in the likelihood function L(C). The
process continues until no protein can be removed to improve the likelihood. This
function evaluates the connectivity among the proteins included in the complex, and
is defined as:
L(C) = ∑
(u,v)∈E(C)
log
β
w(u,v)
+ ∑
u,v∈V (C),(u,v)/∈E(C)
log
1−β
1−w(u,v) ,
where V (C) and E(C) are all the vertices and edges for complex C, and the parameter
β = 0.9 is related to the sensitivity to the connections [206].
3.3 ProDiGe
ProDiGe [135] is a family of kernel-based disease gene prediction methods which
rank all genes within the protein-protein interaction network for a given diseases.
ProDiGe learns missing disease-gene associations using a one-class SVM, where
known associations are seeded as positive labels and the other associations are
unlabelled. The model considers all disease-gene associations at once – i.e. points
are disease-gene tuples ⟨D,G⟩. To cope with points in the disease-gene space, the
authors define the SVM kernel as a product between a disease kernel Kdisease (which
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establishes the pairs of diseases that share targets through a disease similarity matrix)
and a gene kernel Kgene (which establishes a similarity among the genes). Formally,
the kernel between two disease gene pairs is defined as [135]:
Kpair
(
(D,G),(D′,G′)
)
= Kdisease(D,D′)×Kgene(G,G′).
While the approach supports multiple gene kernels, the PPI kernel from the publi-
cation is shown to yield the best results among the first couple hundred predictions
[135] – i.e. Kgene is the symmetric Laplacian of the adjacency matrix of a PPI
network (see Section 2.3.1).
The four methods in the family (ProDiGe1 to 4) differ in the disease kernel used:
ProDiGe1 does not share genes (i.e. Kdisease = I is the identity matrix), ProDiGe2
establishes an uniform low probability to genes from other diseases (i.e. Kdisease =
1+ I is the identity plus a constant), ProDiGe3 allows genes to be shared by using a
disease similarity matrix (i.e. Kdisease =V is the van Driel similarity matrix [205]),
and ProDiGe4 adds the kernels from ProDiGe1 and ProDiGe3 to give additional
weight to the genes coming from the disease of interest (i.e. Kdisease = I+V ).
3.4 CATAPULT
CATAPULT (Combining dATa Across species using Positive-Unlabeled Learning
Techniques) is another SVM based method, which considers a one-class classification
problem to rank missing disease gene associations [186].
CATAPULT is designed to consider that the absence of information does not
imply negative information, and incorporates disease gene associations from mul-
tiple species to provide more information. This produces a kernel composed of
heterogeneous data sources C, defined as:
C =
[
G P
PT Q
]
,
where G is a gene kernel, Q is a disease kernel, and P is a disease-gene association
matrix. The binary matrix G of size g× g is produced by combining edges from
HPRD [160] and HumanNet [103]. The binary matrix P of size g× (p1+ p2+ · · ·+
pn) is used to group gene associations from different species as P = [P1 P2 . . . Pn ],
where Pi is the disease gene association matrix for species i. The block diagonal
matrix Q of size (p1+ p2+ · · ·+ pn)×(p1+ p2+ · · ·+ pn) contains diseases-disease
similarities for the different species. However, the only non-zero block corresponds
to human and contains the van Driel disease similarity [205].
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This kernel considers elements as disease-gene tuples, and is trained using
bagging [14] (for 30 bootstraps) to reduce the variance in the classifier. Furthermore,
it differentiates the penalties for false positive errors (low penalty) and false negatives
(high penalty), to account for the small amount of known gene associations in
comparison to the unlabelled data. The final score is given by the average distance
of the unlabelled point to the 30 trained bootstrap hyperplanes.
3.5 DIAMOnD
DIAMOnD [55] is a recent disease module prediction method based on direct
neighbour analysis which starts from a set of initial seeds and iteratively increases
the module by adding new genes. At each iteration, the algorithm evaluates which
genes have more connections to the existing disease module than expected by random
chance, using the hypergeometric distribution as the null model. Under the model,
the probability of a randomly selected gene with with k interactors to be connected
to ks seeds is:
p(k,ks) =
( s
ks
)(N−s
k−ks
)(N
k
) ,
where N is the number of vertices in the network, and s is the number of genes in
the current disease module. The most significantly connected gene according to
this model is then added and the authors consider the first 200 to 500 genes as the
recovered disease module. The significance of the connections is given by:
signi f icance(k,ks) =
k
∑
ki=ks
p(k,ki),
where the significance can be seen as the p-value of observing ks or more connections
to the seeds. Notice that the set of genes in the module grows by one per iteration,
and the significance is recalculated on each step.
3.6 Discussion
Disease gene prediction comes frequently as a prioritisation procedure, in which all
genes within a set (or graph) are sorted according to their likelihood of association to
a disease. Beyond this generalisation, there is scarce standardisation among authors,
which use different input data and processing methods.
Endeavour can be considered a staple ensemble method. While any given ranking
presented in this algorithm could be considered of particular high quality, their
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combination provides confirmation of non spurious results. However, network based
methods proved to produce better results than this approach. A particular drawback
is that all training is independent, and no lateral information is given between the
instances.
PRINCE is likely to be the most well known disease gene prediction method.
The usage of phenotype similarity to share information between diseases and the
conservation of prior information constituted key developments of this method. A
major drawback for is usage is the lack of an independent executable. Currently,
PRINCE is only available as a Cytoscape plugin called PRINCIPLE [58]. Its usage
requires manual commands and its output is limited to 100 results.
ProDiGe vastly outperforms PRINCE, and is able to integrate multiple sources
to produce gene-gene associations. Furthermore, it provides several versions that are
suitable on different gene recall thresholds. CATAPULT, on the other hand, contains
multiple disease-gene association sources that come from species other than human.
While CATAPULT outperforms ProDiGe4 on the first 100 results on several test
configurations [186], its performance is still comparable to ProDiGe1.
While DIAMOnD is a relatively simple algorithm, it is the only method designed
to retrieve disease modules based on a existing network. The alternative, DiME
(Disease Module Extraction) is a method proposed by Liu et al. [113] that recovers
disease modules through the analysis of gene expression. The goal of the method
is to build a co-expression network between significantly expressed genes, which
shows some desired topological properties (a significant B-score [101] and power-law
degree distribution [10]). This approach does not consider PPI networks neither in
the module construction, or the validation phase. DiME seems to strive for different
goals in the construction of disease modules, and a straightforward comparison
appears hard to produce while considering the evaluations available in the DiME
publication.
ProDiGe1 and ProDiGe4 are chosen as representatives of the disease gene pre-
diction methods as they have been shown to outperform other well known methods,
such as PRINCE [206], Endeavour [3], and a multiple kernel learning approach
(MKL1class) [135] in the top 200 predictions. Additionally, DIAMOnD is used as
the reference disease module prediction method, and as a disease gene prediction
method for completeness. Although DIAMOnD is not intended to be a fully-fledged
disease gene prediction method, the order in which the genes are added to the module
naturally produces a ranking that prioritises disease genes.
Chapter 4
Experimental setup
This Chapter formally defines the disease gene prediction and disease module pre-
diction tasks as used in this work. Then, it describes the evaluation measures and
datasets used for each problem.
4.1 Problem definition
Without loss of generality, the output of a network based gene prioritization method
can be seen as a ranking. If any method produces ties within their ranking, they
can be thought to produce a non-deterministic ranking: tied elements will be sorted
randomly, where each element has a uniform probability to end at one of the tied
positions.
The input of a prediction is defined by a disease of interest (or query) and the
known gene associations. While different networks, data sources or parameters
might be used, those are considered fixed to simplify the discussion. The only
important consideration is that the prediction output only includes genes not known
to be associated to the query.
Given a query and the known gene associations, the prediction output is expected
to rank the yet unknown gene associations as high as possible. Although in real
situations the number of missing genes might be unknown, testable cases contain one
or more expected targets. This work adds a further constraint to limit the evaluation
up to the first 200 predictions, this threshold is comparable to other proposals of
the field [55, 135, 186, 206, 231] and represents a reasonable limit for experimental
validation.
The basic case is the prediction of a single target, where the performance of
the prediction is given by the target rank. Naturally, an ideal prediction ranks the
target in position 1. Experiments with a single target are the most frequently used
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in the literature [213], and the evaluation of a method quantifies the performance
over multiple predictions. In this work, a set of single target predictions is evaluated
by the percentage of targets found upon a number of predictions retrieved (recall at
threshold, presented in Section 4.2.1).
However, the disease module prediction intends to identify multiple genes simul-
taneously. The ideal prediction has all k targets ranked in the first k positions. This
work proposes the usage of a ROC curve normalised for the first 200 false positive
predictions (presented in Section 4.2.1) to evaluate the prediction of disease modules.
While the performance of disease module predictions can be quantified by the
normalised ROC, an in-depth validation the modules involves a qualitative analysis
of topological and biological properties which are presented in Section 4.2.2.
Experiments
This work classifies the experiments based on the number of known genes and the
source of the targets, which offers well-defined scenarios. Queries with 1 or more
known genes are charted, while queries no known genes are uncharted. Gene targets
can be obtained by mining a gene association database in different points in time; the
gene associations added to each disease when comparing the old database to the new
database are used for the time-lapse experiments. Additionally, gene associations can
be removed from a disease in order to be predicted back as targets. These constitute
the synthetic experiments.
Furthermore, these synthetic targets can be produced for charted diseases by
removing a single gene at a time (i.e. leave-one-out) or by removing a percentage
(used for disease modules). The disease module experiments analyse ability of the
prediction to reconstruct different percentages of the module (or the performance
trend when keeping from 0% to 95% of the module as seeds). These experiments
include 10 uniform random samples of target genes for every percentage in order to
reduce sampling bias and excessive costs in module testing.
4.2 Evaluation
4.2.1 Quantitative evaluation measures
The following measures are used to quantify the performance of a prediction given
as a ranking. The recall at threshold is used to evaluate a single target at a time, while
the normalised ROC can be used to evaluate one or multiple targets.
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Fig. 4.1 Example ROC curve normalised to X false positives for a discrete pre-
diction sequence. This example shows a partial ROC curve produced for η = 8
elements, in a sequence with a total of m targets and X false positives. In particular,
it shows the case where the first three targets are ranked in positions 2, 4 and 7.
Recall at threshold
The measure quantifies the performance of n predictions, where each prediction
produced rank ri for target i. The evaluation consists in the percentage of targets
found within the top predictions up to a threshold τ , in particular the top 1, 10, 100
and 200 results. This is, the recall Rτ at the top τ is given as:
Rτ =
#ri ≤ τ
n
,
where #ri ≤ τ is the number of ri ranked τ or higher.
Notice that the different Rτ are not combined, and are given as the output.
Furthermore, the vector R = [R1,R2, . . . ,Rn] produces a ROC curve if normalised in
the x-axis.
Normalised ROC
The measure quantifies the performance of a single prediction for k targets, where
target i is ranked in position ri. The measure is the area under a ROC curve trimmed
and normalised for the first 200 false positive predictions. The ROC curve is defined
as the set of points given by true positive rate (TPR in the y-axis) at a false positive
rate (FPR in the x-axis), by changing the FPR. The following formulation produces
the curve from the ranks ri (Figure 4.1).
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Without loss of generality, let r1 < r2 < · · ·< rk (lower is better). The TPR up to
rank η is given by:
T PRη =
#ri ≤ η
k
,
where #ri ≤ η represents the number true positives, and k represents the total number
of positives. Analogously, the FPR up to rank η is given by:
FPRη =
η−#ri ≤ η
200
,
where η − #ri ≤ η represents the number of false positives, and 200 is the total
number of false elements to be considered. The normalised ROC curve is produced
by tracing the (FPR,TPR) points obtained by increasing η from 1 until the FPR
reaches 1 (i.e. until η−#ri ≤ η = 200).
Two main alternatives to this measure seem intuitive: considering a fixed number
of predictions (instead of a variable number of predictions up to 200 false positives)
for the ROC curve, or a Precision-Recall (PR) curve. However, both of them may
lead to unintuitive or undesirable results:
• The number of elements of the curve is not predefined because it makes
predictions with different number of targets comparable. The usage of a fixed
amount of predictions (e.g. 200) can produce questionable results as illustrated
with a trivial example: a prediction with 198 targets ranked from 2 to 199
would be exceptional and would produce an AUC of 0.5, while a notably
inferior prediction for 2 targets ranked 99 and 100 would also produce an AUC
of 0.5. The current proposal gives an AUC of 0.995 to the former, and 0.505
to the latter prediction, which appears more appropriate.
• The AUPR is an interesting measure to compare pairs of predictions with
the same number of missing targets, as it naturally assigns higher weights
to the top predictions. However, there are some weird effects when the pre-
dictions do not have the same number of targets in every prediction. For
instance, the evaluation of a method for an increasing number of missing
known genes may yield1: APR([1,200]) = 0.505, APR([1,50,200]) = 0.352
and APR([1,10,50,200]) = 0.32, where the average position of the targets gets
better, but the AUPR gets lower. The AUPR measure could make the analysis
for trends in performance for different percentages of missing modules hard.
1APR represents the AUPR function, and the numbers within the brackets represent the ranks in
which the targets are found.
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4.2.2 Qualitative module evaluation
This work also discusses the evaluation of modules by a direct analysis of network
properties and the coherence of biological functions. In particular, the correspon-
dence of network features of putative modules compared to a gold standard. This
case considers that the putative modules contain the gold standard, and the measures
are related to the production of a good matching.
A qualitative analysis is also used for a smaller exploratory analysis on drug
targets (Section 8.4). Notice that drug targets are those proteins that bind or interact
with drugs and have their activity modified, so this is not an evaluation of performance
of drug target sets. The analysis intends to determine if drug targets behave as drug
modules, so the topological features of drug targets are compared to those found
in disease modules. Additionally, it explores how the drug modules overlap with
corresponding disease modules.
Correspondence to a gold standard
The direct evaluation of disease modules involve the validation of the network
properties in comparison to a gold standard. The gold standard is composed of all
diseases within OMIM with 2 or more known genes.
The baseline comparison is a set of random modules is produced by removing all
genes from the gold standard diseases, and populating them from the HPRD genes
with a uniform distribution (each module draws the genes without repetition, but
genes can be repeated in different modules). Following this procedure, the number
of modules and their sizes are preserved. The evaluation of random samples is the
average of 1,000 sets of random disease modules.
The method’s predictions are produced by creating synthetically uncharted dis-
eases and then predicting the entire module. The set of synthetically uncharted
diseases is obtained by taking each disease from the gold standard individually, and
removing all their known gene associations. Notice that while a disease is made
uncharted, all other known gene associations from OMIM are kept to allow the
prediction of the modules.
The Closeness in a network module is measured by the average distance between
all vertex pairs (not necessarily connected). However, the disease modules are
frequently disconnected [127]. To avoid considering infinity in the calculations, the
distance between vertices in different connected components is set as the diameter
of HPRD (the source of the module graph) plus 10.
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Separation, Accuracy and the Jaccard coefficient are measures calculated be-
tween pairs of modules, one of them is the gold standard, and the other is the module
to be evaluated. The Jaccard coefficient is defined as:
J(S,GS) =
|S∩GS|
|S∪GS| , (4.1)
where S is the set of proteins being evaluated, and GS is the set of proteins of the
corresponding gold standard.
Let n and m be the number of gold standard and predicted disease modules, and
{n1, . . . ,nn} and {m1, . . . ,mm} the numbers of proteins of each of those modules.
Let the confusion matrix be Tn×m, where the elements ti, j represent the number of
proteins common to the gold standard module i and the predicted module j. The
separation Sep indicates the correspondence between the modules (ranging from 0
or none, to 1 or perfect), and is defined as:
Sep =
Frow ·Fcol
∥Frow∥∥Fcol∥ , (4.2)
where Frow and Fcol are the marginal sums per row and column of the confusion
matrix T . The cosine distance between the marginal sums represents how the
elements from the gold standard clusters are distributed in the predicted clusters.
If every element predicted the correct cluster, the marginal sums would be equal
Frow = Fcol, and the cosine distance would equal to 1. Other distributions would
cause it to decrease.
The accuracy relates the sensitivity and positive predictive value to penalise
trivial cases of module matching [16]. The Sensitivity Sn is defined as:
Sn =
∑ni=1 max{ti, j|1 < j < m}
∑ni=1 ni
, (4.3)
and the Positive Predictive Value PPV is defined as:
PPV =
∑ni=1 max{ti, j|1 < j < m}
∑ j=1∑ni=1 ti, j
. (4.4)
Then, the Accuracy Acc is defined as:
Acc =
√
Sn×PPV (4.5)
The functional similarity between proteins by measuring the pairwise Gene
Ontology semantic similarity by Yang et al. [225], calculated using GOssTo [19]
with the August 2017 release of the Gene Ontology and Human GAF annotation
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files [31]. The GeneMANIA evaluation uses the March 2017 release of the dataset
[136].
Assessment of modular features
The modular features are similarity in distribution of physical protein distances of
modules and function specificity of a module.
The physical distance between protein targets is the minimum path length be-
tween a pair of proteins in an unweighted and undirected graph, that represents
the HPRD PPI network. The distance distribution within different modules is later
compared using Welch’s t-test, defined as:
t =
A¯− B¯√
σ2A
|A| +
σ2B
|B|
,
where A and B are the sets of all pairwise protein distances within two modules, X¯ is
the mean of set X , σ2X is the variance and |X | is the number of elements.
The overrepresented categories per protein are obtained using Fisher’s exact test
[87]. Then, the pairwise functional similarity for a protein set is calculated using the
Yang et al. semantic similarity [225] as in the previous evaluation.
The function of a drug module can be thought as the aggregation of all individual
drug target functions. This analysis proposes to quantify the function specificity of
a drug module by comparing the pairwise semantic similarities from the module
targets to a global expected similarity. The global drug target similarity is modelled
by approximating a distribution of all pairwise semantic similarities between drug
targets. This baseline distribution is determined by the best fitting random variable
distribution found in the Python SciPY 0.14.1 version.
Exhaustive testing determined the usage of the half logistic distribution as the
model for the cumulative semantic similarity distribution [18]. This is:
F(k) =
1− e−k
1+ e−k
,
where the k value is scaled by the real values a and b:
k = (x−a)/b,
and x is a similarity within the set.
Following this model, a drug module is considered specific if the mean pairwise
similarities is found above the 80 percentile of the baseline distribution.
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4.3 Data sources
4.3.1 Disease Gene Associations
OMIM
The main source for disease gene association data for this work are OMIM databases
[125]. Two versions of the database (2013 and 2017) were mined to allow time-lapse
experiments. These experiments test diseases existing in the 2013 database which
have gained genes in the 2017 database. Table 4.1 contains general information
about the diseases covered on each OMIM database.
Table 4.1 Relevant counts from the OMIM Databases. Only diseases with 2
or more known genes can be used for synthetic leave-one-out experiments. The
number of uncharted diseases accounts for all diseases with no known molecular
basis which have annotated publications (diseases with annotated suspected genes
are not included in this count). The number of unique disease genes is shown as
some genes belong to multiple diseases. The number of disease gene associations
are all unique disease-gene pairs annotated in the OMIM database.
OMIM Release
2013 2017
Diseases with 1 or more known genes 4,870 5,992
Diseases with 2 or more known genes 293 264
Uncharted Diseases 2,670 2,388
Unique Genes 4,040 4,820
Disease Gene Associations 6,303 7,292
The OMIM database is a hand curated collection of experimentally verified data,
so the difference between versions is generally due to the curation of new scientific
publications found between the releases. There are 289 diseases that were uncharted
in the 2013 OMIM database which are charted in 2017. Some of them acquired more
than one gene, which amounts to a total of 292 disease-gene associations available
for the uncharted time-lapse experiments. Likewise, there are 66 charted diseases in
2013 which have additional genes in 2017, for a total of 95 additional disease-gene
associations available for the charted time-lapse experiments.
Notice that while the 2017 OMIM database includes 989 more disease associ-
ations than the 2013 release, over 1,400 associations are not included in the older
version. This difference comes from changes in diseases identifiers between versions,
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changes in the genes associated to the diseases, and diseases removed from the
database.
ClinVar
Additionally, this work uses the ClinVar database [102] that contains protein variants
associated to each phenotype. Only the 2018 version of the ClinVar database is found
available, therefore no time-lapse experiments are performed using this database.
Table 4.2 Relevant counts from the ClinVar database. Only diseases with 2 or
more known genes can be used for synthetic leave-one-out experiments. The number
of unique disease genes is shown as some genes belong to multiple diseases. The
number of disease variants counts all disease to protein variants annotated in the
database (some proteins have multiple SNPs annotated a single disease).
ClinVar
Diseases with 1 or more known genes 3,607
Diseases with 2 or more known genes 133
Unique Genes 2,758
Disease Variant Associations 32,359
ClinVar is focused on the annotation of human variants, and includes additional
polymorphisims not associated to disease. Table 4.2 summarises all database entries
considered for evaluation in this work. These entries are all those associated to an
OMIM identifier.
DIAMOnD disease modules
Ghiassian et al. provide manually curated disease modules for 70 complex diseases
[55]. The dataset contains 1,536 different genes, where some are associated with
more than one disease, for a total of 2,843 disease-gene associations.
This work mapping these diseases to OMIM identifiers by matching disease
names and descriptions found in OMIM. The full mapping is presented in Appendix
B.1.
4.3.2 Interactomes
Several freely available protein protein interaction networks are used to show the
general applicability of the methods proposed in this work. These include weighted
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and binary networks with both experimental and predicted data: HPRD [160], Dia-
mondNet [55] and BioGRID [24] are binary experimental networks; HIPPIE [175]
is a weighted experimental network; FUNCOUP [178] is a large weighted network
including both experimental and predicted data. Table 4.3 presents an overview of
these networks, and their coverage of genes found in the OMIM databases (seen in
Table 4.1).
Table 4.3 Characteristics of protein-protein interaction networks. Coverage
shows the fraction of the different disease genes from the OMIM database found in
the network (see Table 4.1). Evidence describes if the edges are obtained through
experimental validation (exp) or inference (inf). Edge type indicates whether the
edges are binary or weighted.
Network
HPRD DiamondNet BioGRID HIPPIE FUNCOUP
Nodes 9,670 13,460 19,803 16,552 18,113
Coverage
OMIM2013
54% 65% 69% 71% 71%
Coverage
OMIM2017
54% 66% 71% 74% 74%
Edges 39,220 141,296 279,187 239,684 4,476,818
Evidence Exp. Exp. + Inf. Exp. Exp. Exp. + Inf.
Edge Type Binary Binary Binary Weighted Weighted
Note that even if a gene is found in a network some methods can still fail to
predict it. Both ProDiGe and DIAMOnD can only find genes that are found in
the same connected component as the known genes from the query disease. In
practice, the prediction is limited to targets found in the main connected component.
However, Cardigan constructs a vector of initial seeds with every known disease
gene. Therefore, it can predict targets in any connected component that has a known
disease gene from OMIM.
Besides these PPI networks, this work analyses the usage of an interactome
which includes protein interactions through interfaces. The information used here
is provided by the Interactome INSIDER [130], a recently available resource. This
database contains information about the residues which are predicted (with a method
called ECLAIR) to be in the interaction interface. This information can be used to
build a standard PPI network, and this work proposes a construction for a second
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interface-based network which is presented in Section 7.1.1. The procedure creates
a network where the nodes are interfaces, and the edges represent the interaction
between interfaces. Table 4.4 presents a summary of both networks built from
Interactome INSIDER.
Table 4.4 Summary of the networks derived from Interactome INSIDER. PPI
references to a standard protein-protein interaction network built from the database,
and ECLAIR references the interface-interface network proposed in Section 7.1.1.
Coverage shows the fraction of the different disease genes from ClinVar found in the
network (see Table 4.2). LCC stands for the Largest Connected Component.
Network
PPI ECLAIR
Nodes 15,046 17,184
Edges 238,710 238,710
Coverage ClinVar 84% 84%
Connected components 304 477
Proteins in LCC 14,708 14,692
Nodes in LCC 14,708 16,619
Nodes outside the LCC 338 565
Notice that ECLAIR predictions come with a confidence score, and residues
with low confidence scores are not predicted to be in the interface. This yields some
interactions where an interface contains no residues, which are referred to as ∅
interfaces in this work. Therefore, Table 4.5 presents details of the proteins included
in the INSIDER ECLAIR network.
Table 4.5 Details of the proteins included the INSIDER ECLAIR network. Each
row counts the number of proteins found in the network with a given characteristic.
Notice that a protein yields a node per interface in the ECLAIR network.
Total Percent
1 interface 13,078 87%
2 or more interfaces 1,968 13%
contain a ∅ interface 7,062 47%
contain a ∅ and other interface 1613 11%
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Fig. 4.2 Phenotype characterisation of a disease - Caniza similarity. The first
step is to gather PubMed publications describing the diseases (green and orange).
Then, MeSH terms are extracted from those documents, and are annotated onto the
MeSH ontology. Finally, the similarity is quantified as an information content based
distance in the ontology.
4.3.3 The Caniza disease similarity
Caniza et al. [20] proposed to characterise a disease phenotype by collecting MeSH
terms of relevant scientific publications about the disease, and annotating them in
the MeSH ontology (Figure 4.2). The phenotype similarity for a pair of diseases is
quantified through the information content of the lowest common ancestors between
the sets of the annotated terms.
Following the reasoning by Caniza et al., a term with few annotated diseases tells
a lot about those diseases, while very common terms do not aid in telling diseases
apart. Therefore, the importance of the term is defined by its information content.
On the field, the information content of a term IC(t) is commonly quantified by the
negative log-likelihood [180]:
IC(t) =−log(p(t)),
where p(t) is the probability of a disease being annotated on term t.
Then, the similarity between a pair of terms ti and t j is calculated by the informa-
tion content of their most informative common ancestor in the ontology [167]. The
common ancestor represents the conceptual similarity between the terms. Formally:
sim(ti, t j) = max
c∈C(ti,t j)
IC(c),
where C(ti, t j) is the set of common ancestors to both ti and t j in the ontology.
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Since diseases are annotated under multiple terms, the similarity between a
pair of diseases is the maximum similarity between all pairs of terms across the
diseases. Formally, if diseases da and db are annotated with terms ai ∈ A and bi ∈ B
respectively, the Caniza similarity between the diseases S(da,db) is calculated as:
S(da,db) = max
ai∈A, b j∈B
sim(ai,b j).
The Caniza similarity is provided as a symmetric square matrix where the element
i, j represents the similarity between disease i and disease j.
The Caniza similarity considers that two diseases will have a high similarity
if they share any phenotype, even if the aggregation of phenotypes makes them
different. Notice that the similarity is not an Euclidean distance, so it is not transitive.
If a disease is similar to two diseases, the two other diseases are not necessarily
similar (A∼ B∧A∼C ̸→ B∼C).
The similarity is calculated on the MeSH ontologies Anatomy [A], Diseases [C],
Chemicals and Drugs [D], Analytical, Diagnostic and Therapeutic Techniques and
Equipment [E] and Phenomena and Processes [G], combined with an extra root node
which connects all five ontologies [20].
This work uses the Caniza similarity calculated on the 2013 OMIM database,
and the 2017 OMIM database. Notice that the OMIM database holds records of
curated publications associated to each disease as PubMed identifiers [125].

Chapter 5
Mapping disease modules from
phenotype
This Chapter focuses on the usage of phenotype similarity for the characterisation of
disease modules, and its relation to the prediction of disease genes. The characterisa-
tion is given as a disease module prediction method called Ordinal1. Earlier works,
such as the proposals by Li et al. [107], Vanunu et al. [206] and Mordelet et al. [135],
have exploited a human phenome quantification to guide random walks in graphs,
diffusion processes, and inductive semi-supervised models, respectively, to priori-
tise disease genes [205]. However, scant research approaches the general relation
between the modular nature of phenotypes across multiple diseases [9, 55, 113].
5.1 The Ordinal method
Ordinal is a disease phenotype approach to predict disease modules for uncharted
diseases using known disease genes. The idea is based on the fact that a high
phenotypical similarity between diseases correlates to closeness in their genotype
[20]. The predicted modules are directly validated through topological properties
within a PPI network, and indirectly by considering the method within a disease
gene prediction context. The latter validation serves a further purpose, to quantify
the possible gains by including topological completion of the network modules upon
these phenotypical modules.
Ordinal consists of three steps to construct the disease modules: 1) collect a
list of highly similar contributor diseases from which to transfer information; 2) all
1Ordinal is a yet unpublished method produced in collaboration with Horacio Caniza under the
supervision of Prof. Alberto Paccanaro. While the base ideas for method were developed by all the
authors, the code implementation, evaluation for disease gene prediction, and the discussion presented
here are my own.
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Fig. 5.1 The Ordinal Process. Given an uncharted disease in OMIM (orange), a set
of the 20 most similar charted diseases is collected – i.e. the contributor diseases
(Step 1.). The known molecular basis of the contributor diseases are extracted and
become the genes of the putative module (Step 2.). The set of interactions is extracted
from HPRD, their interactions are assembled into a disease module for the uncharted
disease (Step 3).
known molecular basis are extracted from these diseases, which produce the set of
putative proteins; 3) all interactions between the set of putative genes are mined
from HPRD [160], which is a binary PPI network composed of high quality Y2H
experiments. Figure 5.1 shows a sketch of the entire Ordinal pipeline.
5.2 Results
While multiple authors develop pipelines to identify modules of particular diseases
[150, 51], the only general computational method that recovers disease modules
is DIAMOnD [55]. However DIAMOnD requires some known molecular basis
to produce a prediction (see Section 3.5 for further details). A literature review
revealed no methods aimed to the construction of modules for uncharted diseases,
rendering a direct comparison to other methods impossible (arguments regarding
DiME [113] are discussed in Section 3.6). Therefore, the primary evaluation consists
in comparing the predicted modules to a gold standard and random modules using the
qualitative module measures of functional similarity (semantic similarity), closeness
(intra-module distances), separation, accuracy and the Jaccard coefficient. Section
4.2.2 describes the construction of the gold standard (high quality disease modules),
the random sets (baseline proteins found in the network), and the measures.
The first evaluation procedure consists in the observation of the essential guilt-
by-association principle [10]. In this context, the predicted modules must show a
function similarity and maintain a topologically compact module in the interactome
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Fig. 5.2 Histograms of semantic similarity values on the PPI network. Green
bars represent the average on the entire HPRD PPI network. Blue bars show the
pairwise semantic similarity of the proteins in random disease modules and magenta
bars the distribution in the modules predicted by Ordinal. Finally, red bars show
the distribution of pairwise semantic similarity within the Gold Standard disease
modules in OMIM. The solid vertical lines show the average of each distribution,
with the mean value indicated above.
Fig. 5.3 Intra-module distance for Gold-standard, Ordinal and random sets.
The Y-axis shows the average intra-module distance between proteins in the corre-
sponding modules. The table at the top shows the pair-wise t-test p-values between
the sets. The distance between disconnected proteins is defined as the diameter of
HPRD plus 10
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[164, 55, 140]. Figure 5.2 shows the function similarity between all proteins in the
module through the comparison of the annotated GO terms. Figure 5.3 shows the
closeness between the proteins within the predicted modules.
This initial evaluation shows that Ordinal indeed produces modules which are
significantly different from random modules, and approximate the distribution of the
gold standard disease modules. This test is necessary as there are no guaranties that
the closeness in phenotype and genotype will hold for the set of diseases collected
following the Ordinal algorithm.
While these properties are essential for a disease module, Ghiassian et al. show
that topological modules on the interactome are not able to fully capture disease
modules [55]. Table 5.1 shows a benchmark for the produced modules using the
Jaccard coefficient, Separation and Accuracy with respect to its corresponding gold
standard module [16]. The Jaccard coefficient measures similarity between sets,
separation measures how well a given putative module is separated from the other
modules and accuracy measures how well a putative module corresponds to its
corresponding gold standard module.
Table 5.1 Comparison of module quality. The table compares the quality of Or-
dinal’s predictions, measured in terms of Separation, Accuracy and the Jaccard
coefficient, to the quality of randomly generated modules. All scores range from 0 to
1, and higher values are better. We create a composite score summing the individual
values
Module source
Predicted Random
Separation 0.0195 0.00767
Accuracy 0.2979 0.079
Jaccard 0.0238 0.0003
Composite 0.3413 0.087
Finally, Ordinal can also be considered as a fully blown disease gene prediction
method, by ranking the genes of the contributor diseases in order of their similarity.
However, since Ordinal is not able to distinguish between the set of proteins it
brings from a single disease, they are assigned a priority at random, and 100 samples
are generated to produce the results. Figure 5.4 shows that while Ordinal’s design
fails to identify genes between the top 10 predictions, it contains sufficient module
identification power to outperform dedicated methods in the top 200 results. The
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Fig. 5.4 Disease gene prediction for charted diseases in a leave-one-out proce-
dure – average recall. The chart shows a comparison between Ordinal, DIAMOnD
and ProDiGe for disease gene prediction on diseases synthetically missing one gene
(for more details see Section 4.1), on HPRD. The bars show the percentage of targets
found within the first 1, 10, 100 and 200. predictions.
selection of DIAMOnD [55] ProDiGe [135] as methods of reference are further
explained in Section 3.
5.3 Discussion
The guilt-by-association principle established that a closeness in genotype was
reflected in a closeness in phenotype within the protein level [10]. However concept
of phenotype can be thought of in different abstraction levels. Ordinal, despite being
a naive approach, clearly shows the intrinsic correlation between observable disease
phenotypes and the guilt-by-association principle beyond the protein level.
Protein phenotype can be defined by the presence of structural properties (such
as conserved domains, protein interaction interfaces, compound binding interfaces
or motifs), or by the set of interacting proteins [36]. However, many computational
approaches [167, 78, 110, 154, 32, 225] focused on the quantification of phenotype
as a similarity from an ontological description of the known functions and structures
of a protein, mainly by mining GO. The development of these approaches has
repeatedly served as validation of the correlation between protein phenotype and
genotype.
On the other hand, the definition of a disease phenotype originally derives from
a natural macroscopic observation, and ontologies have been built since 1800 [147].
Here, the MeSH ontology [143] serves an analogous purpose to GO. van Driel et
al. [205] and Caniza et al. [20] produced methods to quantify disease similarity
within the MeSH ontology, validating the correlation between disease phenotype and
genotype.
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Since Ordinal manages the construction of protein modules based on disease
phenotype, it shows that both correlations are simultaneously coherent. The disease
modules produced by Ordinal are located in compact areas (Figure 5.3) in the
interactome and contain proteins with coherent functions (Figure 5.2).
The application for disease gene prediction indicates the quality of the disease
modules, and adds support to the idea that topological modules fail to characterise
disease modules [55]. While other functionally related proteins arguably belong
the module, disease genes are the core elements. Ordinal is able to retrieve more
than 50% of the known disease genes within the module, and outperforms the
other methods in this regard. Additionally, this application proves the qualitative
improvement offered by the Caniza et al. similarity over the van Driel et al. similarity
(used within ProDiGe4), and encourages its usage on a dedicated method.
Chapter 6
Charting disease gene associations
This Chapter presents my method named Cardigan (ChARting DIsease Gene As-
sociatioNs) that predicts genes for both charted and uncharted diseases, and can
also predict disease modules. Cardigan is based on a semi-supervised algorithm
that propagates labels on the interactome. These labels integrate disease phenotypic
information expressed as a similarity measure between diseases, which is obtained
by mining and comparing MeSH terms [143] relevant for each disease on the MeSH
ontology.
A Python implementation of Cardigan is downloadable from the paper website
http://www.pacanarolab.org/Cardigan. The code can be downloaded alone, or with
a data bundle, which includes a precomputed Caniza similarity matrix, as well
as parsers for the networks used in the evaluation (HPRD, DiamondNet, Biogrid,
HIPPIE and FUNCOUP). A detailed manual for its usage is presented in Appendix
A.
Section 6.2 presents thorough experimentation which shows that Cardigan out-
performs state-of-the-art methods in disease gene and disease module prediction.
Section 6.3 discusses the evaluation procedure, the main advantages of the proposal,
and the applicability of the method in disease research.
6.1 The Cardigan algorithm
The idea is to exploit the fact that disease modules of diseases with a similar pheno-
type should be placed close-by on the interactome [10]. Therefore, when predicting
disease genes for a specific disease, genes of phenotypically similar diseases should
provide useful information.
To predict disease genes for a given disease (query disease), Cardigan begins
by calculating its phenotypic similarity to every other disease in OMIM using the
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approach developed by Caniza et al. [20]. Next, Cardigan assigns a weight to each
known disease gene. The weight is related to the Caniza similarity between the query
disease and the disease to which the gene is associated (Figure 6.1C). Weights of
disease genes are real values between 0 and 1 and are calculated by rescaling the
Caniza similarity through a sigmoid function (Figure 6.1B), whose parameters are
learned (see 6.1.2). If a gene is associated with more than one disease, Cardigan
uses the highest similarity value1. Genes which are already known to be associated
with the query disease, if any, are assigned a weight equal to 1. For a given query
disease, the set of weights assigned to the disease genes is henceforth called the
Query Weight Set (QWS) for that disease. A detailed formulation of the QWS is
presented in Section 6.1.1.
The next step is to propagate the QWS through the graph with a semi-supervised
learning procedure (transition between C and D in Figure 6.1). Cardigan uses the
consistency graph diffusion method from Zhou et al. [236]. This is a graph labelling
procedure based on minimizing a cost function that takes into account network
weights and an existing set of labels. Let a weighted PPI network with n nodes
be represented as an adjacency matrix Wn×n, where each element Wi j is the weight
between genes i and j (if the network is binary, then all the values in W are binary,
indicating the presence or the absence of an interaction). The final labelling vector F
(of size n) having one element for each gene, whose value is related to the probability
of that gene of being associated with the query disease, is obtained by minimizing
the following cost function:
C(F) =
1
2
 n∑
i, j=1
Wi j
∥∥∥∥∥ Fi√Dii − Fj√D j j
∥∥∥∥∥
2
2
+µ
n
∑
i=1
∥Fi−Yi∥22
 , (6.1)
where vector Y (of size n) is the QWS and µ > 0 is a regularization parameter, and D
is a diagonal matrix (of size n) whose elements are the row-wise sum of the weight
matrix (Dii = ∑nj=1Wi j).
The following analysis gives intuition for the method, and presents a closed form
solution that minimises the cost function. The cost function being minimised is
the sum of two terms. The first term accounts for the consistency of the labels of
adjacent nodes (reflecting the guilt-by-association principle) – this term is minimized
1Roughly speaking, the different weights of the gene represent different phenotypes caused by the
gene. Choosing the highest weight equates to consider only the phenotype caused by the gene most
similar to the query phenotype. E.g. FTL is a known disease gene, and it is associated to iron storage.
The excess or deficiency of this protein leads to different phenotypes. Then, the QWS for Sickle Cell
Anemia will have a high weight for FTL, since it is associated to a phenotype of iron deficiency. It
seems adequate to consider that FTL is likely to be close to the Sickle Cell Anemia genotype, even if
it is associated to other phenotypes.
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Fig. 6.1 The prediction on an uncharted disease using Cardigan. A) The PPI
network with disease genes associated to 4 different diseases (red, green, purple,
blue). B) The Caniza similarity is transformed to a weight. C) The query weight
set (QWS) which serves as initial seed set for the diffusion process. D) Presents
the final state of the network after the diffusion process. Notice how all genes have
acquired a weight. These weights are used to rank all genes and constitute Cardigan’s
prediction.
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when adjacent nodes have similar labels (i.e. the difference between Fi and Fj
becomes small). Also note that the importance of the difference between Fi and Fj
is proportional to the edge weight Wi j – i.e. it is related to the probability of the
interaction. At the same time, the role of the second term is to conserve the initial
labels (QWS), thus emphasise the reliability of the initial data for the prediction –
this term is minimised when the nodes labels Fi are the same as the initial labels Yi.
Finally the µ parameter controls the relative importance of the two terms, while the
Dii terms serve as a normalisation parameters for the node degree. The vector F
that minimizes the above cost function can be interpreted as a gene ranking (Figure
6.1D), and constitutes the output of Cardigan. In particular, Zhou et al. determined
that the minimum of the cost function from Equation 6.1 has the following closed
form solution:
F = β (I−αS)−1Y (6.2)
where S = D−1/2WD−1/2, α = 11+µ , and β =
µ
1+µ .
It is important here to note that Cardigan is able to predict genes both for charted
and uncharted diseases. In fact, the only input for the procedure is the QWS,
which can be obtained for both groups of diseases. The only difference is that
charted diseases will contain genes with label equal to one corresponding to disease
genes already known for those diseases. Furthermore, the method can be used for
the prediction of disease modules, since the top predictions of Cardigan can be
interpreted as the disease module for the query disease.
6.1.1 The Query Weight Set
The QWS is a vector produced by weighting and combining known gene associations
from OMIM. Weights of disease genes are real values between 0 and 1 and are
calculated by rescaling the Caniza similarity through a sigmoid function. Genes
which are already known to be associated with the query disease, if any, are assigned
a weight equal to 1.
Formally, let the binary matrix G of size m×n represent the known disease gene
associations, where the m rows represent diseases and the n columns represent genes
– i.e. Mdi = 1 represents that gene i is associated to disease d. The weighted matrix
H of size m×m represents the Caniza similarity [20], where Hdd′ is the similarity
between disease d and disease d′.
The Caniza similarity is a real positive number where increasing values represent
increasing similarity. These are scaled by a sigmoid to obtain a bounded real number
between 0 and 1. After scaling, diseases close to 1 are expected to be very similar to
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the query and their genes are considered good candidates; on the contrary, diseases
close to 0 are not expected to provide good candidates. Let a scalable sigmoid σs,c
be defined as:
σs,c(x) =
1
1+ e−s(x−c)
, (6.3)
where s is the slope and c is the centre. Note that while values s = 1 and c = 0
produce the standard sigmoid (Figure 6.2a), these parameters are trained (as seen in
Section 6.1.2), to produce the intended scaling.
Genes from all diseases in M outside of the query q are collected in an intermedi-
ate weight vector Xq of size n. The weight Xqi is the Caniza similarity between the q
and the disease d to which the gene i is associated. If gene i is associated to more
than one disease, the highest weight is used. Formally:
Xqi =
{
max{Hqd} if Mdi = 1
0 otherwise
(6.4)
The vector Xq is further scaled by the real number h between 0 and 1, which
represents how important are seeds from similar diseases compared to seeds from
the query disease (this parameter is also learned as seen in Section 6.1.2). Finally,
the QWS is given as vector Y q by setting the known associations of query q with a
value of 1. Formally:
Y qi =
{
1 if Mqi = 1
h ·σs,c(Xqi ) otherwise
(6.5)
Notice that the superindex in Y q is dropped in other sections as the QWS always
refers to a particular query q.
Significance of the sigmoid
The sigmoid is intrinsically related to a two-class classification problem which arises
when deciding whether a gene is a seed disease gene (class C1) or not (class C2)
based on the similarity value. The Bayes theorem defines an identity of conditional
probabilities:
P(A|B) = P(B|A)P(A)
P(B)
. (6.6)
Given that a similarity value x can only belong to one of the two classes C1 or
C2, the law of total probability states that:
P(x) = P(x|C1)P(C1)+P(x|C2)P(C2). (6.7)
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Therefore, the posterior probability of a class given a similarity value can be
written as:
P(Ci|x) = P(x|Ci)P(Ci)P(x|C1)P(C1)+P(x|C2)P(C2) . (6.8)
The equation can be simplified by calculating the log odds between the classes (the
solution for C1 is given without loss of generality):
r = ln
P(x|C1)P(C1)
P(x|C2)P(C2) . (6.9)
Equation 6.8, for i = 1, can be expressed in terms of r as:
P(C1|x) = 11+ exp(−r) = σ(r), (6.10)
which is the sigmoid function [14].
Therefore, by using the sigmoid function, the value assigned to each gene in the
QWS for a query disease can be interpreted as the posterior probability for that gene
to be a disease gene for the query.
6.1.2 Training
Cardigan includes one hyperparameter for the diffusion process and three hyper-
parameters to produce the QWS. The first parameter is the diffusion regularisation
parameter α from Equation 6.2. The following two parameters s and c are the sig-
moid scale from Equation 6.3. The final parameter h is the regularisation parameter
from Equation 6.5.
While the Caniza similarity can be scaled by modifying s and c directly, the
relation between the similarity value and the expected result is not obvious within
this formulation. Therefore, parameters s and c are obtained indirectly in such a
way that a given (low) similarity value a is transformed to 0.1, and another (high)
similarity value b is transformed to 0.9, as shown in Figure6.2b. The values s and c
can be obtained for any pair of values 0 < a < b, by solving an equation system of
two variables:
σs,c(a) = 0.1
σs,c(b) = 0.9
where the σs,c(b) is defined as in Equation 6.3. Note that the disease similarities
between a and b belong to the pseudo-linear domain of the sigmoid.
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(a) Standard sigmoid (b) Modified sigmoid
Fig. 6.2 Visualisation of the standard and modified Sigmoid functions. The
Caniza similarity goes from 0 to a real max value. The sigmoid is used to convert
the similarity to a range between 0 and 1. (a) Shows a regular sigmoid function for
reference. (b) Shows a sigmoid function where the slope and centre are modified
to associate disease similarity a to a low value (0.1) and similarity b to a high value
(0.9). The colourbar on the side illustrates the amount of label gained after the
transformation.
The default parameters are obtained by a greedy procedure to iteratively pick
the parameter value that maximises Cardigan’s performance at predicting genes for
Acute Lymphoblastic Leukemia (MIM:613065) using 2013 data. This disease is
chosen because it gained the largest amount of genes between the 2013 and 2017
editions of the OMIM database. The test evaluates the performance of Cardigan when
all but one gene (among ETV6, RUNX1, PAX5, IKZF1, ABL1, FLT3, NOTCH1,
and PI3K) are removed at a time, and are simultaneously predicted back –i.e. a
keep-one-in experiment, where the performance is evaluated with the ROC AUC
normalised for the first 200 false positives (see Section 4.2.1 for more details).
First, parameter α is tested between 0 and 1 in intervals of 0.01, since the
parameter belongs to a bounded interval. Then, empirical observation of the Caniza
matrix has shown that the similarity values range between 0 and 4 for both 2013 and
2017 versions. Therefore, parameters a and b are tested simultaneously between
0 and 5 (0≤ a < b≤ 5) for intervals of 0.1. Notice that the similarity distribution
is not linear, and the 99 percentile of similarity boundary lies roughly at the 2.5
value [20]. Finally, parameter h is also tested between 0 and 1 in intervals of 0.01.
Notice that while a grid search over the parameters would be a more principled
approach, this granularity would require ∼ 2300 days to finish instead of ∼ 6 hours,
assuming 1 second per prediction (estimated from Table 6.1) and considering 8
predictions per configuration (one for each different seed gene). A simple coarse
granularity grid analysis during the design revealed that the performance was most
sensitive to the pair of parameters a and b, thus they are scanned together over a
grid. The difference between several clusters of good configurations that appear with
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the chosen greedy procedure seemed small enough to not require the usage of more
sophisticated parameter selection techniques. However, an improvement for future
work could be the usage of a Bayesian Optimization framework for the parameter
selection.
The experiments use the following parameters: the binary networks HPRD,
BioGRID and DiamondNet use h = 0.50, a = 3.0, b = 4.0, and α = 0.69; while
the weighted networks FUNCOUP and HIPPIE use h = 0.60, a = 3.0, b = 4.0, and
α = 0.75.
The decision to define default parameters follows the idea that Cardigan’s usage
should be as simple as possible (as the software implementation is delivered with
the method). Furthermore, the exploratory analysis during the developmental stage
showed that the parameters encountered few clusters of configurations close to good
local maxima in performance, and those clusters were similar for several diseases.
While the global maxima varied from disease to disease, the performance on the
other local maxima appeared to be competitive. An in-depth analysis of Cardigan’s
performance with exhaustive parameter training appeared too expensive for the
possible benefits. Notice that the parameter training requires to run Cardigan x
amount of times per gene-association predicted in the train set (currently x = 2700
or ∼ 45 minutes per gene-association). This would amount to ∼ 160 days of training
for all gene-associations of the 2017 OMIM (which would be required for a cross-
validation analysis). Additionally, each fold of cross-validation would require ∼
85 minutes for evaluation (which makes a leave-one-out cross-validation rather
unfeasible). The aforementioned Bayesian Optimization framework could also make
this analysis feasible in future work.
6.2 Results
Cardigan’s performance is compared against ProDiGe1, ProDiGe4 and DIAMOnD at
predicting disease genes. Following previous authors [135, 206, 231], the evaluation
consists in predicting one gene at a time and measuring how often that gene is found
within the first 1,10,100,200 genes output by the different algorithms. Further
details can be seen in Section 4.2.1.
The evaluation of charted and uncharted diseases is presented separately, and
for each type of disease the performance is analysed using both time-lapse data and
a leave-one-out testing procedure. In time-lapse data experiments, the prediction
attempts to retrieve genes which have been associated with diseases in the period
2013-17 using data from 2013. Although these experiments are limited in the size of
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the test set, they are very important as they provide an evaluation of the system in
real life scenarios. In leave-one-out experiments, a single disease-gene association is
removed and the evaluation tells how well the system can retrieve it. Finally, as a
baseline, the evaluation reports the performance obtained by a procedure that selects
disease genes at random. The following results are presented for all the unweighted
networks: HPRD, DiamondNet and BioGRID (see Section 4.3.2 for more details).
6.2.1 Performance on Uncharted diseases
Time-lapse tests
The first evaluation shows the performance of Cardigan at predicting genes which
are associated with diseases in 2017 that were uncharted in 2013, using data from
2013. The 2013 OMIM database has 2670 descriptions of uncharted diseases, and
289 of those diseases appear as charted in the 2017 OMIM database. Cardigan is the
only method that can make predictions for these 289 diseases. In fact ProDiGe4, the
only other method that could in principle make predictions for uncharted diseases, is
not applicable since its disease kernel does not include any of these diseases [205].
Figure 6.3a aggregates the prediction results of the 252 diseases which had genes
found in at least one PPI network, and shows that Cardigan has a good performance
which is stable across the different networks.
Leave-one-out tests
If a given disease has only one known disease gene, then removing it yields a
synthetic uncharted disease. There are 5707 diseases with a single disease gene
in the 2017 OMIM database, for 3,253 of them the disease gene was present in
HPRD, 3,870 are included in DiamondNet and 4,152 are found in BioGRID. For
each of these diseases its gene was removed and the performance of the methods
at predicting it back was measured. Since these are synthetic uncharted diseases,
there is no initial set of disease genes, and therefore ProDiGe4 and Cardigan are
the only methods that can be used for this problem. Figures 6.3b, 6.3c and 6.3d
show that Cardigan clearly outperforms ProDiGe4 for different numbers of retrieved
predictions, and the difference is not an artefact of the network used.
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(a) Time-Lapse uncharted (All networks) (b) Leave-one-out uncharted (HPRD)
(c) Leave-one-out uncharted (DiamondNet) (d) Leave-one-out uncharted (BioGRID)
Fig. 6.3 Disease gene prediction for uncharted diseases. Percentage of disease
genes found in the predictions vs. the number of predictions retrieved. (a) Per-
formance for diseases which were uncharted in 2013, but were charted in 2017,
measured on different PPI networks. The percentage is normalised for the amount
of genes available per network. (b), (c) and (d) Performances for a leave-one-out
testing for diseases with a single known gene in 2017 on HPRD, DiamondNet and
BioGRID respectively.
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6.2.2 Performance on Charted diseases
Time-lapse tests
These experiments test the performance of the different methods at predicting genes
for diseases which were already charted in 2013 and gained further genes by 2017,
using data from 2013. Out of the 1413 disease gene associations which were new
in the 2017 version of OMIM, only 95 of them were added to diseases which
were already charted in 2013. This number is further reduced for testing since
many of these genes were not contained in the PPI networks (their number ranges
between 61 for HPRD, 71 for DiamondNet and BioGRID, and 78 for FUNCOUP).
Results for HPRD are shown in Figure 6.4a, where Cardigan presents a minimum
improvement of 38% with respect to the second best method at any threshold. On all
networks DIAMOnD starts with a better performance than the remaining methods
and ProDiGe1 becomes the second best by the top 100.
Leave-one-out tests
These experiments test the performance of the methods when disease genes known
in 2017 were removed one at a time and predicted back. The 2017 OMIM database
contains 264 diseases with two or more genes, which result in 970 possible test
cases. Out of the 970 test cases, 769 tests can be performed using HPRD, 875 with
DiamondNet and 893 with BioGRID. Figure 6.4b shows how Cardigan outperforms
every method at every threshold – the minimum performance improvement is 55%
with respect to the second best method at any given threshold. Results on the other
networks are similar, while in DiamondNet (Figure 6.4d) the difference is closer
between Cardigan and other methods, it is wider in BioGRID (Figure 6.4f). With
single exception of DIAMOnD, that performs with the same accuracy on HPRD and
DiamondNet over all thresholds, the methods show a reduced performance on the
bigger networks.
6.2.3 Performance on Disease Module detection
Finally, these experiments test how well Cardigan performed at predicting disease
modules, i.e. whether the set of predicted disease genes formed a coherent disease
module. These experiments follow the procedure and use the same dataset as
presented previously by Ghiassian et al. [55]. Their dataset contains 70 diseases
and their respective modules, which had been manually curated. The experiments
evaluate the performance of Cardigan at reconstructing the module after removing
different percentages of genes (i.e. keeping different percentages of the module). The
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(a) Time-lapse charted (HPRD) (b) Leave-one-out charted (HPRD)
(c) Time-lapse charted (DiamondNet) (d) Leave-one-out charted (DiamondNet)
(e) Time-lapse charted (BioGRID) (f) Leave-one-out charted (BioGRID)
Fig. 6.4 Disease gene prediction for charted diseases. Percentage of disease genes
found in the predictions vs. the number of predictions retrieved. (a),(c) and (e)
Performance for predicting the genes that charted diseases have acquired between
2013 and 2017, on HPRD, DiamondNet and BioGRID respectively. (b),(d) and (f)
Performances for a leave-one-out testing using 2017 data, on HPRD, DiamondNet
and BioGRID respectively.
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(a) HPRD (b) DiamondNet
(c) BioGRID
Fig. 6.5 Performance at reconstructing disease modules. Different percentages
of disease modules from Ghiassan et al. are removed and modules are then re-
constructed. The y-axis shows the AUC of the ROC curve normalized for the first
200 false positives predictions. Error bars were calculated using the results for all
diseases, each one with 10 random selections of kept genes. The expected value
for a random prediction is 0.021 for HPRD, 0.0073 for DiamondNet and 0.0066 for
BioGRID.
evaluation measure used is the AUC of the ROC curve normalized for the first 200
false positives predictions, thus matching the sizes of disease modules as described
by Ghiassian et al. (for more details see Section 4.2.1).
Figure 6.5 shows that Cardigan outperforms DIAMOnD consistently when keep-
ing different percentages of the module on all networks. At each percentage, we
performed 10 random selections of the genes that were kept for each disease to
avoid biases on the experiments. The minimum improvement is 85% when 80% of
the module is kept on BioGRID. The performance between the methods decreases
smoothly as the percentage of the module kept also decreases. However, DIAMOnD
suffers a bigger loss when only 5% of the module is kept, where the difference in
performance goes up to 450% when 5% on HPRD. Note how Cardigan is also able
to recover modules even when 0% of the module is kept.
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Table 6.1 Average run times in seconds for a single prediction on different
interactomes. The averages were taken from the same test set with over 100
predictions on the same system. Intel XEON 2.6GHz, 32 GB RAM running Debian
Jessie.
Network
HPRD DiamondNet BioGRID HIPPIE FUNCOUP
Cardigan 0.48 0.62 0.92 0.75 1.10
DIAMOnD 1.32 3.86 7.73 - -
ProDiGe1 2.59 4.79 9.98 - -
ProDiGe4 176 291 433 - -
6.2.4 Execution times
Although the execution times of the methods are not the main interest of this work,
Cardigan is also significantly faster than DIAMOnD and ProDiGe. Table 6.1 shows
the average prediction time for a prediction instance, which is the same for gene or
module prediction – i.e. the retrieval of a single target for disease gene prediction
or multiple targets for module prediction. These measurements do not include the
initial time to load data (i.e. loading any matrices or parsing the interaction data to
build the graph representations) into memory for any of the methods.
Notably, all the presented methods except DIAMOnD produce a ranking for all
genes in the network, while DIAMOnD is only producing 200 predictions. As op-
posed to Cardigan and ProDiGe, iterative nature of DIAMOnD allows the procedure
to stop when a certain number of results is produced.
6.3 Discussion
This chapter presents a novel network medicine based approach for disease gene
prediction. Its key feature is its ability to predict genes for diseases using only their
phenotypic description, which allows the method to predict genes for uncharted
diseases. The approach can be thought of as establishing the location for the modules
of charted diseases and using these to triangulate the location of the modules of
uncharted diseases by exploiting disease phenotypic similarities.
The experiments show that Cardigan can handle networks of different sizes, for
both weighted and binary edges, by testing it on HPRD, DiamondNet, BioGRID,
HIPPIE and FUNCOUP. Furthermore, they demonstrate that Cardigan consistently
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outperforms by a significant margin state-of-the-art methods and is stable on different
types of networks. In particular, Cardigan’s performance remains very high on
BioGRID where other methods show significant drops in performance.
The difference in performance between Cardigan and the other methods is larger
in time-lapse experiments than in leave-one-out tests, which are more commonly
used in the literature. Notably, the former evaluation appears more significant than
the latter, since time-lapse experiments provide a more realistic evaluation of disease
gene prediction methods as they mimic more closely the gene discovery process. In
fact, looking at the evolution of the OMIM database, genes for complex diseases are
frequently discovered (and then added) in groups. The case of adding just one gene
at a time, that is portrayed by leave-one-out tests, is much less frequent.
While the difference in execution times among the different methods might be
negligible on a the research of a single disease, it resulted to be a hindrance for the
experiments presented here. In particular, execution times of ProDiGe4 are within
2 and 3 orders of magnitude higher than Cardigan. Synthetic leave-one-out tests
involve over 3,000 predictions; while Cardigan takes up to two hours for experiments
on FUNCOUP, ProDiGe4 takes weeks to finish on HPRD the same hardware. This
evaluation was performed on HPRD, DiamondNet and BioGRID.
Combining the results over all PPI networks from the time-lapse experiments
and considering results only among the top 200 genes, Cardigan produces the best
gene ranking for 80% of the diseases. Table 6.2 compiles some interesting examples
of Cardigan predictions diseases using the 2013 OMIM database, which were later
verified. It includes diseases which had been studied for long periods of time and
yet, in 2013, were still missing associated genes – all these diseases have papers
in OMIM dated at least from the ’70s. Moreover, Cardigan was run on the entire
OMIM diseases set (without removing any seeds) and the results are available at
paccanarolab.org/cardigan. These constitute Cardigan’s predictions for the missing
genes for the real uncharted diseases, and additional genes for the charted diseases
found in the 2017 OMIM database. While most charted diseases from OMIM are
known to be monogenic and do not require additional genes to be discovered, the
predictions can still be used to identify the disease modules. Most importantly, this
table can be used as a starting point for the experimental discovery of disease genes
for uncharted diseases.
92 Charting disease gene associations
Table 6.2 Examples of Cardigan predictions using 2013 data. All the presented
diseases appeared in the 2013 OMIM database and had multiple papers associated
with them, describing clinical features, inheritance or molecular genetics. However,
OMIM did not include the associations with genes shown in the third column as they
first appeared in the paper shown in the last column. The position on the Cardigan
predicted ranking is also shown.
Disease 2013 Status Gene Position Paper
Fetal Akinesia
Deformation
Sequence
(MIM:208150)
Charted MUSK 1 Tan-Sindhunata et al.
(2015) [196]
Schimmelpenning-
Feuerstein-Mims
syndrome
(MIM:163200)
Charted NRAS 1 Lim et al. (2014)
[109]
Familial Retinal
Arteriolar Tortuosity
(MIM:180000)
Uncharted COL4A1 5 Zenteno et al. (2014)
[232]
Ablepharon-
macrostomia
syndrome
(MIM:200110)
Uncharted TWIST2 10 Marchegiani et al.
(2015) [120]
Chapter 7
Predicting genes from SNPs and
Interfaces
This chapter explores the the usage of inferred protein interfaces (from the Interac-
tome INSIDER database [130]) to build a binary PPI, and a modification for graph
diffusion algorithms [236] to include the interfaces and the localisation of the SNPs.
These modifications are designed to fit within the general approach defined for
Cardigan, and when integrated yield an interesting prototype extension for Cardigan.
The new network graph has nodes that represent protein interfaces, and edges that
represent their interactions. The diffusion algorithm tackles the problem of diffusion
for proteins with multiple interfaces (which appear disconnected in the graph). The
algorithm also identifies of particular interfaces where disease SNPs are located to
prioritise the diffusion on a particular area in the graph. This information is fed into
the model through the initial labelling vector.
The experimental characterisation of protein interfaces entails the analysis of
co-crystal protein structures, which usually banks on the expensive X-ray crystallog-
raphy [189], NMR, and more recently cryo-EM [98]. These structural approaches
identify residue interactions from the quaternary compound structure [97, 157] by
localising close residues from the two interacting proteins (e.g. a radius of 4 Å),
and other structural properties [93]. While computational methods are known to be
successful in the identification of protein interfaces, structural modelling approaches
have extremely high CPU cost [93].
Another trend followed by computational methods, that avoids the construction
of these quaternary structures, is the evaluation of biophysical properties to predict
interfaces on particular study cases [108, 159, 38, 81]. A recent computational
framework by Meyer et al., called ECLAIR (Ensemble Classifier Learning Algo-
rithm to predict Interface Residues), predicts the interfaces on a full interactome,
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Fig. 7.1 Example of a co-crystal structure and the interaction interfaces. The
light regions in the picture represent the residues which lie within the interaction
interface. Notice that while these residues are close in the quaternary and tertiary
structures (i.e. 3D space), they may be distant in the primary structure (i.e. 1D
sequence) of the protein. Picture from Meyer et al.[130].
while improving on the performance of other feature based methods [130]. ECLAIR
models each residue on a protein pair through a series of features, ranging from bio-
physical properties, evolutionary [114, 134], structural features [156], and docking
predictors [71, 157]. Multiple aggregation strategies are used to produce variations
of the features, and which serve to train a collection of classifiers. An ensemble of
the outputs of 8 independent classifiers is used as the overall ECLAIR prediction.
This proposal is certainly novel, as experimental protein interaction interfaces
are scarce, and computational predictions for an interactome level of coverage are
recently available from INSIDER, a database which aggregates high quality ECLAIR
predictions [130]. The extension can be considered to provide Cardigan the capacity
to use networks with interfaces, in addition to binary and weighted PPIs. The usage
of a network with interfaces appears to be interesting for network methods, as its
usage allowed to enhance the performance of Cardigan on Charted diseases and
disease modules.
7.1 Predicting in a protein-interface network
The proposal starts from a data prepossessing step to model the interfaces of each
protein from the interface residues contained in INSIDER. Ideally, the interfaces of
a protein are such that it could simultaneously interact to two other proteins if they
bind on different interfaces, but cannot simultaneously interact with proteins that
bind on the same interface. These protein interfaces are the nodes in the new graph,
and the edges represent the interacting protein interfaces (see Figure 7.2). Following
the Cardigan approach, the production of a protein interface Query Weight Set is
shown in Section 6.1.1. In order to include information about disease gene variants
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(a) (b)
Fig. 7.2 Illustration of a protein interface graph. Genetic variants of different
diseases (blue, green and yellow) are highlighted on the network. (a) A protein
interaction network. The solid circles represent proteins which are the nodes of the
graph, and the edges represent protein-protein interactions. (b) A protein interface
interaction network. The dashed lines represent proteins, and the solid circles
represent the interfaces, which are the nodes of the graph, and edges are interactions
between particular interfaces in a protein.
and SNPs, the known associations are mined from ClinVar [102] instead of OMIM
(more details about ClinVar are shown in Section 4.3.1).
Notice there may be some topological differences due to modelling a PPI network
as a protein interface graph instead of a protein graph. Changes on the number of
connected components, average node degree, and other graph properties can be
expected since the number of edges is likely to remain constant, while the number
of nodes increases. This is illustrated in Figure 7.2b, where the protein graph (left)
is connected, while the protein interface graph (right) has five different connected
components. Ideally, the differences in the topology serve as a better representation
of the interactome and aid the diffusion process. For instance, the yellow disease
appears to belong to a big cluster in the right of Figure 7.2a, however Figure 7.2b
suggests the existence of two different modules. In particular the disease related
module appears to bottom of the cluster, where the two interfaces with a variant are
located. Table 4.4 quantifies the main differences of the graphs used in this analysis.
The structure of the protein interface graph may also produce some unwanted
effects. If the different interfaces of a single protein are completely independent
elements, interactors on different interfaces (of the middle protein) are considered
infinitely far apart (as opposed to 2 hops away in a protein graph). This effect could
limit the ability of the diffusion in considering compounds associated to a disease,
as the diffusion would not carry the label through the different interfaces of the
middle protein. The problem is illustrated by the green disease from Figure 7.2,
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Fig. 7.3 Sketch of overlapping protein interfaces. The sketch depicts the primary
structure of interacting proteins (cyan, which interacts with pink, purple and yellow),
where the interacting residues are connected with straight lines. The first residue
is highlighted to orient the protein. The cyan protein interacts with pink through
residues 2 and 10, with purple though 4 and 11, and with yellow though 13 and
17. The proposed procedure defines two interfaces for the cyan protein: one from
residue 2 to 11, and another from 13 to 17. This considers that the pink and the
purple proteins are not likely to be able to dock simultaneously.
where all genes appear close in the protein graph (left), and spread over two different
connected components in the protein interface graph (right).
Two variants of the diffusion procedure are presented to account for the fact that
the different interfaces of a protein should not be treated as completely independent:
1) The first variant transforms the protein interface graph to a protein graph by a a
linear combination between the nodes corresponding to the different interfaces of
each protein. Thereafter it follows the steps defined by the Cardigan pipeline from
the semi-supervised Zhou et al. [236] diffusion. 2) The second variant presents a
novel formulation of a diffusion process with regularisation on an interface graph.
This yields an interface ranking instead of a protein ranking as an output. Therefore,
the final protein ranking is produced from the first observation of any given interface
of the protein.
7.1.1 Building the interaction network
While INSIDER includes a few gold standard interactions with experimental valida-
tion, most are high quality ECLAIR predictions [130]. Each INSIDER interaction
consists in two sets of residues: the interface residues of protein A, and the inter-
face residues of protein B. As low quality ECLAIR predictions are discarded, an
INSIDER interaction entry may be missing the set of residues for one of the proteins.
The INSIDER database can be directly transformed to a protein residue inter-
action graph G = ⟨V,E⟩, where the nodes V = ⟨p,r⟩ are tuples of proteins p and
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interface residues r = {ri}, that are given as a set (which might be empty r = ∅);
and the edges are:
(⟨p,r⟩,⟨q,s⟩) ∈ E,
where r and s are the interacting residues of proteins p and q respectively. Notice that
each residue may be part of several interfaces, and two interfaces may be different
even if they contain a common residue.
The following is a naive procedure to combine pairs of residue interfaces into
interaction hotspots, where different interactor proteins are expected collide if they
were to bind simultaneously (see Figure 7.3). The procedure only considers the
protein residues within hotspots to be relevant in the construction of the interface
graph, so there is no need for every protein residue to belong to a particular hotspot.
First, the set of residue interfaces r of each node ⟨p,r⟩ is extended as r¯, to include
all residues in between the minimum and maximum element of the set, which yields
the extended tuples ⟨p, r¯⟩. The naive intuition is that the interacting residues and all
residues between them are blocked during the protein binding. All blocked residues
will belong to the interaction hotspot. Formally, each tuple ⟨p,r⟩ is transformed into
an extended tuple ⟨p, r¯⟩, such that:
min{r} ≤ ri ≤max{r}. (7.1)
Then, all the extended tuples ⟨p, r¯⟩ with overlapping residues r¯ are combined
until the remaining sets are disjoint, producing the interaction hotspots1 (p,h). The
naive intuition is that a pair of interactors will collide if they block the same residue2.
Formally, the interaction hotspots (p,h) of a protein p are such that:
r¯∩ s¯ ̸=∅ → r¯∪ s¯⊆ h ∃(p,h)∀⟨p, r¯⟩,⟨p, s¯⟩ ∧
h∩k = ∅ ∀(p,h) ̸= (p,k) ∧⋃
∀⟨p,r¯⟩
r¯ =
⋃
∀(p,h)
h
.
The procedure ends with the graph Gφ =
〈
Vφ ,Eφ
〉
, where the vertices and edges
are translated to protein hotspots. The vertices are simply the set of all protein
1Parenthesis are used instead of angle brackets to add clarity in the notation.
2The naive procedure clearly does not account for several 3-dimensional properties of proteins.
For instance, it does not consider that a residue chain may fold and expose the ends of a residue
chain in one area of the surface, while the middle of the chain is exposed in another; nor does it
consider to block residues beyond the known interface residues, which may also be obstructed in the
3-dimensional space by an interactor. These (and other) considerations could be explored in further
research.
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hotspots Vφ = {(p,h)}. The edges Eφ are such that if two interfaces interact, then,
the hotspots containing those interfaces interact. Formally:
(⟨p,r⟩,⟨q,s⟩) ∈ E →{((p,h),(q,k)) ∈ Eφ |r ⊆ h∧ s⊆ k}.
Notice that with this procedure, the empty interfaces ⟨p,∅⟩ are not combined
into other hotspots, and yield equivalent elements (p,∅). This is an intended feature
because they can be overlapping with any of the defined interfaces, or possibly
through a different still unknown interface.
While the hotspots are not precisely protein interfaces, they represent the same
concept for all intended uses of this network. Henceforth the binary undirected graph
Gφ =
〈
Vφ ,Eφ
〉
is referred as the interface network, with edges Eφ between protein
interfaces in Vφ .
For a future simplification of notation the set of all the interfaces of a protein p
is represented as {p,∗}. The set of edges incident on an interface h is denoted as
{(p,h),∗}, and the edges incident on a protein p as {{p,∗},∗}.
Following this procedure, the INSIDER database yields the interactome with
interfaces, which is referred to as the INSIDER ECLAIR network (represented
by Gφ ). However, INSIDER can be used to produce a simple interactome by
connecting pairs of proteins which have interacting interfaces (essentially ignoring
the interfaces), which is referred to as the INSIDER PPI (compared in 4.4).
7.1.2 Building the Query Weight Set with interfaces
Analogously to Cardigan, the Query Weight Set (QWS) is a collection of weights
associated to the protein interfaces all known diseases, and it is calculated for each
query disease given. The disease-gene associations are mined from ClinVar [102],
which details the particular SNPs associated to each disease. The construction
presented here tweaks the procedure from Section 6.1 to associate the weights to
particular protein interfaces when possible.
The QWS is produced by an iterative procedure, based on the Caniza et al.
similarity [20]. On each iteration, the unweighted proteins associated with the
disease most similar to the query not yet visited are collected. Then, the similarity
between the disease and the query is scaled by a sigmoid function. If the SNP occurs
in a particular interface, it is associated with the weight; otherwise the weight is
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uniformly distributed to all the protein interfaces3. The process continues until all
diseases in the ClinVar database are visited.
Other databases that associate gene variants to phenotypes (such as HGMD [193]
or DisGeNET [158]) could be used instead of ClinVar, although it is possible that
the method parameters would require to be trained again.
7.1.3 Variant 1: Compacting the network
This variant is explained easily following the matrix representation of the consistency
method by Zhou et al.. The procedure entails calculating the matrix representation
of the interface problem (φ ), and a linear combination of the elements corresponding
to the same protein reducing to a protein matrix representation (ρ). Recall that the
label propagation procedure diffuses the initial labels from the QWS (stored in Y )
in order to minimise the cost function C(F) from Equation 6.1. This has the matrix
representation from Equation 6.2:
F = β (I−αS)−1Y,
where K = β (I−αS)−1 is a diffusion kernel [236].
Let Yφ be the initial label distribution given by the interface QWS (following
Section 7.1.2), and Kφ the Zhou diffusion kernel derived from the interface graph
Gφ =
〈
Vφ ,Eφ
〉
. The elements of interface vector Yφ are combined to form protein
vector Yρ following:
Yρ [p] = ∑
h∈{p,∗}
ω[p,h]Yφ [(p,h)] ∀p ∈Vρ,
where Y [i] is element i of the initial vector, and ω[p,h] is the fraction of interactors
of protein p that bind on interface h:
ω[p,h] =
|{(p,h),∗}|+δ [p]
|{{p,∗},∗}| , h ̸=∅
where δ [p] is the chance of getting extra links due to a void interface, defined as:
δ [p] =
|{(p,∅),∗}|
|{p,∗}| .
3Recall that the current methodology is proposed for disease gene prediction, and is not intended
to identify which interface is associated to the disease. Distributing the weight to all interfaces
equates to flagging the entire protein as a seed for diffusion, as no interface can be identified as a
preferential focus for the diffusion. Furthermore, SNPs might cause alterations to the protein folding
or non-functional protein products, so it is sound to consider that a deleterious SNP may affect all
interfaces.
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To allow consistency between the amount of edges:
ω[p,∅] =
δ [p]
|{{p,∗},∗}| .
An analogous process is followed to reduce the dimensionality of Sφ and derive
Sρ as:
Sρ [p,q] = ∑
h∈{p,∗}
ω[p,h] ∑
k∈{q,∗}
ω[q,k]Sφ [(p,h),(q,k)] ∀p,q ∈Vρ ,
where S[i, j] represents row i and column j of matrix S. The protein-wise diffusion
kernel is calculated as Mρ = β (I−αSρ). This variant effectively transforms the
interface network and corresponding diffusion to a protein network and provides a
diffusion kernel to handle the nuance characteristics.
This model has proved to work empirically, however, the diffusion kernel does
not match the mathematical formulation from Equation 6.1 after the transformation.
This has the effect that there are no guaranties that the diffusion process will hold for
any interface graph. The following variant proposes a formulation for a diffusion
process for a graph with interfaces to address the lack of mathematical guarantees.
7.1.4 Variant 2: Diffusion on the interfaces
The second variant presents a full formulation of the cost function C(F) for a
interface graph Gφ =
〈
Vφ ,Eφ
〉
, expanding on theoretical concerns of the Zhou et al.
formulation. The cost function C(F) = 12(C1+C2+C3) is composed of three terms,
where the first penalises the difference in label between connected nodes (as given in
the consistency method):
C1 = ∑
((p,h),(q,k))∈Eφ
W [(p,h),(q,k)]
[
F [(p,h)]√
DW [(p,h),(p,h)]
− F [(q,k)]√
DW [(q,k),(q,k)]
]2
(7.2)
where W is the weight matrix derived from the interface graph, and the diagonal
degree matrix D for a generic matrix A has elements:
DA[(p,h),(p,h)] = ∑
(q,k)∈Vφ
A[(p,h),(q,k)].
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The next addresses the concern of sharing the label across interfaces of the same
protein. This term penalises the difference in label across all different interfaces of a
protein:
C2 = λ ∑
p∈Vρ
1
|{p,∗}| ∑h,k∈{p,∗}
[F [(p,h)]−F [(p,k)]]2 , (7.3)
where λ ∈ (0,∞) is the relative importance of the term, Vρ is the set of all proteins
in the interactome, and |{p,∗}| is the number of interfaces for protein p.
The final term is set to conserve the original labelling, where lower initial
labels are given a lower penalisation if they change. This considers that a low seed
represents that initially there is little information to associate that gene to the disease;
it does not represent that there is information to keep the gene far from the disease.
This is a crucial difference with similar formulations [136, 206, 236] where initial
labels equal to zero are taken as true negative associations. Formally:
C3 = µ ∑
(p,h)∈Vφ
G(Y [(p,h)])(F [(p,h)]−Y [(p,h)])2 , (7.4)
where µ ∈ (0,∞) is the relative importance of the term, the function G(Y [(p,h)]) =
γ +Y [(p,h)] establishes the importance of each initial label, and Y ∈ [0,1] is the
QWS for the protein interface graph. Here, Fi −Yi is the change in label and
Yi+ γ is the penalisation coefficient, where γ is a small positive value to represent
the likelihood of the zero values of the initial labelling to be correct4. A lower
penalisation coefficient equates to give further priority to the adjacent labels, so that
node will approximate better the value of its neighbours when Yi is low.
The addition of Equations 7.2, 7.3 and 7.4 yields C(F). The following for-
mulation uses a subscript notation instead of the full protein notation to ease the
reading:
4A penalization coefficient of zero for all initial values equal to 0 could cause the diffusion method
not to prioritise the module around the high seed values, breaking one of the core principles behind
the methods presented in this work. Consider an extreme case with a single label equal to 1 and
the rest equal to 0. That diffusion would be dominated by the labels of adjacent nodes and other
interfaces (C1 and C2). A final labelling where all nodes of are equal to 1 would minimise that cost
function since there are no differences between pairs of nodes. However, this would not prioritise the
topological module around the seed.
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C(F) =
1
2
 |Vφ |∑
i, j=1
Wi j
∥∥∥∥∥ Fi√Dii − Fj√D j j
∥∥∥∥∥
2
2
+λ
|Vφ |
∑
i, j=1
Bi j
∥∥Fi−Fj∥∥22+µ |Vφ |∑
i=1
Gii ∥Fi−Yi∥22

(7.5)
where the block diagonal matrix B = diag(B1, . . . ,Bn) with square blocks Bp of size
|{p,∗}| connects the interfaces of a each protein p:
Bp[i, j] =
1
|{p,∗}| ∀i, j (7.6)
and the diagonal matrix G = diag(Y1+ γ, . . . ,Y|Vφ |+ γ) represents the trust of each
initial label Y . Notice that the main diagonal of G is strictly positive and therefore it
is symmetric positive definite (SPD) as it is a diagonal matrix [27].
The matrix form of Equation 7.5 can be seen as:
2C(F) = FT (I−D−1/2W WD−1/2W )F +λFT (DB−B)F +µ(F−Y )T G(F−Y )
= FT LsymW F +λF
T LBF +µ(F−Y )T G(F−Y )
(7.7)
where LsymW is the symmetric normalized Laplacian of W , and LB is the Laplacian of
B [27].
Then, the optimum labelling F can be found equating the gradient of C (Equation
7.7) to zero ( ∂C∂F = 0). This yields:
∂C
∂F
= LsymW F +λLBF +µG(F−Y )
(LsymW +λLB+µG)F−µGY = 0,
(7.8)
since LW , LB and G are SPD, their sum is SPD (and is invertible) [27]. Therefore, F
has the following closed form solution:
(LsymW +λLB+µG)F = µGY
F = (LsymW +λLB+µG)
−1µGY
. (7.9)
Notice that GY produces a column vector and that (LsymW + λLB + µG) is a SPD
matrix. Therefore, the solution of the linear system can be found using the Conjugate
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Gradient method. Recall that G is a function of Y , so the Equation matrix must be
calculated for each prediction.
From this formulation the approach follows the Cardigan pipeline to produce the
final results.
7.2 Evaluation
The performance of both Variants is compared directly to Cardigan on the prediction
of ClinVar disease associations5. Other methods (i.e. ProDige1, ProDiGe4 and
DIAMOnD) are excluded due to their subpar performance (see Section 6.2). The
evaluation is centred on charted diseases as the purpose of the extension is to analyse
the applicability of known genetic variants. Cardigan is run on the INSIDER PPI
network, while Variant 1 and Variant 2 are run on the INSIDER ECLAIR network.
This choice is made since the some topological components in the protein network
can become disconnected when considering the interface graph (illustrated in the
bottom-right cluster from Figure 7.2), which could affect Cardigan’s performance.
This configuration causes Cardigan and Variant 1 to directly rank INSIDER
proteins, and Variant 2 to rank INSIDER protein interfaces. The current evaluation
continues to be based on the identification of disease genes. Therefore a protein
interface ranking is made comparable by ranking only proteins based on their first
occurrence in the prediction. The identification disease interfaces, or regions in the
disease protein which might contain SNPs is a completely separate problem. This
problem will require an additional state-of-the-art review to build a new evaluation
pipeline, which escapes the scope of this exploratory analysis.
The following experiments are exclusively composed of test sets from ClinVar
diseases where the target genes are synthetically removed, and later predicted by
the procedures. Gene predictions are evaluated using the recall at thresholds, and
module predictions using the normalised ROC (details on Section 4.2.1). Only the
latest version of the ClinVar database is found available [102], therefore time-lapse
experiments cannot be performed (see Section 4.1).
Variant 1 solves F = (I−αSρ)−1Yρ using all the default diffusion parameters
from Cardigan.
Variant 2 contains a different formulation so its parameters were trained following
Section 6.1.2. The procedure derived in λ = 2.5, µ = 3.8, h = 0.8, a = 2.0 and
b = 3.0. Additionally, the confidence in initial zeros was set as γ = 0.01.
5The ClinVar database provides an OMIM identifier for its diseases which allows the creation of a
QWS (independently for Cardigan and the Variants) using the Caniza similarity. The QWSs created
in these experiments contain only ClinVar diseases and gene associations.
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(a) (b)
Fig. 7.4 Testing Cardigan variants for charted diseases. Performances for a leave-
one-out testing for diseases with a single associated protein in ClinVar. Cardigan
uses the INSIDER PPI, while the variants use the INSIDER ECLAIR networks. (a)
Normalised ROC for the top 10 predictions. (b) Shows the fraction of disease genes
found within the top 1, 10, 100, 200 predictions.
Charted diseases
The initial comparison is a leave-one-out charted experiment. It tests the performance
of Cardigan and Variants when disease genes are removed one at a time and predicted
back. There are 133 diseases with two or more associated proteins in ClinVar, which
yield a total of 416 possible test cases. Out of the 416 cases, 365 can be performed
using proteins from the INSIDER database. Figure 7.4a presents a normalised ROC
curve for the first 10 predictions and shows how both Variants edge over Cardigan
after a few elements. Figure 7.4b shows that the difference is 2% at 10 predictions,
and is sustained up to 200 predictions. Notice that Variant 2 stars with the lowest
performance, but it performs the best at 200.
Uncharted diseases
The second comparison is a leave-one-out uncharted experiment. If a given disease
has only one known disease gene, then removing it yields a synthetic uncharted
disease. There are 3474 diseases with a single gene association in ClinVar. Out of the
3474 possible test cases, 2967 can be performed using proteins from the INSIDER
database. Figure 7.5 shows that Cardigan and the Variants perform very similarly
when no genes are known. The trend where Variant 2 drops a bit in performance and
catches up with the other methods seen among the top 10 results (Figure 7.5a), is
consistent up to 200 predictions (Figure 7.5b). However, the difference is less than
1% and Variant 2 can be considered to produce high-quality results comparable to
Cardigan.
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(a) (b)
Fig. 7.5 Testing Cardigan variants for uncharted diseases. Performances for
a leave-one-out testing for diseases with a single associated protein in ClinVar.
Cardigan uses the INSIDER PPI, while the variants use the INSIDER ECLAIR
networks. (a) Normalised ROC for the top 10 predictions. (b) Shows the fraction of
disease genes found within the top 1, 10, 100, 200 predictions.
Disease modules
Finally, both Variants are evaluated as disease module prediction methods. For this
prediction, the Ghiassian et al. disease module dataset [55] (see Section 4.3.1), as
used for the Cardigan evaluations (see Section 6.2.3). The test consists in removing
different percentages of known genes, and predicting all the targets simultaneously.
The Ghiassian dataset contains 70 diseases and the molecular basis is annotated
with Entrez identifiers [117], which need to be translated for their usage with the
INSIDER network. The proteins are mapped to UniProt [31] using the translation
database provided by the HUGO gene nomenclature committee [226], rendering
1529 proteins and 2831 disease-protein associations available testing (99.6% transla-
tion success).
Figure 7.6 shows how both variants outperform Cardigan in different thresholds.
Variant 1 performs better when the number of missing genes is lower, and Variant 2
performs better when large percentages of the modules are missing. Notice that the
difference in performance shown is in terms of the Normalised AUC, and that many
diseases produced no results, lowering perceived difference.
7.3 Discussion
Pros and cons of the Variants
The novel methodology allows incorporation of clinical variants and protein inter-
faces into a protein interface graph for a network medicine application in disease
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Fig. 7.6 Performance at reconstructing disease modules. Different percentages
of disease modules from Ghiassan et al. are removed and modules are then re-
constructed. The y-axis shows the AUC of the ROC curve normalized for the first
200 false positives predictions. Error bars were calculated using the results for all
diseases, each one with 10 random selections of kept genes. The expected value for
a random prediction is 0.007.
gene prediction. This can be considered an extension to Cardigan, which already
contains interesting features such as allowing predictions for uncharted diseases and
the inclusion of up-to-date phenotypic information.
In principle, different gene variants will affect different modules around the
gene. The intuition is that the usage of interfaces allows the method to differentiates
between the modules. This can be seen when the method prioritises the selection of
candidates along the disrupted interface, while reducing the diffusion through the
unaltered interfaces. The candidates along the disrupted interface can be directly
affected by alterations in the interaction due to a mutant interface. Interactions
through the unaltered interfaces should not be entirely ignored in the procedure as
proteins found through those interfaces do interact with a disease protein. A complex
formed with a disease protein will a potential effect on some biological process.
Variant 1 is produced to test the viability of using networks with interfaces, and
it is remarkable by outperforming Cardigan on charted diseases. These results are
encouraging to consider further development on the interface approach, with possible
improvements on the interface combination procedure. Furthermore, the method can
be extended to include other networks by a natural continuation of this Variant since
∅ interfaces are basically considered to be the normal PPI nodes, as opposed to the
interface nodes. Additional networks can be trivially added to the graph using the
same considerations given to the ∅ interfaces.
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Unfortunately, Variant 1 presents a notable shortcoming regarding its formulation.
The current incarnation essentially transforms a rich network with interfaces into a
weighted protein protein network, through a heuristic procedure. While the extra
information provided by the interfaces is encoded into these weights, the formulation
of the diffusion procedure may lack mathematical rigour when handling the inter-
faces. It is therefore fundamental to produce a new mathematical formulation which
considers the nature of this peculiar graph.
This shortcoming is addressed by Variant 2, which provides a cohesive framework
that integrates the variables at play in this diffusion problem. Section 7.1.4 describes
a theoretically sound diffusion process which includes a network with interfaces and
a formal demonstration of the feasibility of the solution. The inclusion of known
SNPs is natural in this formulation, as they are encoded in the QWS. The QWS is
represented by vector Y , which not only determines the initial labels to diffuse, but
transforms the underlying diffusion pattern as matrix µG (from Equation 7.9) is built
with Y .
Variant 2 is not designed to improve the performance of Variant 1, nonetheless,
the performance of Variant 2 is competitive in all the experiments (it is even the top
performing method for some thresholds in Figure 7.4). This exceeds the expectations
of the approach, and justifies the research of additional considerations to warrant a
better overall performance.
The diffusion formulation from Variant 2 presents some notable characteristics,
which could be usable in other diffusion methods. 1) The formulation shows how an
additional term in the cost function can be used to share a label between disconnected
nodes. Notice that the second term of the formulation (Equation 7.3) controls the
similarity between sets of nodes that have no edges but are joined by a conceptual
grouping (interfaces of the same protein are joined together). An analogous approach
can be used to combine different networks which have the same nodes, but where
the edges have different meanings. The idea is that the nodes of the independent
networks can be seen as interfaces of the node in the aggregation network. This
idea could be used to incorporate data such as protein complexes [140], Pfams [13],
metabolic and transcriptomic data [3, 54] into a single graph suitable for a diffusion
process. 2) The formulation subscribes to the positive-unlabelled (PU) learning
paradigm, in which in the absence of interactions do not represent negative data.
This consideration follows from the fact that experimental biological data is hard to
obtain, and experiments rarely prove negative interactions or associations. Several
methods use PU learning with diffusion [136, 206, 236]. However, this formulation
adds further richness to the model as it considers that the low weighted labels are
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more likely to be wrong than the high weighted labels. The application is seen in the
third term cost term involving the initial labelling vector Y in Equation 7.4.
A drawback of this formulation is the inclusion of extra hyperparameters in the
algorithm. The third term in Equation 7.5 adds the regularization parameter λ , and
increases the training cost of the procedure. However, the hyperparameter training is
not a time constrained step, since it is performed previous to all particular predictions.
The time cost of an individual prediction of Variant 2 is comparable to a prediction
from Cardigan and takes less than a second.
Prediction of disease gene or drug binding interfaces
The prediction of disease gene interfaces is a new problem that appears tractable
with the current proposal (Variant 2). However, this might prove a bit tricky given
the low amount of data current available. Notice the nodes representing ∅ interfaces
do not identify particular regions in the protein, so they do not serve to distinguish
between different interfaces in a protein. Table 4.5 shows that only about 2% of the
proteins have 2 or more predicted interfaces (discarding ∅ interfaces), which yields
∼ 60 disease genes with multiple interfaces. Furthermore, only a fraction of those
genes have SNPs within the interfaces. Such a small set of known disease interfaces
(compared to ∼ 2300 known disease genes used in the current prediction) would
make any leave-one-out validation scarcely significant.
Nonetheless, some changes to the input dataset could make the problem viable for
evaluation. For instance, a database of protein domains could be mined to determine
the possible locations and number of interfaces per protein (this could eliminate the
need of ∅ interfaces). Table 4.5 shows that ∼ 7000 nodes have a ∅ interfaces, which
could potentially derive into multiple interfaces. An increase to the number of known
disease interfaces could be sufficient to make a leave-one-out validation significant.
The fact that drugs do not generally interact with disease genes may suggest that
the prediction of drug interfaces cannot benefit from this approach. However, the
prediction of a drug binding interface appears to be feasible if the protein target is
known (i.e. the problem is the selection of the protein interface most likely to interact
with the drug). In this case, Variant 2 could be used to diffuse the disease QWS,
with no left out genes (the prediction does not intend to match the drug target to any
disease gene). The final labelling will create a priority over all protein interfaces
in the network. Therefore, each interface from the drug target will be prioritised
towards the one more involved with the disease process. It is sound to expect that
the drug would affect the interface most involved with the disease.
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Considering variants from non-coding regions
Currently, the method has no way to include deleterious variants located outside the
exome in the model, since the nodes and edges of the protein interface graph are
defined from protein protein interactions (mined from INSIDER). However, an inter-
face graph could be used to model a transcriptomic/regulatory network, where the
interfaces are based on the binding domains of the regulatory elements. An interface
graph defined exclusively from binding domains will match the considerations made
in this analysis, in particular that all edges represent similar interactions. The nodes
of this network will be the binding domains of transcription factors, enhancers and
promoters. Notice that it is likely that no nodes will show multiple interfaces in this
regulatory network, since transcription factors are not expected to contain multiple
DNA-binding domains [100].
This transcriptomic network might not be sufficient to identify the extension
of the disease modules, since it does not account for the genetic interactions due
to protein activity. The usage of a heterogeneous interface graph, that joins the
protein interface graph to the transcription interface graph, could be useful for this
problem (Section 10.3 discusses possible future work in this direction). Notice that
the transcription factors are proteins common to both networks, so the transcription
factors will have interfaces for DNA-binding and protein interaction. Additionally, a
gene promoter (a node from the transcription graph) could be considered as as an
additional interface of the proteins encoded by that gene, which would integrate the
relationship of protein expression into the model. The edges of this heterogeneous
graph will remain connected to the same nodes as in the independent graphs.
It is unclear if the interface approach could be used to link deleterious variants
to disease using other non-coding region maps, such as topologically associating
domains (TADs). Notice that the usage of interfaces represent independent compart-
ments of a well defined biological unit (e.g. a protein). Each compartment allows
the biological unit an independent set of interactions to other biological units. The
model is focused on the interaction between biological units, and the interfaces only
group independent interactions. TADs represent areas in the DNA that interact with
each other more than expected by random chance. TADs can be certainly seen as
compartments, but the bigger well defined biological units (composed of TADs) are
harder to define. It is also a stretch to consider the TADs as the biological units, since
the interfaces would be collections physically interacting reads. It is unclear on how
such a model will differ from a contact matrix (the result of a Hi-C experiment) [72].

Chapter 8
Additional Research
This Chapter presents an overview of other work and projects related to disease I
have worked on during my PhD.
Sections 8.1 and 8.3 present a short overview of two collaborative projects and
my contributions in those works. Sections 8.2 and 8.4 are independent works derived
from those projects.
8.1 Identification of Cancer genes
This work resulted in a publication in Nature Methods called Subclonal mutation
selection in mouse lymphomagenesis identifies known cancer loci and suggests novel
candidates and is the biggest analysis of murine leukaemia virus (MuLV) induced
lymphomagenesis up to date [216]. It includes 700,000 sequenced mutations from
over 500 lymphoid malignancies at different stages of tumour development. The
study produces a set of novel candidates for cancer. The scale of the work also allows
to map low clonality inserts across multiple tumour samples to regions surrounding
known oncogenes. The analysis shows evidence that rare cancer mutations may
appear more frequently than expected by random chance as a subclonal mutation in
late stage cancer samples. This in turn shows that subclonal mutations can provide
evidence to impute rare cancer drivers.
The work is part of a long collaboration with Dr. Anthony Uren and his research
groups at the MRC London Institute of Medical Sciences and the Institute of Clinical
Sciences, Imperial College London.
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Approach to tumour stage classification
Newborn mice were infected with MuLV which cause a lifelong process of viral
insertions. The accumulation of viral insertions (which can be seen as single nu-
cleotide alterations) cause malignancies, which are studied after the mices’ death.
All 355 mice developed the malignancies between 42 to 300 days after infection.
These lymphoid malignancies were sequenced at different growth stages to derive
the profile of insertions found in the genome. Furthermore, a cohort of 166 animals
were sampled and sequenced at days 9, 14, 28, 56, 84, and 128 after infection for
additional reference of mutation rate.
The outcome of the sequencing process for each sample is the insertion profile
at a 100kb resolution, associated with the age of the sample – i.e. the output is the
sample clonality: a vector with the number of cells with insertions per common
integration site (CIS). However, the stage of the tumour was not known for all
samples, since the aggressiveness of the malignancy significantly varied the stage of
the tumour.
My work consisted in the classification of the tumour stage from the sample
clonality vectors. Manual curation of selected samples showed on one hand that
the CIS clonality values for the early-stage samples are relatively low and uniform.
This distribution can be expected to come mostly from random insertions while
cells with the malignant mutations have not multiplied significantly. On the other
hand, late-stage samples present few CIS with very high clonality values (clonal
CIS) and most with low clonality values (subclonal CIS). The cells with malignant
mutations are expected to multiply more, so driver mutations are expected to be
included within the clonal CISs. Notice that a sample may contain more than one
malignancy. The insertions associated to less aggressive malignancies are expected
to appear as subclonal CISs in several samples.
The difference between the clonality vectors was quantified using the Shannon
entropy [183], to allow samples to be sorted from pre-malignancy to late-stage lym-
phoma. In practice, only the 50 highest clonality values c1,c2, . . . ,c50 are considered
per sample, to limit the number random mutations analysed. The clonality vectors
represent the insertion frequencies, so the normalized insertion frequencies define
a probability distribution of the insertions. This probability distribution is used to
calculate the Shannon entropy. Formally, ci is transformed to pi as:
pi =
ci
50
∑
j=1
c j
.
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(a) Early stage (b) Late stage
Fig. 8.1 Clonality profiles of early and late stage tumour samples. The profiles
plot the distribution of normalised clonality values sorted from higher to lower.
The few clonal CIS observed in the late stage samples suggest the presence of a
cancer mutation, which replicated into many cells of the sample. On the other hand,
subclonal samples may occur as passenger mutations or drivers of earlier stage
malignancies. Notice that the CISs are shown in different orders on each sample,
and the plot only shows a relative distribution of clonality values. Figure excerpt
taken as is from the publication [216].
Then, the Shannon entropy E over a set of probabilities p1, p2, . . . , p50 is calculated
as:
E =−
50
∑
i=1
pi log pi.
The entropy quantifies the spread of a distribution: it is zero when a single pi is
equal to one and all others are equal to zero, and reaches its maximum value when
the probabilities are uniformly distributed (pi = 1/50 for every i). The probability
vector preserves the distribution of the sample clonality vector, so the entropy is
expected to discriminate well the early-stage samples from the late-stage samples.
Probabilities from early-stage samples are closer to a uniform distribution and
therefore the samples will have high entropy values, while the probabilities from
late-stage samples are closer to a spike, providing low entropy values (Figure 8.1
shows one line per sample). Further manual curation established entropy values of
3.5 or higher as late-stage samples.
Additional work
I have performed additional tasks under this collaboration which remain unpublished.
Most of them are related to statistical validation of putative gene sets, in particular
validation that includes PPI networks. The integration of human and mouse genes
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derived on a heterogeneous interactome which includes genes from human and
mouse origin presented in Section 8.2.
The network-based statistical validation consists in an over-representation analy-
sis of known oncogenes compared to the set of putative genes and all their interactors
in the PPI (neighbourhood-1 of the putative genes). This model considers the
hypergeometric distribution as the null model:
p =
(K
k
)(N−K
n−k
)(N
n
)
where N is the network size, n is the size of the neighbourhood-1, K is the number
of oncogenes considered, and k is the number of oncogenes in the neighbourhood-1.
This validation was produced to identify the genes close to a high clonality
CIS most likely to be an oncogene. Over 900 genes were found close to the 300
CISs with the highest clonality values across different late-stage samples. An over-
representation analysis of the ∼ 900 genes reported a huge enrichment for known
cancer genes from the COSMIC [49] database, which provided an overall validation
for the selection method.
The set of candidates was narrowed by selecting mutated genes which appeared
significantly biased in one of 4 categories1: found more often in the top 50 CIS of
late stage samples (compared to early stage), preferential insertions in the forward
or the reverse strand (strand specificity), developed preferentially into T cell or B
cell lymphomas (lymphoma subtype specificity), or if the mutated gene developed
lymphoma significantly more rapidly in the wild type or BCL2 transgenic (genotype
specificity). A gene that fits any one of this criteria is considered as a valid candidate.
Therefore, the 420 genes that fit at least one criteria are set as candidates.
Notably, 47 of those candidate genes are part of a high quality consensus list of
291 known cancer genes [52]. Out of those, 21 were verified as subclonal mutations
with a late stage bias. This shows that subclonal mutations can provide statistical
evidence to identify cancer drivers with insufficient clonal mutations [216].
8.2 Human Mouse Interactome
This project describes a general procedure to combine protein-protein interaction
networks from different organisms into a single heterogeneous interactome [17]. The
1The bias of a gene towards a category is evaluated with an over-representation analysis of the
gene in a particular category. No network components are involved in this evaluation.
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approach is suggested to be useful for the analysis of genetic experiments performed
in organisms other than the intended target.
This pipeline was used to construct a human-mouse network which was used
during the research stages of the lymphomagenesis project. This network served to
contextualize the candidate mouse proteins in a human interactome. The publication
intends to share a working pipeline, and to discuss some common issues found when
mapping proteins from different databases.
The publication includes a detailed mathematical notation and formal criteria
to map gene synonyms in databases with possibly conflicting identifiers. These
details are skipped here for the sake of simplicity, and the mapping between different
databases is considered to be seamless. Nonetheless, the results strongly suggest that
the usage of gene symbol synonyms produces erroneous protein matching.
Producing a combined interactome
The first step to combine two organism graphs Ga = ⟨Va,Ea⟩ and Gb = ⟨Vb,Eb⟩
is to obtain the set of equivalent vertices. The equivalent vertices merge all the
homologous proteins found in the pair of organisms – i.e. vertices va ∈ Va and
vb ∈Vb are merged vab if va is homologous to vb. Notice that two vertices of the same
organism a can be merged into a single combined vertex if they are homologous
to the same vertex of the other organism b. The combined vertices Vab can be
considered to belong to different homology classes.
The edges of the combined interactome Eab are aggregations of the edges of
the independent graphs Ea and Eb. If the vertices of an organism have an edge, the
combined vertices will also have an edge ((va,ua)∈ Ea∨(vb,ub)∈ Eb → (vab,uab)∈
Eab). This yields edges with three possible evidence types: evidence from a, evidence
from b or evidence from both. This concludes generation of the the combined graph
Gab = ⟨Vab,Eab⟩.
In particular, the human-mouse interactome is produced from the BioGRID v3.2
database [24], which includes protein-protein interaction networks for human and
mouse. Furthermore, BioGRID includes a some proteins human proteins in the
mouse interactome, and conversely mouse proteins in the human interactome. This
mapping is used as the homology mapping when possible. Additional homology
pairs are mined from the Human-Mouse homology database [45] provided by the
Mouse Genome Informatics (MGI) project.
The final human-mouse interactome consists of 17,644 vertices and 169,458
edges. Notably 6,139 out of 6,824 of the mouse genes mined from the 2014 BioGRID
database were homologous to a human gene. Considering the increase in size from
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the mouse interactome, the final combination represents an increase of over 150% in
the number of vertices, and an increase of over 430% in the number of edges. This
number comes much closer to the expected 25,000 genes in a mouse interactome
[61]. Notice that recent releases of BioGRID have considerably increased the size
of its mouse interactome, so this procedure is no longer needed to complete that
network. However, the approach is still useful for other organisms with smaller
known interactomes.
A short lesson on synonym mapping
Genetic databases frequently identify genes or proteins by “standardised” gene
symbols and proprietary identifiers [24, 31, 117, 226]. To match heterogeneous
updates in nomenclature, the PPI databases frequently contain synonyms to a main
symbol. However, these synonyms are not equivalent names for the protein in the
mathematical sense.
In maths, an equivalence relation≡ is a binary relation which is reflexive (a≡ a),
symmetric (a ≡ b → b ≡ a) and transitive (a ≡ b∧ b ≡ c → a ≡ c). This relation
can be used to build the equivalence class of an element [a]≡, which is defined by
elements related to a by ≡.
Considering gene symbol synonyms as equivalences, finding the set of all equiv-
alence classes in BioGRID yields a class containing more than 2,500 genes. These
genes are definitely not equivalent (or homologous) in a biological sense.
Gene synonyms are not transitive.
8.3 Prediction of drug cocktails for Chagas Disease
This project consists in the prediction of drug cocktails using FDA approved drugs,
with putative effect against the Trypanosoma cruzi (T. cruzi) during the chronic phase.
The T. cruzi is vector based parasite, that produces Chagas disease and is endemic to
Latin American countries. The disease has two phases: acute and chronic. There
are two drugs effective against the disease during the acute phase (benznidazole
and nifurtimox), however this phase is often asymptomatic and the disease remains
undetected until the chronic phase. While some individuals never develop symptoms,
the chronic phase affects the digestive system, nervous system, or heart and may
result in sudden death.
The computational analysis is divided into two approaches to produce sets of
putative drugs, a multi-objective approach to select the drug cocktails and in vitro
experimental validation of the cocktails. This work derived in an IEEE Xplore
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publication called Drug cocktail selection for the treatment of chagas disease: A
multi-objective approach [198].
The project is collaboration with research groups from the Universidad Católica
“Nuestra Señora de la Asunción” (UCA) and Centro para el Desarrollo de la Investi-
gación Científica (CEDIC) from Paraguay.
Overview
The first approach selects drugs based on homology and includes different layers.
The organism layer selects drugs designed for organisms close to the T. cruzi. The
organisms are considered close based on an evolutionary distance in the tree of life
and similarity of the 18S rRNA. The metabolic pathway layer selects drugs which
target enzymes homologous to those found in T. cruzi pathways. The pathways were
inferred using the Pathway Tools suite [84] and mined from KEGG [82].
The second parallel approach produces machine learning models to predict an
antitrypanosomal drug effect. The models are trained on results of small molecule
screening studies and include chemical features and feature-connectivity fingerprints
[169] to build a Quantitative Structure Property Relationship (QSPR) model [201].
The selection of drug cocktails is considered a multi-objective approach, which
integrates the biological concepts from the homology approach to the output of
the machine learning model. The cocktail is expected to maximise the number of
enzymes targeted, the number of pathways targeted, and the percentage of enzymes
covered per pathway. All these measures are intended to increase the likelihood of
disrupting essential genes or processes in the T. cruzi. Notice that the multi-objective
approach naturally deals with the possibly conflictive objectives. For instance, given
a reasonable cocktail size (e.g. less than 6 drugs), an increase in number of pathways
targeted is likely to reduce the percentage of enzymes covered per pathway.
Due to constraints for in vitro verifications, about a dozen cocktails were tested
so far prioritising new candidate drugs. While these showed modest effectiveness
against the disease, several drugs generated from the machine learning approach were
included in previous studies against Chagas [94]. This suggests that the methodology
is sound and that it may produce results of biological significance.
My work in this collaboration consisted mainly in guiding graduate students
from the UCA, in particular for the homology approach, and producing the drug
combinations.
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8.4 Characterisation of Drug Modules
This is a personal work [18] which considers a complementary characterisation of
disease by analysing drugs used for their treatment. The working hypothesis is that
drug targets should interact with the disease module in order to produce an effect to
treat the condition. While ideally drug targets would be part of the disease module,
drug mechanisms of action are incredibly heterogeneous.
Some drugs can be reasonably expected to interact with the disease module,
such as supplements, which are designed to replace missing nutrients or compounds.
Therefore, these drugs would be part of a metabolic pathway related to the condi-
tion. However, drugs are far more frequently designed to treat the symptoms of a
disease, and may incur in complex interactions to produce the desired effect [73].
Common examples are painkillers (i.e. anti inflammatories and opioids), anti-acids
(i.e. histamine antagonists, proton pump inhibitors), and blood thinners. Among
these drugs, opioids are particularly not expected to belong to disease modules, since
they produce an effect by blocking signalling pathways [73].
These complex interactions prompted the usage of network analysis to understand
the role of drug targets and disease. Drug targets are rarely protein products of
essential genes. However, they still target proteins inside topological modules. The
average drug target degree is above the network average and below the essential gene
average2 [227]. These properties proved helpful for the identification of functional
modules affected by the drugs other than the intended effect, which in turn yielded
applications for drug repurposing [70].
This work develops a general basis to analyse the phenotypic and genotypic
relation between drugs and heritable diseases by proposing drug modules. Since
drugs and diseases are a priori incomparable, a disease-drug category mapping is
initially produced. The disease categories are used roughly as disease families, and
define disease modules [90, 139, 148], while the drug categories yield a novel lax
approximation to the drug target counterpart of disease modules – i.e. drug target
modules.
The analysis has two components, a characterisation of drug target modularity
by the assessment of modular features, and later a comparison between drug and
disease category modules (see Section 4.2.2 for more details). Target locality and
functional similarity of drug targets to quantify their specificity and possible side
effects, which can be exploited for drug repositioning.
2The essentiality of a gene is known to correlate to the degree of the protein it encodes. In average,
essential proteins have significantly higher degree than the network average [227].
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Results
Category mapping
This is a hand curated association between the Goh et al. disease categories [57] and
ATC categories [146]. While many categories can be found in both Goh and ATC,
some are not included in comparable groups, thus DrugBank’s pharmacological
action categories [219] are used as fall-back whenever the Goh category did not
match an ATC category. The entire mapping and a summary of the number of
elements per category can be found in the Appendix B.2.
PPI analysis
The average distance between all disease genes is 3.45, while the average inter-
actome distance is 3.58. Drug targets appear to be somewhat closer than random
genes, with an average distance of 3.25. Welch’s t-test confirms that the distance
distribution from drug targets is significantly different from a random choice in
the interactome (p-value < 1.0×10−300). The slight modularity suggests that there
are some functions which are particularly good as gene targets. Figure 8.2 shows
that intra-category proteins are not in general closer than inter-category proteins,
however Cancer and Endocrine drug targets are notably close. Looking at individual
rows, Bone, Developmental, Gastrointestinal and Immunological modules appear
to be located in particular areas of the network, as their intra-modular distance
is smaller than their inter-modular distance. These results seem to indicate that
most drugs do not affect specific modules in the network, but rather target proteins
which have an indirect effect on the disease. This is supported by the fact that many
drugs treat the symptoms of the disease rather than the causes (e.g. painkillers and
anti-inflammatory drugs).
Taking the known genes from the drug categories as the gold standard, gives
an average Jaccard coefficient of 0.027 for all drug and disease categories (this is
comparable to Ordinal predictions from Section 4.2.2). Figure 8.3 illustrates the
pairwise overlap between drug and disease categories (notice that only the diagonal
is used to calculate the average Jaccard).
Functional analysis
The GO over-representation analysis yields a high amount of signalling, transport
and binding functions for most categories, suggesting that drug compounds target
peripheral mechanisms to produce their effect. Signalling pathways are known
to coordinate cell responses, while binding and transport functions mediate the
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Fig. 8.2 Heatmap of drug target distance for category pairs. Colors indicate the
average distance between all drug targets from category A to targets from category B.
Fig. 8.3 Heatmap of the Jaccard coefficient between disease proteins and drug
targets by category. Colours are based on the Jaccard coefficient, while labels
indicate the actual number of common elements in the categories.
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availability of substances in the organism. These mechanism of action seem to
control the downstream effects of disease genes, which supports the idea that drugs
frequently target symptoms rather than causes of the disease. The significance
analysis clearly discriminates between few drug categories which target specific
functions (in particular Bone, Developmental, Gastrointestinal and Renal), and most
drug categories which target a broad spectrum of functions (in particular Cancer and
Cardiovascular).
These results can expected from the PPI analysis and known trends of drug
development (i.e. Cancer drugs are known to have large amounts of side effects and
are used as an extreme measure [46]). The notable exception is the specificity of
Renal drug targets, however the small size of the module could explain a bias in the
PPI experiment (only 10 drug targets were found in HPRD).
8.5 Network Visualisation
The massive amount of data involving biological networks, makes the presentation
of the information in a useful way (and if possible, grant a user friendly interaction)
one of the major concerns of Systems Biology. Common examples of such networks
are PPI networks with 9 thousand to 20 thousand proteins, and 40 thousand to 4
million interactions [160, 144], 4 thousand disease genes [125], 4 thousand drug
targets [219], and other networks of comparable sizes [9].
Handling the networks as a big data collection is most useful for automated anal-
ysis of biological systems, since adding evidential support offers machine learning
techniques bigger test sets to make better predictions. On the other hand, expert
analysis is rarely efficient on such hefty data collections. Normal approaches of
handling big data collections would use both types of analysis, automated analy-
sis prioritise data for a detailed expert analysis, so the likelihood of encountering
significant results in the study would increase.
During the past years I have worked with lab members to build a couple of
network visualisation tools, mainly focused to aid the research of disease. The first
tool called LanDis, which is a freely available web-based interactive application
www.paccanarolab.org/landis that allows domain experts, medical doctors and the
larger scientific community to graphically navigate the landscape of human disease
similarities. This particular project is ready and a working manuscript going through
an extensive publication process.
The second tool is developed for an ongoing research project, focused on the
effects of a particular drug for the treatment of Multiple Sclerosis (MS). This tool
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Fig. 8.4 LanDis: The Disease Similarity Landscape Explorer. LanDis allows the
exploration of the disease similarity landscape based on disease phenotype, and
offers the possibility of detailed pairwise disease comparisons to analyse the factors
of the similarity.
allows the visualisation of MS proteins, their neighbourhoods, and their relationship
with proteins of significantly similar diseases or proteins of relevant biological
pathways involved in the disease. As this is an ongoing project, we cannot make this
tool public and it’s not yet clear if this tool will be available for public use in the
future.
Although tools development is not a priority of the research, these tools are still
valuable contributions for the Biological Systems community.
Chapter 9
General discussion and conclusions
This chapter focuses on the contextualisation of the different outcomes of this work
within the field of network medicine. Since this work includes a compilation of
multiple correlated methods and projects, the particular contributions are presented
in their corresponding chapters. The ideas presented here are related to general
concerns of the discipline which are worth revisiting, and the nuances offered by this
work.
Section 9.1 presents an overview of the challenges in the prediction of genes
for molecularly uncharacterised diseases. It analyses possible reasons for the re-
duced performance on prediction, and how these reasons match the different testing
configurations.
Section 9.2 analyses several factors that contribute to the performance of Cardi-
gan and the variant on protein interface networks. The analysis includes a comparison
between the performance in the predictions of entirely novel genes and genes asso-
ciated to multiple diseases, the trade-off given by the usage of different networks,
vertex coverage, weighted edges, edge density, and different diffusion methods on
the ECLAIR network.
Section 9.3 serves as a summary of the contributions of about network module
principles presented in this work after a short overview of the field.
Section 10.2 presents a novel empirical framework to assess the expected per-
formance from Cardigan, and shows a procedure to select diseases where a high
performance can be expected.
9.1 Predicting on uncharted diseases
The existence of millions of SNPs and other mutations give a nearly unending
amount of variance in the human genome. Due to the computational and financial
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costs associated to whole genome studies, exome studies are frequently considered
to study human disease. The human exome contains between 12 thousand to 35
thousand SNPs, out of a total estimate of 500 thousand SNPs. In average, 40%
of the mutations are synonymous, 59% are non-synonymous and 1% are nonsense
[29, 224]. This abundance of alleles renders the identification of causal genes for
rare diseases a dismal task.
Network based methods facilitate the task by narrowing the number of candidate
genes, which allows for a greater statistical significance of the mutations. However,
they work as supervised or semi-supervised learning approaches, which require
initial data to be fed to the network [235]. So far, the only network methods able to
predict genes for uncharted disease without sequence data use disease phenotype to
create initial labels [135, 206] (see Chapter 3). However, they operate with matrices
calculated with outdated phenotype data [205], and are proven unable to predict
any genes which became associated to a disease in OMIM for the past 4 years (see
Section 6.2.1).
Cardigan allows the prediction for uncharted diseases by providing a seamless
integration with OMIM databases to obtain disease gene associations. The disease
phenotype is also obtained through OMIM databases, and is calculated as the seman-
tic similarity between the MeSH terms describing the diseases found in scientific
publications (see Section 4.3.3). Initial data for the prediction consists in weighted
labels from genes belonging to diseases similar to the query, and the weights are
given by the similarity of the disease they belong to and the query disease. This initial
data already takes the shape of a putative disease module for the query disease (see
Chapter 5). The labels are finally diffused through an interactome to produce a gene
prioritisation as a ranking for all genes in the network. Cardigan uniquely is able
to predict recent OMIM associations and vastly outperforms other state-of-the-art
methods on several testing environments (see Section 6.2).
The presented disease gene prediction evaluation consists of two different vari-
ables: knowledge of molecular basis and cause of the missing target. Charted
diseases have some known molecular basis while uncharted disease have no molecu-
lar basis, in both cases a single missing gene is predicted. Time-lapse experiments
consist in using 2013 OMIM data is taken to predict genes which were associated to
OMIM in the 2013-2017 period. Leave-one-out experiments synthetically remove
one known gene at a time, and predict it back using 2017 OMIM data. Figure 9.1
compares the performance of Cardigan under the different testing conditions.
It is reasonable to think that the fluctuation in performance for the different
environments depends exclusively on the amount of data available. The significant
decrease in performance between the time-lapse charted and uncharted tests is
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Fig. 9.1 Cardigan’s performance for different testing environments. Percentage
of disease genes found in the predictions vs. the number of predictions retrieved. All
predictions are made using HPRD.
expected as uncharted diseases are likely to have fewest scientific publications and
are the most difficult to predict. However, leave-one-out uncharted experiments
suggests a dramatically different scenario as it appears to produce 80%-90% of the
accuracy of a leave-one-out charted prediction.
The difference in accuracy between time-lapse and leave-one-out experiments
can be explained as the removal of the gene association does not discard other
information included in the method prediction. For instance, the discovery of the
gene could lead to a better phenotype characterisation, enhancing the phenotype
similarity matrices. Another difference is that studies for complex disease frequently
find entire new sets of genes associated to a trait [63], so finding one gene missing
out of a coherent module can be expected to be easier than finding the entire module.
In this way, time-lapse experiments reflect real scenarios where missing genes are
predicted, while leave-one-out experiments reflect a scenario where diseases have
many scientific publications where a single causal gene is yet to be found. Thus,
time-lapse testing approximates the average performance of the method on real
studies, while leave-one-out testing approximates the upper bound in performance
expected of the method.
Unfortunately these considerations are frequently disregarded in many publica-
tions of the field, which only include leave-one-out testing environments [3, 50, 55,
90, 107, 111, 139, 148, 165, 184, 186, 206, 222, 223, 231].
Analysis of particular time-lapse examples
While time-lapse experiments are better characterisations of the disease gene discov-
ery process, some unknown associations are somewhat artificial due to the way in
which OMIM annotates diseases. All the following examples presented no genes
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associated for the disorder in the 2013 OMIM database, and had an association made
available sometime before the 2017 OMIM database.
• Glass Syndrome (MIM:612313) is characterised by mental retardation, fa-
cial abnormalities, microcephaly, scalloped skin [56]. Multiple case studies
revealed a linkage with the SATB2 gene, at least for some of the presented
clinical features [170, 203], however only by December 2013 a study was
published associating the syndrome through and underlying genetic interaction
between SATB2 and the UPF3B gene [104]. This gene was predicted as the
second prediction by Cardigan using the HPRD interactome.
• Bruck Syndrome (MIM:259450) is characterised by contractions, growth
deformities such as pterygia, webbing and clubfeet, and multiple fractures
from childhood. Early documentation of the rare syndrome dates from 1969
[155]; while multiple papers analysed particular patients [15, 126]. Later, a
chromosomal region appeared to be identified by 2010 [181]. A posterior
analysis, identified the same mutation (nucleotide deletion) in both alleles of
the FKBP10 gene on September 2013 [11], which is posterior to the publication
of the old database used. Cardigan was able to predict FKBP10 as the fifth
prediction with the FUNCOUP interactome.
• Abruzzo-Erikson Syndrome – ABERS (MIM:302905) was described as a new
syndrome of cleft palate, coloboma, hypospadias, deafness, short stature, and
radial synostosis in 1977 [1]. The publication which associated the TBX22
gene to the syndrome was published on April 2013, but was not included on
the 2013 OMIM database used for this prediction. No documentation curated
by OMIM linked the TBX22 gene to ABERS, however Cardigan was able to
predict TBX22 as the tenth prediction using HPRD.
These examples come from an experiment not tractable for the other methods
analysed, however some information about their molecular basis is known. The Glass
Syndrome case included several papers which suggested the gene to be associated,
but the gene remained to be annotated in OMIM. The Bruck Syndrome had cases
analysed through a long time and suggestions of chromosomal areas where the gene
was later found. And finally, ABERS had no papers linked to genetic positions.
However, the gene was associated to a dummy disease related to cleft palate in the
2013 OMIM. While all of these cases are computationally hard, experts in the field
are expected to know about these putative genes limiting the novelty of the predicted
association.
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Notice that after a literature review all the disease examples presented for Cardi-
gan in Table 6.2, contain genes not found in publications related to the examples
older than the 2013 OMIM database release. That suggests that Cardigan indeed
contributes to find genes for real molecularly uncharacterised diseases.
9.2 Factors that influence performance
9.2.1 Novel disease genes
Given the fact that Cardigan has a strong baseline prediction given by the shared
genes of other diseases (i.e. the Ordinal prioritisation), it is interesting to decompose
the analysis into the prediction of genes found in OMIM or outside the database.
The first question is how many genes in Cardigan’s output are known for other
diseases, but are not known to be associated with the query. In average, 28% of
the top 200 predictions are genes not known to be associated with any disease on
time-lapse experiments, and 26% for leave-one-out experiments. The fact that more
known targets are predicted is expected since the training set contained a similar
distribution of genes with known and unknown associations as targets.
The second question is the difference in performance while predicting genes
known to be associated with multiple OMIM diseases (i.e. shared targets) or genes
not known to be associated with other OMIM diseases (i.e. novel targets). From
the 769 OMIM disease gene associations for diseases with two or more genes
predictable in HPRD (leave-one-out charted), 201 (26.1%) are genes associated to a
single disease in OMIM. Analogously, 1,442 (44.3%) of the 3,252 diseases with one
gene association (leave-one-out uncharted) are synthetic novel targets. Figure 9.2
shows that predictions are much harder for novel targets, however that performance
is still significantly higher than what is expected by random chance. Notice that
some scenarios are more favourable for the prediction of novel targets, for instance
the performance for the first prediction of charted diseases is equal for novel and
shared targets.
These experiments show that Cardigan is not only able to predict genes for
uncharted diseases, but also provides novel gene candidates.
The results on time-lapse experiments are also cited for the sake of completeness.
Charted time-lapse experiments contain 8 (13.1%) genes not associated to any disease
in the 2013 OMIM release and none were predicted among the top 200 predictions.
Uncharted time-lapse experiments contain 80 (53.7%) genes not associated to any
disease in the 2013 OMIM, and 2.5% of them were found among the top 100 and 200
predictions. These results continue to show the difference in performance between
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(a) Leave-one-out charted (b) Leave-one-out uncharted
Fig. 9.2 Cardigan’s performance at predicting novel and shared disease genes.
Percentage of disease genes found in the predictions possible per network vs. the
number of predictions retrieved on HPRD. The bars show the performance nor-
malised for the amount of predictions available for each dataset. Shared targets are
genes known for other diseases and start with a seed for the diffusion. Novel targets
are not associated to any disease (synthetically removed from the query) and do not
have a seed. The stacked Overall bar is the performance on the entire dataset, the
pieces in the stack are highlighted to reference the contribution of shared (dark) and
novel (light) targets. (a) Performances for a leave-one-out testing for diseases with
two or more known genes in 2017. (b) Performances for a leave-one-out testing for
diseases with a single known gene in 2017.
time-lapse and leave-one-out experiments. Furthermore, it suggests that a good
option of follow up development is enhancing the prediction of entirely novel disease
genes.
9.2.2 Trade-off in real networks
The network medicine paradigm relies on the fact that these biological networks en-
code the complex interplay between cellular components, into a simple yet powerful
data representation. While in depth genetic research (i.e. protein interactions, drug
affinity or function) is vital to characterise a disease, it frequently derives to knowl-
edge specific to the phenotype under observation or expensive research pipelines
[141, 173]. These studies, however, provide data which allows the construction of
biological networks sprinkled with high quality information. Modern computational
methods gain insight from the initial information by exploiting local and global
patterns, and produce inferences with reasonable support. Naturally, the inference
quality hinges on the amount of known data, network characteristics and critically
the inference method.
It is essential to recognise that binary representations may not be ideal to depict
many biological phenomenons. It may seem intuitive to pursue a binary model for
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(a) Time-lapse uncharted (b) Leave-one-out uncharted
(c) Time-lapse charted (d) Leave-one-out charted
Fig. 9.3 Cardigan’s performance on different networks. Percentage of disease
genes found in the predictions possible per network vs. the number of predictions
retrieved. (a) Performance for diseases which were uncharted in 2013, but were
charted in 2017, measured on different PPI networks. (b) Performances for a
leave-one-out testing for diseases with a single known gene in 2017 on HPRD. (c)
Performance for predicting the genes that charted diseases have acquired between
2013 and 2017. (d) Performances for a leave-one-out testing using 2017 data.
protein-protein interactions, where a pair of proteins either interacts or not. However,
proteins have complex interaction preferences with other proteins, which are partially
explained by the interaction affinity. Further complexity can be seen as the affinity
between a pair of proteins is not static, and may change due to interactions with
other proteins or compounds [85]. While both binary and weighted PPI networks
lead to biases in the recognition of network modules if they present incomplete or
inaccurate data [238], binary networks are intrinsically bound to contain both.
The compilation of high quality data and predictions comes at the cost of com-
pleteness. This can be seen in PPI databases such as the sparser hand curated HPRD
[160] in contrast with the dense and experimental FUNCOUP [144, 178], in disease
gene prediction methods the highly specific Navlakha 1 and Navlakha 2 variants
[139] over the generalist Oti et al. method [148], or in protein function predictions
as a trend among participating methods in the CAFA competition [79, 164].
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(a) Time-lapse uncharted (b) Leave-one-out uncharted
(c) Time-lapse charted (d) Leave-one-out charted
Fig. 9.4 Cardigan’s total recall on different networks. Total disease genes found
among the top predictions vs. the number of predictions retrieved. (a) Performance
for diseases which were uncharted in 2013, but were charted in 2017, measured on
different PPI networks. (b) Performances for a leave-one-out testing for diseases
with a single known gene in 2017 on HPRD. (c) Performance for predicting the
genes that charted diseases have acquired between 2013 and 2017. (d) Performances
for a leave-one-out testing using 2017 data.
Cardigan is designed to handle binary, weighted, experimental and inferred inter-
actomes, and allows the user to run the predictions with their network of preference.
Figure 9.3 shows how Cardigan handles different networks on multiple arrangements
for disease gene prediction.
While the performance decreases on the larger networks (see the lighter bars on
Figure 9.3), they are expected to be harder predictions. As more nodes are added to
the network the number of true positives stays the same (i.e. the single target being
predicted), while the number of true negatives grows (all other nodes).
However, Figure 9.4 shows that the total number of genes found among the
intervals improves, as more disease genes are contained within the interactomes.
Figure 9.3 shows that the average performance of the method decreases for the
bigger networks, however Figure 9.4 shows that the bigger networks contain indeed
more information, and serve to identify more disease genes than the smaller networks.
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Fig. 9.5 Comparison of performance between binary and weighted networks
Performance of Cardigan for a leave-one-out charted testing on FUNCUP using the
edge weights or binary edges.
The difference between the figures is particularly large for time-lapse uncharted
targets. Notice that BioGRID and FUNCOUP have roughly double the amount of
genes of HPRD (see Table 4.3), so they include more disease genes annotated in
OMIM (BioGRID and FUNCOUP cover ∼ 70% of the OMIM genes and HPRD
∼ 50%). The drop in average performance seems reasonable, considering that there
is a much larger number of negative samples in each prediction. The criteria to select
one network over the other is likely to be a complex issue and cannot be answered in
a general way; the final user of the method must deal with the inescapable trade-off
between precision and recall.
9.2.3 Contribution of weights, coverage and density
The following experiments are designed to weigh the contribution of the factors
that contribute to the network performance: edge type (binary or weighted), protein
coverage (amount of vertices in the network) and edge density (amount of edges
in the network). This analysis fixes the network to FUNCOUP [178], and modifies
vertices or edges to test the different features. Furthermore, the experiments evaluate
the performance in leave-one-out tests for diseases with two or more genes associated
in OMIM.
The first experiment compares weighted and binary edge types (Figure 9.5).
The binary edges were produced by setting all connected edges in FUNCOUP with
a weight of 1. While different thresholds could be tried, all the edges available in
FUNCOUP are already considered above a baseline confidence threshold [178]. The
baseline performance for this comparison is set by Ordinal, which can be considered
as the network with no diffusion. Figure 9.5 shows that the difference in performance
is particularly sensitive for the top results, where they drop nearly by 50% in the first
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(a) Vertex sensitivity (b) Normalised vertex sensitivity
Fig. 9.6 Comparison of performance by variation of node coverage. The experi-
ments consist in Cardigan predictions on synthetic leave-one-out tests for OMIM
charted diseases, using the FUNCOUP network and percentages of vertices are kept
in the network. The error bars show the standard deviation of 10 random samples. (a)
Shows the percentage of possible targets from the complete network being retrieved.
(b) Normalises the measure to show the percentage of targets still available in the
network to be found.
prediction, and by 20% in the top 10 predictions. However, in average the prediction
is halfway between the baseline and the usage of weights.
The second experiment compares the sensitivity to the network coverage (Fig-
ure 9.6). The baseline given here is a random selection of genes, as there are
no changes intrinsic to the diffusion process. Figure 9.6a shows that the recall is
extremely sensitive to the amount of nodes available in the network, as expected.
However, Figure 9.6b shows that taking into account the available results, the method
maintains a stable performance.
The third experiment compares the sensitivity to the network density (Figure
9.7). The baseline is Ordinal, to show a case with no diffusion. Figure 9.7 shows a
non-linear relation between the number of edges dropped and the performance, and
a big variance in performance on high edge removal cases. The removal of the first
20% of edges results in a small loss of performance, which could be explained by
the density of the network and the inferred nature of the edges. The perturbation is
massive when 80% of the edges are removed, causing frequently a lower performance
after diffusion. The fluctuation in performance is likely to respond to changes in
the connectivity in the network, and suggests the existence of essential connected
components network.
While most experiments confirm the notion that more information is useful, the
edge density suggests that some very incomplete datasets may skew the predictions
and hurt the performance. In these experiments, the effects of using of binary edges
equates to a drop of about 50% edges throughout the top 200 predictions. The
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Fig. 9.7 Comparison of performance by variation of edge density. The exper-
iments consist in Cardigan predictions on leave-one-out tests for OMIM charted
diseases, using the FUNCOUP network. The error bars show the standard deviation
of 10 random samples. (a) Different percentages of vertices kept in the network. (b)
Different percentages of edges kept in the network.
vertex coverage shows a different effect pattern, which appears roughly as a linear
fluctuation in performance.
9.2.4 Contribution of network interfaces
It appears that under a consistent testing scheme, the addition of data always produces
better results. However, the improvements can only be seen when the system is
prepared to handle the data. Chapter 7 presented the benefits of adding data (in the
form of interfaces) to a PPI. It might seem intuitive that Cardigan would benefit
alone from its usage. However, Figure 9.8 shows how the usage of the network with
interfaces decreases the performance of Cardigan if the diffusion method stays the
same.
The results of the evaluation can be better understood by taking into account
the difference between the INSIDER PPI and the INSIDER ECLAIR graphs (con-
struction shown in Section 7.1.1, and summaries shown in Tables 4.4 and 4.5). It
is interesting that the INSIDER ECLAIR graph has only 14% more nodes than the
INSIDER PPI graph. In fact, 36% of the proteins have no high quality interfaces
(which appear as ∅ interfaces in the graph), and 51% of the proteins have a single
high quality interface. Therefore, the entire difference between the graphs is ac-
counted by 13% of the INSIDER proteins with 2 or more interfaces. While Section
7.1, addresses that a possible drawback of using an interface graph is the reduction in
connectivity, the small amount of multi-interface proteins currently predicted greatly
diminishes this effect. In fact, only 0.1% of the INSIDER proteins have no single
interface in the largest connected component of the ECLAIR graph.
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(a) (b)
Fig. 9.8 The consistency method on a PPI with interfaces. Comparison in perfor-
mance by using the INSIDER-PPI and INSIDER-ECLAIR networks (see Section
7.1.1) for the standard Cardigan diffusion method (see Section 6.1). The experiments
are leave-one-out tests for ClinVar diseases with more than one associated protein –
i.e. Charted tests. (a) Percentage of disease genes found in the predictions vs. the
number of predictions retrieved. (b) Normalised ROC for the first 10 false negatives.
(a) (b)
Fig. 9.9 Comparison diffusion methods on a PPI with interfaces. Cardigan uses
the consistency method (see Section 6.1) for diffusion and Variant 2 uses an interface
directed proposal (see Section 7.1.4). The experiments are leave-one-out tests for
ClinVar diseases with more than one associated protein – i.e. Charted tests. Both
algorithms use the INSIDER ECLAIR network (see Section 7.1.1). (a) Percentage
of disease genes found in the predictions vs. the number of predictions retrieved. (b)
Normalised ROC for the first 10 false negatives.
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Recall that Figure 9.8 shows that Cardigan loses performance when expanding the
protein graph into the protein interface graph; this suggests that the Zhou diffusion
cannot account for the composite nature of the protein interface nodes. Figure 9.9
shows that a diffusion method designed for protein interface graphs (Variant 2) is
in fact better at using the INSIDER ECLAIR graph. The difference in Figure 9.9
is comparable to using 60% or 100% of the network edges from Figure 9.7, which
speaks for the benefits of an appropriate diffusion method. Figure 7.4b (from Section
7.2) showed that using Variant 2 on the protein interface graph produced better results
than the Zhou diffusion on the protein graph for the top 10 predictions and onwards.
The difference in Figure 7.4b is comparable to using 80% or 100% of the network
edges from Figure 9.7, which speaks for the information gained by considering the
protein interfaces.
Overall, this analysis shows that the availability of more network data might
be a double edged sword. On one hand, more information helps to provide a more
accurate characterisation of biological phenomenons, and enables some inferences
not available in simpler models. On the other hand, it presents confounding factors
that may lead to inaccurate conclusions when the underlying meaning of the data is
not accounted for.
9.3 Network Modules
The notion of modules is embedded into the conception of network medicine through
the guilt-by-association principle [10]. While multiple authors [10, 16, 20, 32, 36,
70, 154, 238] have studied the modularity of many biological phenomenons and the
genotype-phenotype interplay, they were mostly studied within different contexts.
This work portrays different ways in which these different modules connect.
Within the network medicine paradigm, the genotype is defined by a subset of
nodes of interest in a biological network [10], while phenotype has a looser definition
regarding the object in study. The gene phenotype generally refers to systemic
function it serves and it is characterised by the Gene Ontology [3, 121, 139, 148, 238],
however it can also refer to the protein interactors as a gain or loss of function [36, 88].
The phenotype can also refer to the observable traits of other processes which occur
in an organism, such as disease [20, 26, 90, 205, 207] or drug response [70, 227].
The biological counterpart to the network medicine approach is as follows:
different sets of genes are involved in the different cellular functions and response
external stimulus, which consist of complex biochemical interactions [12]. These
responses can be seen in a cellular level as progression through the cell cycle, changes
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in the cytoskeletal structure, cell adhesion, cell migration and cell metabolism, among
others, and imply fluctuations in gene expression useful within the intracellular
biochemical pathways [152]. Both disease and drug response can be also associated
with the up or down regulation of intracellular pathways [76]. Network modules
are interesting from a biological point of view since these sets of genes universally
appear to cluster in signalling, metabolic, regulatory and PPI networks, and bring a
systemic point of view to gene function [212].
However, it is unclear how the modules obtained through the different approaches
relate to one another [212]. This work shows that modules of phenotypically similar
diseases are coherent with protein function (see Chapter 5), and it continues to
validate the usage of network dynamics to prioritise disease gene candidates within
the topological module (see Chapter 6). Furthermore, it shows that while drug
targets form topological modules, they are heterogeneous and few of them match
the corresponding disease module. In particular, Cancer drugs are shown to affect a
broad amount of protein functions, as opposed to Bone drugs which target specific
functions and affect disease genes.
9.4 Selecting diseases to reduce the noise in Cardi-
gan’s prediction
The current understanding of disease mechanisms shows that genetic diseases are
very varied. The elucidation of disease’s mechanisms of action are often required
for the development of detection methods or treatments. At a molecular level, this
involves the identification of SNPs and their effects.
Individual or collections of SNPs can cause problems with the gene expression,
or affect the protein expressed by the gene. SNPs in a non-coding region may cause
under or over expression of a particular gene, both of which can be associated to
disease [210]. SNPs in coding regions are associated with changes in the protein
structure, which in turn derive into traits associated to disease. Common traits are:
loss or gain of function, reduction or gain in activity and interference in activity
[217]. It is understandable that at a molecular biology level, the study the mutation
trait (e.g. loss-of-function) will benefit from the study of other cases that share the
same trait.
Another way to look at the mechanisms of action is from the main phenotypes at
an organism level or pathogenesis. Some common pathogenesis are inflammation,
alterations to the immune response, growth abnormalities, among others. The
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research on this area can also link together diseases that share similar phenotypes,
and discover biological subsystems involved in those phenotypes [21, 63].
Therefore, it makes sense that a similar approach could be used in computa-
tional disease gene prediction models, in particular to avoid noise from possibly
confounding mechanisms of action. For instance, the prediction of a mutation on a
coding region which derives into loss-of-function, may benefit if the model focuses
on diseases which are known to derive from loss-of-function. Then, it is possible for
Cardigan to benefit from having a limited amount of diseases in the QWS, to reduce
the noise of other phenotypes.
The knowledge that a disease is caused by a genetic loss-of-function is likely to
come after the mutant gene is discovered. Therefore, this is not the same stage in
which Cardigan is thought to be useful. Cardigan only intends to discover disease-
gene associations, so the SNP effect is unlikely to be known at the time of prediction.
Notice that if there is a high similarity between the phenotypes of the disease of
interest to other diseases that suffer from loss-of-function, it would be reflected
in the Caniza similarity. A literature revision of the diseases most similar to the
query (measured with the Caniza similarity) is suggested to provide insight on its
mechanism of action.
Reducing the set of diseases to focus on a particular phenotype however is not
entirely without merit. I believe such a study could be useful, particularly when
dealing with a complex disease. Since many genes are expected to cause the disease,
it is reasonable to expect that different subsets of genes cause the different traits.
For instance if the query disease involves an autoimmune response, it would be
interesting to see the top ranked genes while only allowing autoimmune diseases to
be in the QWS.
However, only considering particular subsets of diseases to construct the QWS
may cause the resulting prediction not to reflect the proper disease module. In
principle, Cardigan finds the disease module by approximating modules of other
diseases which match every phenotypic characteristic. Recall that the two diseases
would be similar according to Caniza similarity if they share any particular phenotype,
even if they show other different traits (see 4.3.3). This draws genes that could explain
every phenotype shown in the query disease into the Cardigan module. Leaving
any of those pieces out may to leave some unexplained phenotypes in the Cardigan
prediction. Therefore, I consider that having every possible disease in the QWS is
the best solution if a single disease gene must be predicted.
Another way to prioritise Cardigan to match a particular subset of diseases is to
retrain the method parameters. This option is certainly a sound strategy to reduce the
noise of the prediction. Keeping the previous example, if the researcher is focused on
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predicting genes for an autoimmune disease, all (or a subset) of other autoimmune
diseases could be used to optimize the diffusion parameters on a leave-one-out
procedure. This would replace the parameters trained for Acute Lymphoblastic
Leukemia in Section 6.1.2. The QWS for the prediction will still contain associations
from all the diseases from OMIM, but the balance in the diffusion parameters will
be tuned towards characteristics that benefit the discovery of genes for autoimmune
diseases.
Notice that the training might take a long time if the training set contains many
disease gene associations. A possible drawback of this approach is that the parame-
ters might be overfitted. A cross-validation analysis could be useful to understand
the best number of diseases to keep in the training set. Recall that a cross-validation
analysis could be very time consuming (as discussed in Section 6.1.2). However,such
an analysis could be interesting for future work.
Chapter 10
Future Work
The following projects are continuations of current work or exploratory work that
shows promising applications after further development.
10.1 Cardigan Web
This is a web application intended to be included as a follow up publication for
Cardigan. The application is designed contextualise the putative genes given by
Cardigan through a network visualisation of the results.
Current features prompt the user to select a query disease, after which Cardigan
predicts gene targets for the query which are retrieved to the user (the current
implementation calculates the results on the fly, and does not store predictions
made for other users). Cardigan Web loads the known disease genes into the Gene
Explorer, and all their neighbours using the preferred network. The genes in this
neighbourhood are highlighted according to the priority assigned by Cardigan.
Notice that this web application is built on HTML5 and JavaScript to produce
the visualisation. This allows the server to handle big networks without much of an
overload, as the visualisation is rendered entirely on the user’s device.
Figure 10.1 shows screenshots from a development stage of the tool, which
allows visualisations of how the method changes from known seeds, to the Query
Weight Set and to the final prioritisation. The visualisation shows an example of a
time-lapse gene prediciton where one gene is the seed found in HPRD for Acute
Lymphocytic Leukemia (ALL - MIM:613065), and genes known in 2017 (shown in
large circles) are the desired prediction. Notice that while the feature which allows
experimental tests resulted interesting during the development of Cardigan, it is
likely to be excluded from the final version of Cardigan Web.
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(a) Similarity
(b) Final labelling
Fig. 10.1 Visualisation of a synthetic gene prediction. The large nodes are the
known disease genes and the green one is the gene used as seed for the diffusion
process). Genes other than the seed are coloured according to the label in that stage
(blue is low and red is high). (a) Shows the genes with the Caniza similarity, and (b)
shows the labels after the diffusion process.
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10.2 Prediction confidence
This analysis focuses on the possibility of deciding whether it is possible or not to
predict which diseases will get a good Cardigan prediction. For instance, Cardigan
gets 48% of the targets for time-lapse charted diseases within the top 200 results,
and 13% of them are predicted in the first position. The problem is to identify which
diseases are more likely to be ranked among the top.
The analysis shows that some features based on the semantic similarity of the
query disease appear to correlate to the quality of the prediction, and further develop-
ment appears to be possible. In particular, the generalisation of the analysis appears
feasible for methods other than Cardigan, as multiple methods are able to identify
some common disease-gene associations among the top predictions.
Analysis of the diffusion input
It is noticeable that not all predictions are equally challenging for the method. In
particular, Section 6.2 shows that in average Cardigan has a lower performance on
uncharted diseases than on charted diseases. The following proposal considers that
the difference Cardigan’s performance on different diseases is based on the amount
of information used as input for the prediction.
From a machine learning perspective, every instance of disease gene prediction
has the same amount of seeds1, and each disease just changes the initial value of
each of those seeds. In fact, the seeds QWS has all the genes known in OMIM: the
known genes from the query are set to 1, and genes from other diseases have a value
proportional to the similarity of the query (see Section 6.1.1 for the definition of the
QWS).
Therefore, each extracted feature is bound to depend on the distribution of values
in the QWS representing the query disease. However, the QWS value distribution
is not the only important information source, the network connections of the genes
associated to the weights are an important orthogonal information source.
Besides the number of known genes |S|, two out of several devised features have
showed to correlate with the Cardigan’s performance: seedness and connectedness.
Let X (Y q) be Cardigan’s performance for disease q using Y q as the input QWS,
then, the SeednessS is defined as:
S (Y q) = ∑
i∈Y q
yi,
1Unless the particular experiment removes some known disease gene associations from the
database, such as the leave-one- out predictions.
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where yi is the seed held for gene i in the QWS. The seedness represents the total
amount of information known about the disease in q in the QWS. Connectedness C
is defined as:
C (Y q) = ∑
(i, j)∈E
yiy jWi j,
where E is the set of edges of the network and Wi j is the weight of the edge. The
connectedness represents how coherent the QWS information is.
The correlation between the measures (S andC ) and the corresponding perfor-
mances (X ) is calculated with a linear regression model. The linear model is used
to predict the performances A = [X ] with the measures B = [S ,C ] – i.e. finding β
which minimises the RMSE of A = βB [14]. Each performanceX (Y q) is kept in a
[0,1] interval by using the AUC of the ROC curve normalised for the first 200 false
positives (see Section 4.2.1). Table 10.1 summarises the regression parameters for
charted and uncharted diseases.
Table 10.1 Regression expected gene ranking for seedness and connectedness.
Results are given by leave-one-out tests.
Test set β0 |S| S C
Charted 0.6159 -0.0080 0.0001 -5.623e-05
Uncharted 0.2141 0.1307 4.431e-05 -7.431e-06
Correlation values are not very high, but they suffice to give an idea of the
expected performance. The real value corresponding to a predicted performance x
can be evaluated by grouping diseases according to ranges of expected performances,
and observing the average of the real performance. Table 10.2 shows the results
of classifying charted and uncharted diseases in 10 possible bins by their expected
performance.
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Table 10.2 Average performances vs expected performances of disease predic-
tions. The predicted performance of the diseases is used to bin the experiments into
brackets. The Real column shows average performance of the prediction and the
Expected column shows the average expected performance for the diseases in the
bin.
Charted Uncharted
Range Real Expected Real Expected
0.2 - 0.3 0.316368 0.260080 - -
0.3 - 0.4 0.386553 0.351363 0.306688 0.375035
0.4 - 0.5 0.397828 0.454885 0.463839 0.473384
0.5 - 0.6 0.597903 0.545644 0.531207 0.525721
0.6 - 0.7 0.625189 0.655033 - -
0.7 - 0.8 0.748609 0.749621 - -
0.8 - 0.9 0.807604 0.834941 - -
While there is variance inside each bin, the real performance matches the expected
performance. Nonetheless, it is clear that the regression cannot identify the conditions
that grant very low or high performances, and the predictions have a noticeably small
range for uncharted diseases. This suggests the validity of the approach and leaves
the possibility for further development.
10.3 Integration of heterogeneous networks
The mathematical formulation of the diffusion method for the graph with interfaces
(Section 7.1.4) somewhat equates to the unification several diffusion processes that
occur on the same protein through different interfaces. Following this intuition,
diffusions on several protein networks (e.g. PPI, metabolic, transcriptomic, or others)
could be unified considering that the protein will have one interface per network.
The method proposed in Section 7.1.4 (Variant 2) could predict genes in such
a network out of the box. However, it is unlikely that each network will bring the
same amount of information to the process. The contribution of each network can be
controlled with a variation of the interface-interface combination matrix (Bi j from
Equation 7.5). Another way to control the contributions is to rescale the edge weights
of each individual network and give more weight to the most relevant networks.
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Other works have used heterogeneous networks for disease gene prediction
[50, 54, 107, 223, 231], and can be used as a baseline for the expected gain in
performance compared to using only a PPI network.
The problem, objective, tools and basic evaluation procedures seem well defined,
making this a good project for further development.
Appendix A
Cardigan Manual
This Appendix serves as a manual for the usage of the Cardigan software. This
software is designed as a Python2.7 package, which has been used to produce all the
results found in the paper. The software can be downloaded from www.paccanarolab.
org/cardigan.
A.1 Quick and simple
Cardigan offers a library to both run the Cardigan algorithm and handle multiple PPI
networks, and disease-gene interaction sources (such as OMIM)
Installing
These instructions will show how to setup Cardigan and allow its usage as a Python
module.
Prerequisites
Cardigan requires the installation of NumPY and SciPY:
$ pip install scipy
Furthermore, you need to provide at least one PPI network, a Caniza disease
similarity matrix, and both OMIM morbidmap and OMIM mim2gene datasets. The
datasets are located by default under the data folder in default folder scheme:
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CARDIGAN_HOME
bin
data
dissim
omim
ppi
biogrid
diamond
funcoup
hippie
hprd
user
lib
LICENSE
README.md
The Caniza disease similarity calculated with the 2017 OMIM is provided in the
data bundle, otherwise it must be computed by the user. The software to produce the
matrix can be downloaded from the paper website.
At least one of the networks (found under data/ppi) should be provided. BioGRID
in TAB2 format, and DiamondNet from the Ghiassian et al. paper (S1 file), FUN-
COUP v3.0, HIPPIE and HPRD in their standard format. The custom PPI network
should be a tab separated file with Entrez identifiers (called data/ppi/user/ppi.txt
as default), and may include a third column with the edge weight (all edges should
include weights if the PPI is weighted). The default network can be established in
the setPPI(ppiType) method found lib/Config.py (it defaults to ’custom’).
All file names and locations can be changed in lib/Config.py.
Library setup
The modules can run as they are, however, the Caniza similarity must be pre-
processed for faster access within the method. The pre-process and data availability
can be done launching the setup:
$ cd CARDIGAN_HOME/bin
$ python setup.py
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If the setup is not executed, the Caniza similarity will be pre-processed the first
time Cardigan runs.
Running Cardigan
You can find working examples under the bin folder.
The following example is the default use case of the library. Further details are
provided by the Cookbook Section, which shows examples to run the experiments
from this work.
Minimum working example
This is the basic usage of the software
1 import sys
2 sys.path.append(’../lib’)
3
4 import Cardigan
5
6 # load the module using the default configuration
7 cardigan = Cardigan.Cardigan()
8
9 # predict genes for BDPLT16 (MIM: 187800)
10 out = cardigan.predict([’187800’])
11 print out
A.2 Cookbook
This section covers the most frequent usage of Cardigan with short and simple
examples. In general these recipes can be combined according to the user’s need.
Customise the known genes
If the seeds are defined all known genes for the disease are replaced with the provided
seeds
1 import sys
2 sys.path.append(’../lib’)
3
4 import Cardigan
5
6 # load the module using the default configuration
7 cardigan = Cardigan.Cardigan()
8
9 # predict genes for BDPLT16 (MIM: 187800)
10 # set gene 3690 as a seed
11 out = cardigan.predict([’187800’],[’3690’])
12
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13 print out
Customise the targets and evaluate
Cardigan offers some evaluation measures to assess the predictions. Providing a
target allows Cardigan the ability to evaluate the last prediction. Importantly, the
target cannot be one of the known seeds of the disease being predicted.
This example defines seeds and targets to predict a synthetically removed disease
gene
1 import sys
2 sys.path.append(’../lib’)
3
4 import Cardigan
5
6 # load the module using the default configuration
7 cardigan = Cardigan.Cardigan()
8
9 # predict genes for BDPLT16 (MIM: 187800)
10 out = cardigan.predict([’187800’],seedGenes=[’3690’],targetGenes=[’3674’])
11 targetPos = cardigan.evaluate()
12
13 print targetPos
Changing the PPI network
You can establish the network by loading the appropriate config to Cardigan:
1 import sys
2 sys.path.append(’../lib’)
3
4
5 import Cardigan
6 import Config
7
8 # load the configuration module
9 config = Config.Config()
10 config.setPPI(’hprd’)
11 # load the module with the modified configuration
12 cardigan = Cardigan.Cardigan(config)
13
14 # predict genes for BDPLT16 (MIM: 187800)
15 # keep gene 3690 as a seed and use 3674 as a target
16 out = cardigan.predict([’187800’],[’3690’],[’3674’])
17 targetPos = cardigan.evaluate()
18 print targetPos
The supported networks are ’hprd’, ’diamondnet’, ’biogrid’, ’hippie’, ’funcoup’,
and ’custom’ (which is explained in A.3.1).
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Experimental setups
In addition to the prediction method, Cardigan offers further utilities to handle the
gene associations and produce different experimental setups.
Time-lapse experiments
These experiments require both old and new disease gene association files
1 import sys
2 sys.path.append(’../lib’)
3
4 import Config
5 import OMIMUtilities
6
7 # load the configuration file
8 config = Config.Config()
9
10 # OMIM provides a gene MIM to Entrez mapping, which is loaded here
11 mim2gene = OMIMUtilities.Mim2Gene(config.mim2gene)
12 # then the disease gene association mapping is loaded
13 # for the old OMIM
14 mmo = OMIMUtilities.MorbidMap(config.morbidMapOld,
15 separator=config.morbidMapOldSep, mim2gene=mim2gene)
16 # and for the new OMIM
17 mmn = OMIMUtilities.MorbidMap(config.morbidMapNew, separator=config.
morbidMapNewSep, mim2gene=mim2gene, oldMorbidmap=mmo)
18
19 print ’Diseases with more genes’, len(mmn.geneAdditions)
20 print ’Previously uncharted diseases’, len(mmn.diseaseAdditions)
Then, the experiment can be produced in a loop
1 import Cardigan
2
3 # load the module using the default configuration
4 cardigan = Cardigan.Cardigan()
5
6 # for each charted disease that gained some more
7 for disease in mmn.geneAdditions:
8 print ’Disease’,disease
9
10 # get one target at a time
11 for target in mmn.geneAdditions[disease]:
12
13 # predict using the seeds from the old database
14 out = cardigan.predict(disease, mmo.getGenes(disease), target)
15
16 # evaluate the position of the target
17 targetPos = cardigan.evaluate()
18 print target, ’found in position’, targetPos
Leave-one-out experiments
These experiments require a single gene association file
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1 import sys
2 sys.path.append(’../lib’)
3
4 import Config
5 import OMIMUtilities
6
7 # load the configuration file
8 config = Config.Config()
9
10 # OMIM provides a gene MIM to Entrez mapping, which is loaded here
11 mim2gene = OMIMUtilities.Mim2Gene(config.mim2gene)
12 # then the disease gene association mapping is loaded
13 morbidMap = OMIMUtilities.MorbidMap(config.morbidMap, separator=config.
morbidMapSep, mim2gene=mim2gene)
14
15 # obtain the genes associated to BDPLT16 (MIM: 187800)
16 disease = [’187800’]
17 knownGenes = morbidMap.getGenes(disease)
18
19 print knownGenes
Then, the leave-one-out procedure is a simple loop
1 import Cardigan
2
3 # load the module using the default configuration
4 cardigan = Cardigan.Cardigan()
5
6 # get one target at a time
7 for target in knownGenes:
8 # all other known genes are set as seeds
9 # i.e. one gene was left out
10 seeds = [x for x in knownGenes if x != target]
11
12 # predict using the left over seeds
13 out = cardigan.predict(disease, seeds, target)
14
15 # evaluate the position of the target
16 targetPos = cardigan.evaluate()
17 print target, ’found in position’, targetPos
A.3 Configuration
A.3.1 Network handlers
The network handlers are objects which parse text-based protein-protein interaction
networks and provide an interface for Cardigan.
Expected use
The user can provide a custom PPI network in a TSV format, which is located by
default in data/ppi/user/ppi.txt.
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# lines starting with # are comments
# Entrez_Protein_A Entrez_Protein_B Weight
entrezA entrezB WeightAB
entrezA entrezC WeightAC
entrezB entrezD WeightBD
After providing the interaction file, set the custom PPI in the configuration
1 import sys
2 sys.path.append(’../lib’)
3
4
5 import Cardigan
6 import Config
7
8 # load the configuration module
9 config = Config.Config()
10 config.setPPI(’custom’)
11 # load the module with the modified configuration
12 cardigan = Cardigan.Cardigan(config)
13
14 # predict genes for BDPLT16 (MIM: 187800)
15 out = cardigan.predict([’187800’])
16 print out
Advanced use
The user can directly produce a PPI object and override the configuration object for
its usage within Cardigan. The modifications follow the structure:
1 import sys
2 sys.path.append(’../lib’)
3
4 import PPIUtilities
5 import Config
6 import Cardigan
7
8 # load the configuration file
9 config = Config.Config()
10
11 # Load the PPI object
12 ppi = PPIUtilities.PPI(’../data/ppi/user/myCustomPPI.tsv’, **myCustomParameters)
13
14 # update the configuration with the custom PPI
15 config.ppiObject = ppi
16 # load the module with the modified configuration
17 cardigan = Cardigan.Cardigan(config)
18
19 # predict genes for BDPLT16 (MIM: 187800)
20 out = cardigan.predict([’187800’])
21 print out
All intended functionality is provider from the object constructor
1 PPIUtilities.PPI(filename, columns, ppiName, mainIdentifier,
2 separator, synSeparator, translateFile, translateCols,
3 verbose, simplify)
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• filename is the only mandatory field and should reference a text file.
• columns is a list of column identifiers which should match the number of
columns from the file. E. g. [’entrez_a’,’entrez_b’,’weight’], where the end-
ings ’_a’ and ’_b’ are not optional.
• ppiName is a string to identify the object.
• mainIdentifier is a string representing the column identifiers to be considered
for the network. E. g. ’entrez’.
• separator is the column separator (i.e. ’\t’ for a tab separated file).
• synSeparator is the character user to separate gene symbols. Gene symbols
(identified by columns ’symbol_a’ and ’symbol_b’) are used in the lines where
the main identifier is missing.
• translateFile is a reference to an additional 2 column tab separated file used
to translate the main identifier. It is used for instance if the custom dataset
contains UNIPROT identifiers that must be translated to Entrez.
• translateCols is the list [’source’,’target’] or [’target’,’source’], which spec-
ifies the order of the columns in the translate file.
• verbose is a boolean where False prevents the summary of the network mapping
to be printed in the console,True is the default otherwise.
• simplify is a boolean where False indicates that self loops are allowed, True is
the default otherwise.
Appendix B
Data mapping
Auxiliary data mappings crafted for different projects are presented here.
B.1 Diseases to OMIM
The following table presents a translation between disease names and OMIM iden-
tifiers. The disease names are defined by Ghiassian et al. [55] and serve roughly
as disease families which were used for several disease gene prediction methods
[90, 139, 148]. The OMIM identifiers are obtained by collecting diseases with
similar names or by matching the description.
Notice that the OMIM identifiers provided here are used as the query for Cardi-
gan. While each individual disease from the family contains known gene associations
within OMIM, all those genes are synthetically removed from OMIM for the con-
struction of the Query Weight Set. Instead, the disease family is associated to the
genes provided by the Ghiassian mapping [55].
Table B.1 Ghiassian to OMIM identifier translation. Each disease name is as-
sociated to a set of OMIM identifiers, which is considered to define the disease
(family).
No Disease OMIM
1 adrenal gland diseases 219080, 300200, 613677, 202010,
201710, 201910, 201810, 300018
2 alzheimer disease 104300, 607822, 104310, 606889
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No Disease OMIM
3 amino acid metabolism inborn errors 222700, 609924, 608643, 231670,
220100
4 amyotrophic lateral sclerosis 105400, 205100, 611895, 606070,
608627, 602433, 602099, 614696
5 anemia aplastic 609135
6 anemia hemolytic 205700, 613470, 266120, 612631,
300908, 235700, 612300, 231900,
102730, 230450
7 aneurysm 607086, 105805
8 arrhythmias cardiac 115000
9 arterial occlusive diseases 602531
10 arteriosclerosis 208060
11 arthritis rheumatoid 180300, 604302
12 asthma 600807
13 basal ganglia diseases 213600, 606656, 615007, 615483,
616413, 114100
14 behcet syndrome 109650
15 bile duct diseases 603003, 608063
16 blood coagulation disorders 306700, 306900, 227500, 227600,
612416
17 blood platelet disorders 139090, 601399, 601709, 609821,
605249, 231200
18 breast neoplasms 114480
19 carbohydrate metabolism inborn
errors
212066, 212065
20 carcinoma renal cell 144700
continues on next page
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No Disease OMIM
21 cardiomyopathies 500000, 115210
22 cardiomyopathy hypertrophic 115200, 192600
23 celiac disease 212750
24 cerebellar ataxia 224050, 604121
25 cerebrovascular disorders 182410, 601367, 301500
26 charcot-marie-tooth disease 118220, 118200
27 colitis ulcerative 266600
28 colorectal neoplasms 114500
29 coronary artery disease 608320, 168820
30 crohn disease 266600
31 death sudden 272120
32 diabetes mellitus type 2 125853
33 dwarfism 210710, 168400
34 esophageal diseases 614266, 164280, 109350
35 exophthalmos 605039, 259775, 170100
36 glomerulonephritis 305800, 248760
37 gout 300661
38 graves disease 275000, 300351
39 head and neck neoplasms 275355, 162200
40 hypothalamic diseases 262400, 143100, 275120, 176270,
614962
41 leukemia b-cell 613065
42 leukemia myeloid 601626
43 lipid metabolism disorders 275630, 602579, 212065, 107730
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No Disease OMIM
44 liver cirrhosis 215600
45 liver cirrhosis biliary 109720, 613007, 613008, 614220,
614221
46 lung diseases obstructive 606963
47 lupus erythematosus 152700, 607279
48 lymphoma 605027, 151430, 186960
49 lysosomal storage diseases 300257, 256540, 232300, 248500,
230500
50 macular degeneration 603075, 607921
51 metabolic syndrome x 605552
52 motor neuron disease 600333, 105550
53 multiple sclerosis 126200, 612594, 612595, 612596,
614810
54 muscular dystrophies 300377, 158900, 310200
55 mycobacterium infections 607948, 209950
56 myeloproliferative disorders 613523, 131440
57 nutritional and metabolic diseases 277400, 603358
58 peroxisomal disorders 214100, 601539
59 psoriasis 177900, 602723
60 purine-pyrimidine metabolism
inborn errors
613161, 274270
61 renal tubular transport inborn errors 602722, 611590, 179800
62 sarcoma 300813, 259500, 117600
63 spastic paraplegia hereditary 182600
64 spinocerebellar ataxias 164400
continues on next page
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No Disease OMIM
65 spinocerebellar degenerations 183090
66 spondylarthropathies 106300
67 tauopathies 600274
68 uveal diseases 155720, 120433
69 varicose veins 192200
70 vasculitis 192310, 609817
B.2 DrugBank Categories
The following mapping associates Disease categories to Drug categories. Drugs
from a given category are expected to be used for the treatment of diseases from the
corresponding category. This mapping covers about 60% of the FDA approved drugs
found in DrugBank 5.05 [219].
The Goh et al. categories [57] are used to define the disease categories. The
corresponding drug categories are Anatomical Therapeutic Chemical (ATC) cate-
gories [146] when possible, or DrugBank categories [219] on defect. The complete
mapping is presented in Table B.2.
Table B.2 Disease category to Drug category mapping. Disease categories are
based on the Goh et al. classification and drug categories are provided ATC when
possible or fallback to DrugBank categories.
Disease Category Drug Category
Goh ATC DrugBank
Bone - DBCAT000089, DBCAT002165
Cancer L01 -
Cardiovascular C, V09G -
Connective tissue V03AK -
Dermatological D -
Developmental H01 -
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Disease Category Drug Category
Goh ATC DrugBank
Ear-Nose-Throat S02 DBCAT002159, DBCAT002106
Endocrine L02 -
Gastrointestinal A03 -
Hematological B -
Immunological L03, L04 -
Metabolic A09, A14, A15, A16 -
Muscular, Skeletal M -
Neurological N -
Nutritional - DBCAT000234, DBCAT002733
Ophthalmologic S01 -
Psychiatric - DBCAT000529
Renal - DBCAT000629
Respiratory R -
Notice that the Multiple Goh category is left out of the mapping, as each disease
requires an independent drug association. The Muscular and Skeletal Goh categories
are matched to the DrugBank Musculoskeletal category (M), to avoid inaccurate
separations of the musculoskeletal drugs. A summary of the FDA approved drugs,
drug targets and disease proteins per category is shown in Table B.3. Over 60% of
FDA approved drugs are mapped to a Goh category. This provides a good coverage of
the drug set, and a mapping extension may reduce the confidence in the associations
of drugs to Goh categories without expert curation.
Table B.3 Summary of the Goh to DrugBank category mapping. The middle and
right column show the number of drugs and diseases per category. Notice that the
total is not the direct sum of the numbers as some diseases and drugs belong to
multiple categories.
Category Diseases Drugs
Bone 52 25
Cancer 198 138
Cardiovascular 98 223
Connective tissue 49 0
continues on next page
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Category Diseases Drugs
Dermatological 95 140
Developmental 51 21
Ear-Nose-Throat 52 62
Endocrine 99 22
Gastrointestinal 34 25
Hematological 157 96
Immunological 105 58
Metabolic 291 32
Musculoskeletal 167 91
Neurological 270 302
Nutritional 12 47
Ophthalmologic 149 137
Psychiatric 26 47
Renal 59 14
Respiratory 22 145
Overall 1928 1302
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